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Summary
The optic nerve represents an important model for neurodegenerative diseases in 
addition to a number of neurodestructive ocular conditions. Among these, glaucoma is 
a common cause of optic nerve damage usually associated with an elevated 
intraocular pressure (IOP), retrodisplacement of the lamina cribrosa, reduced 
retrograde neurotrophic support and pathological cellular changes. Retinal ganglion 
cell (RGC) loss can continue after reduction of IOP to normal levels, indicating 
attenuated secondary neurodegeneration during which glia activate and proliferate. 
Activated glia may exacerbate glaucoma during secondary degeneration.
Experimental glaucoma was induced in Brown Norway rats using episcleral drainage 
vessel sclerosis. Neurodegeneration and cell death were assessed as a function of IOP 
variables. The effects of ocular hypertension on optic nerve microglia, immune cells, 
astrocytes and nitric oxide synthase (NOS) were determined by qualitative analysis of 
label-specific immunofluorescence
Ocular hypertension induced significant RGC death (P<0.05) and degeneration. 
Significant astrocytic GFAP elevation occurred following initiation of disease 
(P<0.05). Correlation of macrophage and microglial marker alterations indicated 
significant increases in both cell types following the induction of ocular hypertension 
and RGC death (P<0.05). Initial microglial up regulation appeared to be regulated by 
CD200 axis activity. Peripheral immune cells, including B lymphocytes, may have 
infiltrated the optic nerve during late stages of disease. Significant upregulation of 
nitric oxide synthase isoforms 1 and 2 in the optic nerve head, also demonstrated a 
positive correlation with microglial/macrophage increases (P<0.05). NOS3 was not 
upregulated following the induction of ocular hypertension.
Disrupted neuroglial interactions via the CD200 axis are likely to be involved in the 
initial glial response to ocular hypertension. Astrocytic and microglial activation may 
play a role in initiating and maintaining RGC death during chronic glaucoma. The 
production of NOS by these cells, particularly NOS2 by microglia, may serve to 
either promote or prevent optic nerve neurodegeneration.
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Chapter I General Introduction
Chapter I 
General Introduction
1.1 The Human and Rat Optic Nerve
1.1.1 The course and nature of the optic nerve
Despite its relative structural simplicity, the rat optic nerve has anatomic parallels 
with that of humans and other primates. Although optic nerve features are similar 
across species, the rat optic nerve comprises only around 120,000 fibres (Hughes, 
1977) as compared to the 1.1 to 1.3 million fibres of the human and 1.5 to 1.8 million 
fibres of the rhesus monkey optic nerve (Potts et al., 1972a).
The optic nerve is an extension of the central nervous system, beginning at the retina 
as the optic nerve head or disc, and extending to the optic chiasm. On leaving the 
globe, nerve circumference increases due to individual fibre myelination and 
acquisition of a three-layered connective tissue meningeal sheath (Anderson, 1969). 
The optic nerve is devoid of a neurolemmal sheath, unlike peripheral nerves, which 
compromises its regenerative capacity. Damage to the optic nerves, similar to the 
brains white matter, is mostly irreversible (Scharenberg, 1953). The rodent and human 
optic nerves travel through the optic foramen and optic canal to enter the cranium. 
The nerves unite at the sub-thalamic optic chiasm where fibres of the human nerve 
semi-decussate. Semi-decussation is only partial in the rat. Visual fibres then proceed 
as oval bands to the peduncles where they diverge. The vast majority (90%) of human 
visual fibres terminate in the lateral geniculate nucleus (LGN) of the thalamus, while 
only few rat visual fibres project to this region. Some human visual fibres continue to 
the superior colliculi to form the superior brachium (Yamadori and Yamauchi, 1983), 
while the majority of rat visual fibres terminate 
here. Other fibres leave the optic tract before reaching the LGN and terminate in mid 
and hind brain oculomotor centres. The majority of human fibres take the 
retinogeniculocortical pathway as simplified in Figure 1.1.
1
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The Visual Pathway
Optic Chiasm
Loop
Optic Nerve 
Optic Tract
Figure 1.1 The retinogeniculocortical pathway This route is taken by the majority 
o f human retinal neurons from the retina, through the optic nerve to higher brain 
centres. The optic nerve projects from the eye and enters the brain. Partial 
decussation occurs at the optic chiasm, from where the majority o f fibres project in 
the optic tract to the LGN. From here, fibres progress in their optic radiations to 
deliver visual information to higher brain centres in the cortex (Zigmond et al., 2000).
1.1.2 The optic nerve head
The optic nerve head or neck is formed from a coalescence of unmyelinated retinal 
ganglion cell (RGC) axons as they enter the optic disc from the retina. The rat optic 
nerve head has a distinctive architecture (Morrison et al., 1995) and is horizontally 
oval in shape, compared with the more circular human optic nerve head (Anderson 
and Hoyt, 1969). All retinal layers terminate at the optic nerve head, excluding the 
nerve fibre axons, which pass through from ambient intraocular pressure (IOP) to 
lower pressure in the optic nerve (Ernest and Potts, 1968). The inner layer of the optic
2
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disc is concave, forming a physiological cup, lined with residual intraorbital astroglia 
of the limiting membrane of Elschnig (Anderson et al., 1967). Optic nerve axons are 
separated into fascicles by these specialised support astrocytes, which are orientated 
similarly to lamina cribrosa astrocytes (Anderson and Hoyt, 1969; Elkington et al., 
1990; Ogden et al., 1988; Trivino et al., 1996).
1.13 The lamina cribrosa
The collagenous projections of the lamina cribrosa, through which retinal axons pass, 
occupies the optic nerve head almost entirely. The rat equivalent has a conical shape 
with the beginnings of myelination and an almost identical protein content to the 
human lamina cribrosa (Morrison et al., 1995). These similarities are useful in 
modelling human optic nerve disease, including glaucoma.
The human optic nerve becomes divided into bundles at the lamina cribrosa by 10 
successive fenestrated collagen sheets (cribriform layers) projecting from the 
meningeal dural layer (Quigley and Addicks, 1981). The human lamina is shown 
clearly in Figure 1.2. The prominence of the rat lamina cribrosa in terms of 
collagenous material is less than that of the human (Morrison et al., 1995).
Both the neck and transition zone of the rodent optic nerve exhibit transverse vessels 
with wide collagen filled perivascular spaces and astrocytic borders. These 
collagenous structures are ultrastructurally similar to primate lamina beams, and 
consist mainly of collagen types I, III and VI with some elastin (Morrison et al.,
1995). Chondroitin and dermatan sulphate-containing proteoglycans, with collagens I, 
III and VI, make up. the lamina core surrounded by laminin and collagen IV (Morrison 
etal., 1995).
Collagen IV and laminin are produced by astrocytes and vascular endothelial cells of 
the lamina cribrosa, as well as cultured lamina cribrosa cells (Hernandez et al., 1988). 
The specialised supportive lamina cribrosa astrocytes also contain glial filaments 
including glial fibrillary acidic protein (GFAP). The lamina sheets are separated by 
astrocytes, whose processes are perpendicular to optic nerve axons, and directly 
contact the unmyelinated axons by entering the nerve fibre bundles (Anderson, 1969; 
Elkington et al., 1990; Trivino et al., 1996).
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Figure 1.2 The human lamina cribrosa This structure consists o f collagenous 
projections into the nerve which separate the nerve fibre bundles into fasicles. 
Numbered regions: 1, central retinal vessels; 2, intermediary tissue o f Kuhnt; 3, 
border tissue o f Elschnig; 4, anterior lamina cribrosa; 5, posterior lamina cribrosa. 
Abbreviations: Du, dura mater; Ar, arachnoid; Pia, pia mater; GIM, periperal glial 
mantle o f Fuchs; GIC, glial columns; Sep, pial septa. (Anderson and Hoyt, 1969).
The lamina cribrosa provides support to optic nerve axons and protects them upon 
exit from the globe. Collagenous projections into the nerve at the lamina cribrosa 
constitute a threat to ganglion cell survival under conditions of stress. The role of the 
lamina cribrosa in resisting pressure from within the eye may become compromised, 
and give rise to diseases such as glaucoma (Quigley and Addicks, 1981). The site of 
RGC axonal damage in glaucomatous optic neuropathy is indeed the lamina cribrosa 
(Quigley, 1981).
1.1.4 The post laminar region
The optic nerve proper begins posterior to the lamina cribrosa, where individual axons 
become myelinated by oligodendrocytes. Consequently, nerve diameter increases, and
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the measurement or quantification of nerve fibre loss can be performed more easily. 
The supportive framework alters to become pial septae, with similar constituents to 
the cribriform plates of the laminal region. Collagen types I, II, IV and V, laminin and 
fibronectin have all been localised here. Postlaminar regions differ structurally from 
the lamina cribrosa; less compact septae are orientated at right angles to the lamina 
supports (Sawaguchi et al., 1994).
1.2 Glaucoma
1.2.1 Introduction to glaucoma
The glaucomas are a heterogeneous group of optic neuropathies with differing 
pathophysiological mechanisms. All share common characteristics of excessive optic 
disc excavation, accompanied by a specific pattern of retinal ganglion cell (RGC) 
degeneration and loss. Photoreceptors and retinal intemeurons rely on RGCs to 
package and transmit quanta of visual information for use by higher brain structures. 
During glaucoma, RGC death results in a functional deficit over time. Normally this 
deficit is associated with an increased intraocular pressure (IOP), but vascular and 
structural alterations at the optic nerve head can also contribute. Visual field loss 
begins with peripheral vision, advances to the remaining visual field, and eventually 
compromises central vision (Sears, 1979).
1.2.2 History of glaucoma
The first recorded incidence of glaucoma by Sams-ed-Din, a fourteenth century Arab 
physician, described blindness accompanied by pain, immobile pupils and elevated 
IOP. Glaucoma was not described in Europe until the seventeenth century. Sir 
William Lawrence coined the term during the early nineteenth century, and in 1830, 
William Mackenzie associated the disease changes with IOP. Ophthalmoscopy 
enabled the discovery that glaucomatous optic disc cupping, and not disc elevation, 
resulted from IOP elevation (Duke-Elder, 1940).
1.2.3 Diagnosis
The glaucomas can be differentiated between and from other ocular conditions by an 
elevated IOP of over 21 mmHg (which occurs frequently, but not always),
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accompanied by excessive optic disc excavation, and a specific pattern of visual field 
defect. Symptoms such as pain or deterioration of visual function can occur at any 
level from normal vision to complete blindness. However, pathophysiology can begin 
in a preceding asymptomatic phase (Quigley et al., 19821), diagnosed by a nasal step 
in the visual field, a notch in the optic disc, angle pathological signs, or afferent 
pupillary defect (Hitchings and Spaeth, 1976). The presence of pathological signs 
does not always indicate that symptoms will develop further, as although most 
glaucomas are progressive, some are stable (Martinez-Bello et al., 2000).
1.2.4 Forms of glaucoma
Glaucoma can be divided into three primary categories: open-angle, closed-angle and 
congenital, as well as secondary, dependent on the primary defect.
1.2.4.1 Primary open-angle glaucoma
During primary (or idiopathic) open-angle glaucoma (POAG), chronic elevated IOP is 
partly responsible for bilateral optic nerve atrophy with an unknown initiation factor. 
As many as 25% of POAG patients have a normal IOP below 21 mmHg (Sommer,
1996). POAG can be subdivided by optic disc characteristics into focal, diffuse and 
vasospastic glaucoma, and typically has a late onset age. Open-angle glaucoma can 
also be secondary to vasospasm, trauma, and many other factors.
1.2.4.2 Primary angle-closure glaucoma
Narrow anterior chamber angles are associated with primary angle-closure glaucoma. 
Effects of angle-closure include mechanical blockage of aqueous outflow from the 
eye with associated IOP elevation. Inherited in a multifactorial manner, with a late 
onset age, angle-closure glaucoma can be divided into subtypes of acute, subacute and 
chronic. Angle-closure can also occur due to secondary insults such as ocular trauma.
1.2.4.3 Primary congenital glaucoma
Primary congenital glaucoma is an autosomal recessive disease with a higher 
incidence in males. The inheritance rate of primary congenital glaucoma is low, with
6
Chapter I General Introduction
an incidence in siblings of 3-11%. Developmental aberrations in the anterior chamber 
angle, trabecular meshwork, iris and/or ciliary body are responsible for this disease.
1.2.5 Incidence
Glaucoma has serious implications for public health, accounting for 13% of all new 
registrations of blindness annually (Evans and Bird, 1996). Susceptibility to the 
disease depends on age, race and family history. It is estimated that 2% of Europeans 
and around 8% of African-Americans and Affican-Caribbeans over the age of 40 are 
affected (Egbert, 2002), making it the most common cause of blindness for the latter. 
Table 1.1 below shows the incidence of the different types of glaucoma.
Table 1.1 The incidence of glaucoma
Category of glaucoma Proportion of glaucoma patients
Primary open-angle 66%
Primary closed-angle 28%
Primary congenital 1%
Secondary 5%
POAG has the highest rate of occurrence of all the glaucomas in a normal population, 
with an incidence of 0.5%. Acute angle closure glaucoma, the next most prevalent 
form of the disease, has an incidence of 0.1%. Congenital glaucoma has the lowest 
prevalence, occurring in 1 in every 30,000 live births.
1.2.6 Risk factors
Elevated IOP is considered one of the most important predisposing factors to 
glaucoma other than age (Armaly et al., 1980; Wilson et al, 1987). Increased IOP can 
produce many optic nerve alterations, including compromise of vascularisation, 
reduced retrograde transport, and glial scarring (Yucel et al., 1999), all of which may 
contribute to neurodegeneration (Soares et al., 2003). However, IOP varies naturally, 
and glaucoma often occurs in normotensive eyes (Sommer et al., 1991), with the 
majority of hypertensive eyes not developing glaucoma. Despite the importance of
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elevated IOP, predisposition to glaucoma can result from a number of other factors 
(Georgopoulos et al., 1997; Le et al., 2003; Wilson et al., 1987).
Ocular conditions not associated with IOP may render affected eyes more susceptible 
to glaucomatous damage, for example myopia (Georgopoulos et al., 1997; Grodum et 
al., 2001; Le et al., 2003; Perkins and Phelps, 1982). Social factors can also be 
important (Fraser et al., 2001; Wilson et al., 1987). These factors are covered 
comprehensively in Table 1.2.
Table 1.2 Risk factors for glaucoma
Demographic factors Age
Race
Familv history (heredity)
Ocular risk factors Angle configuration
Large cupping of the optic nerve head
Ocular ischaemia
Glaucomatous damage to the fellow eye 
Elevated intraocular pressure 
Myopia
Pigment dispersion 
Exfoliation syndrome 
Angle recession
Systemic risk factors Peripheral vascular diseases 
Hyperviscosity states
Arteriosclerotic and ischemic vascular diseases 
Malnutrition
Hypotension or hypertension 
Diabetes mellitus 
Migraine
Lifestyle Obesity
Lack of exercise 
Smoking
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1.2.7 Aqueous humor dynamics and intraocular pressure
An increased basal IOP is a major treatable risk factor for glaucomatous damage 
(Brubaker, 1996). IOP maintenance is a function of the aqueous humor, the drainage 
and production of which helps maintain globe structure and eye functions. Average 
ocular tensions of 19mmHg for the human (Armaly, 1965) and 15mmHg for the rat 
are considered average normal pressures. Deviation from these levels may be a result 
of increased production and/or limited drainage of the intraocular aqueous.
1.2.7.1 Aqueous humor production
Aqueous is produced at a rate of 2.4 +/- 0.6 pl/hour. Circadian variation reduces 
production during the night for diurnal and during the day for nocturnal species 
(Gharagozloo et al., 1988; Pointer, 1997). Control of aqueous humor diffusion or 
active secretion from the ciliary body is a function of the suprachiasmatic nucleus 
(SCN). The SCN receives a direct retinal projection and belongs to a system 
responsible for circadian timing, to which it is connected by sparse efferent 
hypothalamic projections (Stephan and Zucker, 1972). Coupled oscillator SCN 
neurons form a pacemaker within the core or ventrolateral SCN (Moore et al, 1996).
Core SCN neurons contain vasoactive intestinal polypeptide, calretinin, somatostatin, 
substance P, gastrin releasing peptide (Karatsoreos et al., 2004) and y-amino butyric 
acid (GABA). All may have a role in the complex sympathetic control of circadian 
rhythm. The core SCN receives primary entraining afferents and contains pacemaker 
neurons responsible for circadian oscillations including that of IOP. The sympathetic 
nervous system and p-adrenergic receptors are important in control of these 
oscillations and circadian aqueous flow (Nii et al., 2001). Epinephrine can reduce IOP 
(Wang et al., 2002), and selective p-receptor antagonists can increase aqueous 
production.
1.2.7.2 Aqueous humor drainage
Aqueous humor exits the eye via two main drainage routes. The direct outflow 
pathway accounts for 80% of drainage via the trabecular meshwork, Schlemm’s 
canal, and collector channels into the intrascleral and episcleral venous plexus (Figure
9
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1.3). The uveoscleral outflow pathway allows 10% of indirect outflow, with the 
remaining 10% accounted for by aqueous humor outflow via the iris stroma.
Figure 1.3 The direct aqueous drainage 
pathway The direct outflow pathway that 
accounts for 90% o f aqueous leaving the eye 
is shown to the left. The upper diagram shows 
the eye and subsequent images are o f ocular 
areas with relevance to aqueous drainage. 
The ciliary processes just below the iris 
produces aqueous humor, which travels 
around the iris to rest behind the cornea in 
the anterior chamber. Aqueous is drained 
mainly through the trabecular meshwork 
which lies at the irido-corneal junction. For 
alternative aqueous drainage pathways see 
text fwww.harthosp.org/eyes/ procedures 
/glaucoma.htm).
1.2.7.3 The trabecular meshwork and glaucoma
The posterior trabecular meshwork forms a self-cleaning filter over Schlemm’s canal, 
consisting of a uveal, corneoscleral, and endothelial meshwork. Glaucoma may affect 
this filter, reducing aqueous outflow, and increasing IOP. Plaques of extracellular 
debris around the endothelial meshwork increase in abundance with age, and even 
more so with glaucoma (Rohen, 1983). The cellular component of the trabecular 
meshwork is also decreased with POAG (Alvarado et al., 1984). In advanced 
glaucoma, uveal and corneoscleral meshworks become completely obstructed through
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trabecular beam hyalinisation. Lack of endothelial lining causes the subendothelial 
basement membranes to thicken and fuse. Uveal meshwork trabecular cells also 
become enlarged (Lutjen-Drecoll 1996). Other glaucoma types, exluding juvenile and 
normotensive glaucoma, all have aqueous humor outflow defects contributing to an 
increased IOP (Furuyoshi et al, 1997).
1.2.8 Heredity and genetics
Glaucoma is passed on to a certain degree by inheritance (Georgopoulos et al., 1997). 
First-degree relatives of glaucoma sufferers have a six-fold greater prevalence than 
others (Davies, 1968). However, inherited mutations are not common causes of 
glaucoma (Richards et al, 1998). Various disease attributes can have a genetic 
component, including increased IOP, cup-to-disc ratio, ocular dimensions, as well as 
decreased aqueous humor drainage. Particular forms of glaucoma are associated with 
other diseases or phenotypes, for example diabetes, suggesting inheritance (Le et al., 
2003; Wilson et al., 1987). Genetic markers of glaucoma are not inherited in simple 
Mendelian fashion, and the disease is multifactorial.
For example, myocilin (also known as trabecular meshwork-inducible glucocorticoid 
response protein) is found in RGC axons and astrocytes at the lamina cribrosa (Karali 
et al., 2000). Mutations in this protein are associated with juvenile open-angle 
glaucoma (Sheffield et al., 1993; Wiggs et al., 1994). Elevated IOP upregulates other 
physiologically relevant trabecular meshwork genes; the products suggest a 
homeostatic mechanism in the regulation of aqueous humor drainage similar to the 
regulation of blood vessel permeability (Gonzalez et al., 2000). Elevated genes 
include transcripts for proteins involved in vascular permeability, secretion, 
extracellular matrix remodelling, cytoskeleton reorganisation and reactive oxygen 
species scavengers (Gonzalez et al., 2000).
1.2.9 Treatment
Glaucoma treatments are numerous and varied, as might be expected from such a 
multi-faceted disease (reviewed by Schwartz and Budenz, 2004 and Sung and Barton, 
2004). Despite the high incidence of glaucoma, no treatment exists which can prevent 
or repair the continued RGC loss typical of the disease. At present the most a patient
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can hope for is a delay in the loss of visual field. Similar treatments are used for 
patients with hypertensive and normotensive glaucoma (Goldberg, 2003), as reduction 
of IOP for relatively normotensive eyes is also beneficial. The specific course of 
treatment does vary to some extent with the type of glaucoma.
Pharmaceutical glaucoma treatment most commonly targets reduction of aqueous 
production and secretion in combination therapies. Prostaglandin analogues, such as 
latanoprost, increase uveoscleral aqueous outflow. Alpha(2)-adreonoreceptor agonists 
and beta-adrenoreceptor antagonists can reduce aqueous production by interaction 
with the neuroendocrine epinephrine system responsible for aqueous secretion.
Drug treatments are commonly complemented by surgical treatment when no 
improvements are found. Surgical treatment similarly focuses on IOP reduction. Laser 
trabeculoplasty and filtration surgery are often used to reduce resistance to aqueous 
outflow in the trabecular meshwork or to create a new direct outflow route. These 
procedures will often need to be repeated to sustain IOP reduction.
Less invasive and more effective treatments are sought for the prevention of RGC 
loss, and possible restoration of visual function. New therapeutic strategies need to be 
explored due to surgical side effects (such as loss of vision), and the progression of 
glaucoma despite a reduction in IOP. Once the exact mechanisms of RGC 
pathophysiology during glaucoma are known, it will be much simpler to devise 
appropriate and efficient therapeutics. These will need to be used in conjunction with 
early clinical detection for optimal patient outcome.
1.3 Pathophysiology of the Optic Nerve Head
Glaucomatous degeneration of the optic nerve head is heterogeneous. However, 
damage always affects the retinal nerve fibre layer (NFL) and the visual field. 
Depending on the optic nerve head pathology or type of glaucoma, the NFL is 
targeted in either a focal or diffuse manner.
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1.3.1 Optic disc changes
The optic nerve head is often the first and most commonly affected tissue during 
glaucoma (Quigley and Addicks, 1981) Non-sequential characteristic changes of the 
optic disc occur. Generally these involve an increasingly enlarged physiologic cup, 
which retrogradely displaces the optic disc (Burgoyne et al., 1995), increasing the 
cup-to-disc ratio.
1.3.1.1 Optic disc pallor
The normal optic disc is a pink-orange colour. Disc pallor occurs during glaucoma 
(Tuulonen et al., 1987), indicating that IOP has persistently risen causing capillary 
drop out. Optic nerve damage, and/or neuroretinal rim tissue degeneration can also be 
indicated by pallor (Caprioli and Miller, 1988; Quigley et al., 1982b).
1.3.1.2 Optic cup changes
The optic nerve head surface can become altered in a three-dimensional fashion 
during normal development and glaucoma. Overpass cupping, where the material 
between the inner limiting membrane of Elschnig and the lamina cribrosa are 
destroyed (Hitchings and Spaeth, 1976), and optic cup asymmetry are common in 
glaucoma. Concentric enlargement of the optic cup from loss of neuroretinal rim 
tissue and vertical enlargement due to loss of laminar tissue with a similar cup/disc 
ratio in all axes can be associated with glaucoma (Figure 1.4). Sometimes optic cup 
enlargement includes notching at the superior and inferior poles. During glaucoma the 
optic cup becomes large compared to the total disc size.
1.3.1.3 Vascular changes in and around the optic disc
Optic disc blood vessels can become altered or insufficient in association with 
glaucoma (Cioffi and Sullivan, 1999). Haemorrhages at the outer edge of the 
inferotemporal sector of the optic disc are found in 4 to 7% of glaucomatous eyes 
(Drance et al., 1977; Drance, 1989; Healey et al., 1998). This frequently results in 
localised nerve damage, notching of the disc, or aquired pit of the optic nerve and 
occurs most often in normotensive glaucoma (Airaksinen et al., 1981). Haemorrhage
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may be due to chronic ischemia or to structural optic nerve alterations causing 
damage to blood vessels.
Elevated IOP can compromise normal blood flow producing vascular looping on the 
optic disc and a nasal shift in the optic disc’s blood supply (Jonas et al., 1989). 
Decreased blood flow may also result in dilation of retinal veins and narrowing of 
retinal arteries (Rader et al., 1994). Retinal pigment epithelium and choriocapillaries 
can sometimes deteriorate adjacent to the optic disc (the p zone), which becomes 
enlarged and atrophied during glaucoma. Peripheral to this area, irregular 
pigmentation can occur (the a  zone) in peripapilliary chorioretinal atrophy, 
characteristic of glaucoma.
Normal optic nerve Early glaucom a Advanced glaucoma
Optic d isk
O ptic
nerve
Optic d isk
Optic
cup
Severe dam age
Figure 1.4 Progressive glaucomatous changes at the lamina cribrosa and optic disc 
In the normal optic nerve the optic cup is relatively small, and the lamina cribrosa 
appears straight. The ratio o f rim to disc area is normal. In early glaucoma slight 
enlargement o f the cup, with a reduction in the rim to disc ratio is seen. This is 
accompanied by retrograde bowing o f the lamina cribrosa. In advanced glaucoma the 
lamina cribrosa suffers severe retrograde displacement. The optic cup is typically 
enlarged, and the ratio o f rim to disc is further reduced 
(www. merckfrosst. caI. ../what is/home. html).
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1.3.1.4 Lamina cribrosa
Lamina cribrosa pathophysiology can involve collapse and rotation of the cribriform 
plates due to elevated IOP, leading to crush injury of RGC axons (Quigley et al., 
1981b; Quigley et al., 1982a). Retrograde bowing and degeneration of the lamina 
cribrosa can also occur (Bellezza et al., 2003), which is more likely with increasing 
age (Albon et al., 1995; Albon et al., 2000). This leads to increased optic cup depth 
(Figure 1.4). During glaucomatous degeneration the lamina pores become visible and 
compressed due to elevated IOP and death of nerves (Maeda et al., 1999).
1.3.2 Visual field loss
A characteristic pattern of visual field loss is followed during glaucoma (Quigley et 
al., 1982a). Visual acuity remains unaffected, and early detection of the disease can 
be difficult. Visual field degeneration begins as general or localised, eventually 
becoming advanced. During ocular hypertension loss of vision begins in the 
periphery, and progresses eventually to the central vision. However, in normotensive 
glaucoma central defects can precede those of the periphery.
1.3.2.1 Generalized visual field defects
Generalised decreased sensitivity to visual stimuli can often occur early in glaucoma 
and other forms of visual degeneration due to diffuse loss of RGCs. Asymmetric 
visual field loss occurs frequently during glaucoma, for example in hemifield 
asymmetry where the extent of optic disc damage varies between superior and inferior 
poles. Characteristically, the upper nasal quadrant of the field is first affected, and the 
last area to remain unaffected in advanced glaucoma is the temporal inferior visual 
field (Ferandez et al., 1993).
1.3.2.2 Localised visual defects
The first detectable localised glaucomatous defect is acute scotoma, when arcuate (or 
bow shaped) RGCs have suffered damage resulting in insensitivity to stimuli. Damage 
then progresses to the superonasal periphery, followed by inferior arcuate scotoma 
and then damage to the inferonasal periphery (Kitazawa and Yamamoto, 1997).
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1.3.2.3 Advanced field loss
Advanced visual field loss or tunnel vision involves preservation of only central 
and/or temporal vision, with complete loss of vision in the periphery. Eventually 
central and temporal vision will be lost, should the disease remain and persist 
untreated.
1.3.3 Retinal nerve fibre defects
RGC axons, astrocytes, blood vessels and Muller cell processes comprise the retinal 
NFL, where abnormalities associated with glaucoma may occur. It is proposed that 
larger diameter RGC axons localised in the majority to superior and inferior retinal 
poles degenerate more quickly than smaller diameter axons, possibly due to less 
resistance to ischemic damage or IOP (Yablonski and Asamoto, 1993).
Defects in the NFL can appear as small, narrow slits or grooves, which extend to the 
optic disc margin. Peripherally enlarged wedges of the disc (Jonas and 
Papastathopoulos, 1996; Quigley, 1987), represent areas of localised nerve damage, 
and often occur as a result of haemorrhage. The glaucomatous NFL also suffers 
diffuse atrophy frequently accompanied by concentric enlargement of the optic cup 
and reduced retinal sensitivity. Loss of neuroretinal rim, including retinal nerve fibres, 
can be diffuse and affect any sector of the optic disc, appearing as notching or 
acquired pit of the optic nerve (Jonas and Papastathopoulos, 1996).
The presentation of NFL defects depends on the stage of glaucoma (Javitt et al., 
1990). Normally, defects do not occur until the rim tissue is less than 0.5 as part of the 
rim/disc ratio (Jonas et al., 1988) and then correlate with the pattern of visual field 
loss.
1.4 Mechanisms of Retinal Ganglion Cell Death
1.4.1 Introduction
Glaucomatous degeneration coincides with considerable loss of RGCs, normally via 
apoptosis (Kerrigan-Baumrind et al., 2000). Subsequent to initial damage and primary 
RGC loss, secondary damage occurs, which may be initiated by factors separate to
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those involved in primary loss (Schwartz et al., 1996). RGCs normally respond to 
injury with a low regenerative capacity. Thus there is virtually no return of function 
following degeneration.
1.4.1.1 Elevated intraocular pressure
Elevated IOP is a major risk factor for glaucoma. However, other disease features 
may define the role of IOP during initiation and chronic RGC degeneration. These 
other factors, such as vasospasm or mechanical properties of the lamina cribrosa, may 
also have a role during initiation of cell death. During chronic glaucoma, RGC 
degeneration continues despite reduction of IOP to normal levels, indicating that other 
factors may be involved in secondary degeneration (Brubaker, 1996; Cockbum et al., 
1983). This is supported by a similar loss of RGCs during normotensive glaucoma.
1.4.2 Axonal transport blockade
Axoplasmic transport involves bi-directional organelle and metabolite movement 
along the axon. Both orthograde and anterograde components, as well as fast and slow 
phases can become blocked during glaucoma. The degree of axonal blockage can be 
correlated with duration and magnitude of IOP elevation (Johansson, 1983; 
Samuelson and Spaeth, 1983). However, axoplasmic obstruction has been found in 
some normotensive, low perfusion pressure eyes, and it does not always occur in 
conditions of high IOP or ischaemia (Sugiyama et al., 1995; Cincaglini, 2001).
The lamina cribrosa is the anatomical barrier between the IOP and subarachnoid 
pressure that commonly becomes obstructed when axoplasmic transport is blocked 
(Quigley et al., 1981i). Pressure gradient alterations distort the lamina cribrosa beam 
structure leading to mechanical axonal injury and accumulation of mitochondria and 
microvessels (Minckler and Spaeth, 1981; Yablonski and Asamoto, 1993). Axons at 
the periphery of a bundle are more likely to suffer damage, as are bundles at the poles 
of the disc. These areas are populated by arcuate fibres, which are therefore more 
likely to suffer initial damage (Fizgibbon and Taylor, 1996; Quigley and Anderson, 
1977).
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1.4.3 The neurotrophin hypothesis
The neurotrophins are polypeptide growth factors involved in development, 
differentiation and survival. Neurotrophins signal through either tyrosine kinase (trk) 
or p75 receptors. Trk A, B and C bind specifically to different neurotrophins, while 
p75 binds is non-neurotrophin specific. Normally, neurotrophic factors, produced by 
the LGN and superior colliculus (SC), travel retrogradely to RGC bodies. The RGC 
response to neurotrophins is likely to be modulated by astrocytes and lamina cribrosa 
cells through paracrine signalling (Lambert et al., 2001).
The axonal transport blockade leads to deprivation of neurotrophins and RGC death 
from lack of neurotrophic support (Quigley and Anderson, 1977). This is thought to 
involve specific and sequential changes in receptor and neurotrophin distribution at 
the optic nerve head, RGCs, LGN and superior colliculus. The temporal response to 
IOP indicates that cessation of neurotrophin transport should be considered, amongst 
other pathological factors, to contribute to RGC death (Johnson et al., 2000). 
However, neurotrophic support is not the only or principal factor involved.
Neurotrophin-3, neurotrophin4/5, nerve growth factor, ciliary-derived neurotrophic 
factor and fibroblast growth factors are neuroprotective, and reduce apoptotic death of 
RGCs previously deprived of neurotrophic factors (Quigley et al., 1995). However, 
RGC supporting growth factors can compensate for each other (Cellerino et al., 
1997). If a particular neurotrophin is present in the cell, it will compensate for the loss 
of another due to redundancy among the neurotrophin family. Also, the Trk B 
receptor is not essential for adult neuronal survival (Rohrer et al., 2001). The effect of 
neurotrophin deprivation is therefore unlikely to be the primary cause of damaging 
glaucomatous changes (Nickells, 1996).
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1.4.4 Vascular factors and ischemia
Disturbance of vascular circulation is involved in RGC death in glaucoma. Decreased 
blood flow, or low blood pressure and its consequences are important predisposing 
factors frequently associated with glaucoma (Johnson and Matsumoto, 2000). 
Decreased blood pressure in the retina, leading to ischaemic damage is responsible for 
disease pathology, particularly in normal-tension glaucoma (Drance et al., 1973; 
Gasser, 1999). Reduced blood flow in the choroid and optic nerve head can also 
produce damage (Wolf et al., 1993).
1.4.4.1 Endothelin in vasospasm
Endothelin-1 levels are important in maintaining vascular tone. During normotensive 
and hypertensive glaucoma endothelin-1 levels are increased (Michaelson, 1996; 
Tezel et al., 1997). This promotes vasoconstriction in the ocular circulation, 
particularly at the optic nerve, resulting in ischaemic damage. This vasospasm is 
thought to be localised to ciliary or choroidal vessels, and can be prevented by 
calcium-channel blockers (Toriu et al., 2001), which also improve the visual field. 
These antagonists are believed to prevent the normal response to endothelin-1, but 
various other factors could be involved due to the complex physiology of calcium 
channels, and the many different causes of glaucoma. Also, astrocytes synthesise and 
are targets for endothelin-1, and thus endothelin levels may affect their proliferation 
in glaucoma (Prasanna et al., 2002; Ripodas et al., 2001).
1.4.4.2 Ischaemia
Evidence suggests that ischaemia participates in prevention of axoplasmic transport 
and subsequent RGC death, during increased IOP (Luo et al., 2001). Optic nerve head 
ischaemia in experimental hypertension can produce morphological alterations in 
RGCs. These changes include accumulation of organelles in the lamina region, and 
swelling of axons at the optic disc. Attempts to prevent ischaemia under conditions of 
elevated IOP do not alleviate axonal blockage (Hayreh et al., 1979). Therefore, it is
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likely that other factors are more paramount in the prevention of axonal transport 
during glaucoma.
Haemodynamics can contribute to optic nerve head damage independent of the IOP 
level. The role of chronic or acute ischaemia in the glaucomatous axonal transport 
blockade is uncertain, and may involve excitotoxicity or free-radical damage. It is 
possible that neurotoxins such as nitric oxide (NO), released during ischaemia, are 
involved in cell death.
1.4.5 Excitotoxicity
Glutamate is an excitatory amino acid neurotransmitter, which is excitotoxic at high 
concentrations. Glutamate is likely to be the excitatory neurotransmitter used by 
RGCs, and it also has a role in neuronal plasticity and survival (Kleinschmidt, Bear 
and Singer, 1987; Lipton and Kater, 1989). Glutamate from damaged neurons can 
accumulate in the synaptic cleft to a toxic concentration during growth factor 
deprivation, hypoxia, ischaemia or excitotoxicity. Excess activation of N-methyl-D- 
aspartate (NMDA) receptors by increased glutamate results in over-stimulation of 
calcium channels; intracellular calcium concentration elevates, and overloads the cell. 
Apoptosis of RGCs can be caused by the neurotoxicity of excess glutamate (Varma 
1996). However, survival is improved by the presence of retinal glia, particularly 
Muller cells as well as NMDA receptor inhibition (Kitano, Morgan and Caprioli, 
1996). Muller cells are thought to have a role in excitatory signalling in the normal 
retina (Rauen et al., 1998). It is likely that the protective action of these cells is 
mediated through the glutamate receptor GLAST-1, which has a high affinity for 
glutamate (Rauen et al., 1998).
Toxic levels of glutamate have been shown in monkey and human glaucoma in the 
optic nerve (Dreyer et al., 1996). Glutamate-mediated excitotoxicity may also be 
involved in other central disorders such as stroke. However, prevention of 
excitotoxicity through NMDA receptor antagonism is not an effective neuroprotective 
strategy following stroke. This may be due to the interference with normal neuronal 
signalling as well as the induction of excitotoxicity very early in disease (reviewed by
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Hoyt et al., 2004; Ikonomidou and Turski, 2002). Therefore, this type of intervention 
following glaucoma should be approached with caution.
1.4.6 Neurodegeneration
Following lethal insult to the RGC, death will ensue via processes typical of classical 
neurodegeneration in a retrograde manner (Richardson et al., 1982). This includes 
Wallerian degeneration, the chromatolytic reaction and apoptosis or necrosis.
1.4.6.1 The pattern and rate o f neurodegeneration
Neurodegeneration typically begins in the superior retina during rodent experimental 
glaucoma, indicated by reduction of neurotrophins and loss of RGCs (Johnson et al., 
2000). The superior retina is the focus of RGC damage, with other areas becoming 
affected only in severe cases (Johnson et al., 2000). RGC degeneration is detectable 
twenty hours after the induction of elevated IOP in rodent experimental glaucoma 
(Naskar et al., 2002), and continues at a rate whereby 4% o f cells are lost per week 
(Laquis et al., 1998).
1.4.6.2 Wallerian degeneration
Axotomy involves transection of axons by either cutting or crushing (Wall, 1979), for 
example, when the damaged lamina cribrosa crushes optic nerve fibres. Axons distal 
to the site of injury slowly degenerate due to detachment from the cell body. 
Neurotransmission is prevented, myelin is degraded and surrounding glia are affected. 
Phagocytic peripheral macrophages and glial cells eventually remove fragmented glia 
and axonal remains from the degenerating nerve (Lassmann et al., 1978; Ling, 1989; 
Mueller et al., 2003; Shen and Liu, 1984). This process is called Wallerian 
degeneration and proceeds in a protracted retrograde manner (Liu et al., 2000; 
Richardson et al., 1982).
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1.4.6.3 Chromatolysis
After injury, the proximal RGC axon and cell body show features typical of the 
chromatolytic reaction (Gennarelli et al., 1989; Maxwell et al., 1994; Shibuya et al.,
1993). Chromatolysis involves a sequential set of changes occurring in the 
perikaryon, beginning with swelling, eccentric positioning of the nucleus, and 
fragmentation of rough endoplasmic reticulum. These changes are accompanied by 
metabolic alterations including an increase in protein and RNA synthesis as well as 
altered gene expression. Survival of chromatolysis normally occurs at a high rate in 
peripheral nerves in stark contrast to the neurons in the central nervous system 
(Ahmed et al., 2001), including the optic nerve (Kermer et al., 2001).
1.4.6.4 Apoptosis and Necrosis
Neuronal death in disease is usually via apoptosis or necrosis. Apoptosis is an active 
process involving induction of certain genes, and is the most common form of cell 
death (Schulze-Osthoff et al., 1998). However, some neurodegenerative diseases 
involve nerve death via neither of these routes, for example, Huntington’s disease 
(Turmaine et al., 2000).
Apoptosis classically begins with a reduction in ATP levels, DNA fragmentation and 
condensation of chromatin at the inner nuclear envelope to fill the nucleus, and cell 
shrinkage. The cell degrades into small membrane-bound vesicles. Neighbouring cells 
phagocytose cellular remains without causing an immune response. Necrosis involves 
swelling of the cell, disruption of membrane integrity and DNA fragmentation. Unlike 
apoptosis, cellular contents are released into the surrounding area, eliciting an 
immune response. Most often the process of cell death will follow an intermediate 
route between apoptosis and necrosis (Nicotera et al., 1997; Bonfoco et al., 1995).
Apoptosis, or programmed cell death is the likely pathway of neuronal loss in 
glaucoma. Similarly optic nerve transection induces loss of 80-90% of RGCs within 
14 days. In the majority, death is via apoptosis, with necrosis occurring to a lesser 
extent (Kermer et al., 2001).
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1.5 Animal Models Used to Study Retinal Ganglion Cell Death
1.5.1 Introduction
Research into the precise mechanisms of glaucomatous damage to RGCs has 
progressed with the development of appropriate and suitable laboratory animal 
models in which to study this phenomenon. Various animal models of glaucoma exist, 
which utilise a range of species and techniques. The main focus of experimentally 
induced glaucoma involves rat and primate models developed to assess the effect of 
high IOP on optic nerve axonal damage. These models can be used to investigate 
therapeutic measures for preventing such damage.
1.5.2 Animal models of ocular hypertension
Models of ocular hypertension provide insights on optic disc cupping 
pathophysiology and optic nerve degeneration found in human glaucoma (Sawada and 
Neufeld, 1999). Considerable evidence exists to this effect. For example, information 
on lamina cribrosa distortion, axonal transport blockade and neurotrophin deprivation 
(Johnson et al., 2000) has been supplied by such models. Axoplasmic transport is 
blocked following hypertension in the optic nerve many glaucoma models including 
mammals and primates (Quigley and Addicks, 1980). Rodent and primate models are 
the most widely used and where possible findings are compared to and confirmed in 
human eyes.
1.5.2.1 Primate experimental glaucoma
The monkey eye and optic nerve are very similar to that of the human. Costly primate 
glaucoma models are particularly informative, and well suited to pharmaceutical 
testing.
Methods for the induction of elevated IOP in primates include injection of a- 
chymotrypsin into the posterior chamber. Chymotrypsin causes lysis of zonular fibres 
which blocks the trabecular meshwork, minimising drainage from the eye (Chee and
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Hamasaki, 1971). More commonly, laser-induced chronic IOP-dependant primate 
glaucoma is induced by laser scarification of the trabecular meshwork (Carter- 
Dawson et a l, 2002; Lam et a l, 2003; May et a l, 1997; Pederson and Gaasterland, 
1984; Radius and Pederson, 1984; Wang et a l, 1998). Trabecular meshwork outflow 
can also be compromised by the injection of sterile latex microspheres into the 
anterior chamber (Weber and Zelenak, 1991).
In primate experimental glaucoma, as in the human disease, elevated IOP can result in 
axonal transport blockade and consequent nerve damage (Anderson and Davis 1974; 
Quigley and Addicks, 1980), including alterations in viability and size of both the 
axon and soma (Lampert et a l, 1968; Weber et a l, 1998). Primate models also 
exhibit glial changes in the prelaminar region (Furuyoshi et a l, 2000), 
oligodendrocyte degeneration, phagocyte increase, and astrocyte activation (Varela 
and Hernandez, 1997; Lampert et a l, 1968). Neuronal loss extends to the LGN and 
primary visual cortex (Vickers et a l, 1997; Yucel et a l, 2003). Primary visual cortical 
plasticity can also be affected (Lam et a l, 2003a).
1.5.2.2 Lapine glaucoma models
Rabbit glaucoma models are not commonplace due to low structural prominence of 
the lamina cribrosa, myelination of the retinal nerve fibre layer and a lack of central 
retinal vasculature (Sugiyama et al., 1992). IOP-lowering drugs and the pathways of 
aqueous control are investigated in the rabbit. Ocular hypertension can be induced in 
the rabbit using laser-induced trabecular meshwork photocoagulation with consequent 
size-dependent RGC death. However, the absence of NFL loss in early disease means 
that NFL thickness cannot be used as an accurate diagnostic measure of glaucoma in 
this model.
15.2.3 Murine models and genetics
The potential genetic causes and molecular pathways of glaucomatous degeneration 
can be elucidated using mouse glaucoma models (John et al., 1999). Screening and 
characterisation of glaucomatous mouse strains with various phenotypes have helped
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to improve our understanding of glaucoma despite the lack of a lamina cribrosa (May 
and Lutjen-Drecoll, 2002).
In particular inbred AKXD-28/Ty and DBA/2J mouse strains are affected by inherited 
glaucoma (Anderson et al, 2001; John et al., 1998). Both strains develop IOP-induced 
age-related glaucoma with optic nerve damage and RGC degeneration (Anderson et 
al., 2001). DBA/2J is genetically very homogenous, allowing extremely accurate 
assessment of glaucoma-associated phenotypes.
1.5.2.4 Modelling glaucoma in the rat
The rat optic nerve is similar in structure to that of the human, unlike other rodents, 
such as the mouse (May and Lutjen-Drecoll, 2002; Morrison et al., 1995). 
Consequently the rat is useful in studies of glaucoma. This is supported by the fact 
that experimentally elevated IOP in the rat produces changes homologous to those 
found in human glaucoma (Johnson et al., 1996; Johnson et al., 2000).
The most recent glaucoma model in the rat consists of chronically developing 
inherited glaucoma. Royal College of Surgeons rats have been bred to produce the 
only high incidence rat strain with genetically elevated IOP and other glaucoma 
symptoms (Thanos and Naskar, 2004). As POAG has the highest incidence of all the 
glaucomas, models of this form of the disease are preferred to the less clinically 
relevant spontaneous and secondary glaucoma models.
Experimental glaucoma can also be induced in the rat by translimbal laser 
photocoagulation of the trabecular meshwork (Levkovitch-Verbin et al, 2002). Laser 
photocoagulation can be preceded by injection of India ink into the anterior chamber 
(Ueda et al., 1998). This is often performed on albino rats, whose RGC survival 
following injury may be compromised through lack of melanin (LaVail and Gorrin, 
1987). Despite drawbacks in terms of expense, this model is useful for the production 
of ocular hypertension-induced RGC death, and produces a measurable functional 
deficit (Grozdanic et al., 2004).
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Injection of S-antigen into the anterior chamber of the rat eye is also used to produce a 
glaucoma model (Mermoud et al.,- 1994). This model has' some severe drawbacks 
including the invasive nature of the anterior chamber injection. The immune reaction 
caused by S-antigen injection and the resulting uveitis are not representative of human 
glaucoma. However, a sustained IOP elevation of around 75% can be maintained for 
up to 20 days using this method (Mermoud et al., 1994).
More commonly, uniocular hypertension is produced in rats by cauterisation of limbal 
aqueous drainage veins (Garcia-Valenzuela et al., 1995; Sawada and Neufeld, 1999). 
The degree of ocular hypertension is proportional to the number of veins occluded; 
hence single vein cautery will produce mild (1.5-fold) elevation (Neufeld, 1999), 
while cauterisation of two or more veins results in at least a 2-fold increase in IOP 
(Garcia-Valenzuela et al., 1995). The ability to manipulate the magnitude of pressure 
increase is a desirable feature of ocular hypertension models. Also favourable are the 
technical simplicity and the reliable increase in IOP. However, cauterisation of the 
limbal veins limits venous blood return from the eye. It is likely that vascular 
congestion affects IOP (reviewed by Goldblum and Mittag, 2002).
Direct unilateral injection of mild sclerosants into the aqueous humor outflow 
pathway can be used to increase IOP in inbred Norwegian brown rats (Morrison et 
al., 1995). Mild sclerosants collapse a single aqueous drainage vessel and impede 
aqueous humor outflow, resulting in IOP elevations from 7 to 20 mmHg above 
control eye pressure. Sclerosant injections were repeated if unsuccessful, or IOP was 
reduced over time. Chronic primary glaucoma was modelled by increasing IOP by 10 
-  20mmHg for three weeks, or more than 20mmHg for one week. These animals 
exhibited degeneration throughout the optic nerve, with veiy few axons appearing 
normal. Extracellular matrix components were deposited at the optic nerve head in 
plaques similar to human glaucoma, and axoplasmic transport was affected (Johnson 
etal., 1996).
This model minimises circadian flux of IOP to prevent distortion of experimental 
results. Normal IOP varies from 21 mmHg in the light to 31 mmHg in the dark in 
animals subjected to a normal 12:12 lightidark cycle. The peak of IOP during the dark
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phase of the circadian cycle, and the compromise of aqueous drainage, would result in 
the greatest modulation of IOP following treatment occurring during the night. 
Constant light introduced for a minimum of three days in this model ensures 
elimination of circadian control of IOP. Consequently IOP could be reliably measured 
at any time.
In the glaucoma model developed by Morrison et al. (1995), experimental ocular 
hypertension can be induced with various degrees and durations of pressure elevation 
to emulate primary open angle glaucoma, the most common form of the human 
disease. Changes observed in this model correspond to degeneration observed in 
human glaucoma studies (Johnson et al., 2000).
1.6 Biochemical and Cellular Changes During Glaucoma
1.6.1 Extracellular matrix
The lamina cribrosa is the region most studied in terms of extracellular changes 
during glaucoma. The lamina cribrosa undergoes considerable changes during the 
disease process, as well as throughout normal ageing (Albon et al., 2000; Albon et 
al., 1995; May, 2003; Quigley et al., 1994). The normal lamina cribrosa extracellular 
matrix (ECM) is structurally supportive, elastic and is thought to provide nutrients for 
RGCs.
During glaucoma, the collagenous composition of the cribriform plate is reduced, and 
fibre number is decreased. Collagens I, III, IV, VI, laminin, chondroitin and dermatan 
suphate proteoglycans occupy the areas left vacant by nerve fibre loss (Johnson et al., 
1996). Collagen type VI increases, due to glial activation (Aguayo et al., 1991; 
Johnson et al., 2000). Elastin fibres become fragmented, disorganised and form 
plaques of nonfibrillar elastic-like material (Quigley et al., 1994). In more severe 
glaucoma, extensive loss of elastin fibrils is seen.
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These changes alter the mechanical properties of the lamina cribrosa, and may be 
involved in predisposing the lamina cribrosa to pressure-related changes, or be a 
consequence of these changes (Burgoyne et al., 2004). Structural, vascular and axonal 
alterations may all be related, primarily or secondarily, to glial changes (Fitch and 
Silver, 1997; Hernandez and Condes-Lara, 1992).
1.6.2 Glial cells
Glia are most prominent in the myelinated retrolaminar optic nerve where they may 
be involved in glaucomatous degeneration that is slightly different to prelaminar 
degeneration (Furuyoshi et al, 2000). There are two major divisions among glia: the 
macroglia (oligodendrocytes and astrocytes) and microglia. Oligodendrocytes are 
present only in the retrobulbar optic nerve. Astrocytes and microglia can be found in 
the majority at the optic nerve head, as well as dispersed in low numbers throughout 
the retrobulbar nerve in glial columns between the nerve fibre fascicles (Varela and 
Hernandez, 1997). In cell culture of the nerve head, lamina cribrosa cells of an 
undetermined phenotype are also present (Hernandez et al., 1988).
Changes in oligodendrocytes, increases in microglia, as well as activation of 
astrocytes and microglia have been described in glaucoma models (Lampert et al, 
1968). Glia surrounding optic nerve axons also influence the regenerative capacity of 
the nerve depending on the production of factors from mature oligodendrocytes, 
astrocytes and microglia (Aguayo et al, 1991). Glial alterations are also important in 
other central nervous system disorders. For example, the 6-hydroxydopamine 
pathway involved in Parkinson’s disease is modulated by astrocytes and microglia 
(Rodrigues et al 2001). Multiple sclerosis (reviewed by Carson, 2002), Alzheimer’s 
disease, gliomas and aquired immunodeficiency syndrome (AIDS) dementia all 
involve reactive gliosis.
Decreased axonal density following laser-induced chronic glaucoma in primate 
studies coincides with glial expansion and the stress response, indicated by increased 
immunoreactivity to glial fibrillary acidic protein (GFAP), vimentin and aB- 
crystallin. Neuronal tissue is partially replaced with non-proliferative glia (Quigley et
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al., 1980; Quigley et al. 1981a), and collapsed connective tissue (Johnson et a l, 
1996). Glial changes during glaucomatous neurodegeneration are similar to the 
changes seen during typical Wallerian degeneration (Furuyoshi et al., 2000).
1.6.2.1 Astrocytes
Astrocytes are the major cellular component of the optic nerve head, and have an 
extremely important supportive role. They envelop retinal axons immediately 
posterior to the perikaryon (Stone et al., 1995), and provide a suitable extracellular 
environment through maintenance of ionic balance and removal of glutamate 
(Waniewski and Martin, 1986; Farinelli and Nicklas 1992; Swanson, 1992; Ranson et 
al., 1997) as well as neurotrophic support (Gross et al., 1998). Astrocytes are 
connected through gap junctions with neurons (Cotrina et al., 2001; Ramirez et al., 
1996; Quigley and Anderson, 1977; Quigley, 1977), which allow them to buffer 
extracellular calcium and potassium ions to maintain extracellular conditions (Lee et 
al., 1994).
At the choroidal lamina, astrocytic processes form tubes through which axons of 
RGCs can pass (Trivino et al., 1996). Astrocytes have a role in maintaining structural 
elements of the mature optic nerve head (Trivino et al., 1996). Laminar beams are 
juxtaposed to astrocytes, which produce the core collagen and elastin of the beams 
(Hernandez and Ye, 1993). Astrocytes have the capacity to remodel the laminar 
region and consequently affect axonal function. The role of the astrocyte in glaucoma 
may stem from sensitivity to mechanical or ischaemic injury combined with 
resistance to degeneration from these insults (Trivino et al., 1996).
Type 1 astrocytes can be subdivided into two types. Type IB astrocytes express both 
GFAP (Figure 1.5) and neural cell adhesion molecule (N-CAM), and are the 
predominant astrocyte at the optic nerve head, where they function as a physiological 
intermediate between connective and vascular elements (Ye and Hernandez, 1995). 
Type 1A astrocytes do not express N-CAM, but are GFAP-positive (Ye et al., 1995), 
their role is predominantly as a supportive structure (Ye and Hernandez, 1995).
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Astrocytes are joined at the optic nerve head by GFAP-negative lamina cribrosa cells, 
which are thought to have a similar supportive role (Hernandez et al., 1988).
Figure 1.5 Astrocytes labelled fo r  GFAP Astrocytes are stellate shaped cells with 
multiple dendritic processes. All astrocytes express GFAP, which has been used here 
to label them with a green fluorescent signal (Image taken from Giuliani et al., 2003).
During glaucoma, activated astrocytes exhibit a denser GFAP distribution (Furuyoshi 
et al., 2000; Trivino et al. 1996; Varela and Hernandez, 1997; Wang et al., 2002) and 
form a glial scar (Yucel et al., 1999). Type 1A astrocytes cannot be found in the 
glaucomatous optic nerve head (Varela and Hernandez, 1997). GFAP elevation may 
be associated with both neuroprotective and neurodegenerative mechanisms (Lam et 
al. 2003 ; Privat, 2003). For example, synthesis of neuroprotective small heat-shock 
proteins (Tezel et al., 2000; Salvador-Silva et al. 2001; reviewed by Tezel et al., 
2004') and increased transforming growth factor (TGF) as well as p cytokine 
production, which may contribute to microglial activation. The glial scar however,
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forms a physical barrier to neuroregeneration. Activated astrocytes are antigen- 
presenting cells, the implications of which are not fully understood for glaucoma 
(Yang e ta i,  20012).
Changes in optic nerve astrocyte activity can be altered in models of glaucoma to 
prevent RGC death (Neufeld, 1999), for example, by decreasing the production of 
cytotoxic microglial activation molecules. The astrocyte-axon relationship is currently 
being studied to understand the initiation of RGC death, and could be modulated to 
prevent RGC death in glaucoma.
1.6.2.2 Microglia
Microglia are residents of the central nervous system, which migrate and mature in 
nervous tissue during development. The normal optic nerve is scattered with a 
population of OX42-positive quiescent dendritic microglia (Lam et al., 2003 ). 
Following injury, the immune response of the central nervous system is mediated by 
activated microglial cells. Infiltrating blood monocytes are also involved depending 
on the nature and strength of the insult (Graeber et al. 1998; Kreutzberg, 1996; 
Mueller et al., 2003; Streit et al. 1988).
Normally microglia are quiescent, but rapidly become activated following insults, 
such as presentation with bacterial lipopolysaccharide (LPS) and interferon-y (IF-y) 
(Bouscein et al. 2000). Activation of microglia involves morphological alterations 
(Figure 1.6), migration, proliferation and changes in cell surface markers, including 
MHCII and CD45 (Neufeld, 1999), as well as OX41 (Rao et a/, 2003). However, 
0X42 expression is preserved in both quiescent and active optic nerve microglia 
(Lam et al., 20032). Changes during activation render resident phagocytic microglia 
almost indistinguishable from infiltrating macrophages (Raibon et al 2002; Rao et al, 
2003). It is therefore extremely difficult to determine the role of central and / or 
peripheral immune systems during neurodegeneration (reviewed by Guillemin and 
Brew, 2004).
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Figure 1.6 Microglial morphology Resting microglia are dendritic cells (a). 
Following activation signals microglia can become elongated in preparation for 
migration (b). Activation continues with reduction in dendritic field (c) followed by 
thickening o f processes (d). Eventually activated microglia become amoeboid and 
phagocytic (e, after Streit et al., 1999).
Activated microglia are present in the glaucomatous retina and optic nerve head 
following the initiation of apoptosis (Naskar et al., 2002). Chronic activation of 
microglia as a result of glaucoma has been reported in the retina (Naskar et al., 2002). 
Following clinical glaucoma, microglia are present in the optic nerve head in areas of 
peripapilliary chorioretinal atrophy (Neufeld, 1999). However, studies of the optic 
nerve head in experimental glaucoma only extend to 14 days post-induction of ocular 
hypertension (Lam et al., 2003b).
The role of microglia during glaucoma is uncertain. There is evidence to suggest that 
they perform a scavenger function by engulfing axonal debris, but are not involved 
during the initiation of disease (Garcia-Valenzuela and Sharma, 1999; Naskar et al.,
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2002; Schuetz and Thanos, 2004). However, once activated, microglia are capable of 
producing neurotoxic and inflammatory factors, which could mediate secondary 
neurodegeneration, or “bystander” damage (Banati and Graeber, 1994; Gehrmann et 
al., 1995). Microglial protease inhibition and administration of non-steroidal anti­
inflammatory agents prevent microglial activation, and in combination, are efficient at 
neuroprotection of the RGC and improving cell survival (Thanos and Thiel, 1991).
Activated microglial cells are capable of a full immune response. This response 
includes phagocytosis and production of neurotoxins, such as NO (reviewed by Banati 
et al., 1993). Microglial toxins are released into the normally supportive extracellular 
matrix (ECM), encouraging apoptotic cell death of surrounding neurons (Kawahara et 
al. 2001; Takeuchi et al., 1998). The production of toxins by these cells affects the 
ECM during glaucoma and development to negatively regulate growth or regeneration 
of optic nerve axons. Deprivation of neurotrophic factors is considered to be equally 
important in regulating RGC survival following insult (Thanos and Thiel, 1991). As is 
disruption of oligodendrocyte-mediated myelination of the optic nerve proper.
1.63 Neuroglial interactions
Unsurprisingly, due to the anatomical proximity of glia and axon at the optic nerve 
head, during glaucoma it is possible that neuroglial interactions become disturbed. 
This may be through loss of neurons or activation of glia. There are many neuroglial 
signalling pathways that are known to be disrupted during chronic neurodegenerative 
diseases. These include CD45 interactions in multiple sclerosis, and the CD200 axis 
during retinal inflammation (Dick et al., 2003).
1.6.3.1 The CD200 axis
CD200 (OX2) is a 41 to 47 kd membrane-bound immunoglobulin found on neurons, 
activated T cells, B cells, follicular dendritic cells and endothelium (Dick et al., 2001; 
Wright et al., 2001). Retinal CD200 is localised to neurons and vascular endothelium. 
The CD200 receptor is found only on myeloid cells, including microglia, and has a 
similar structure to CD200 with a more extensive intracellular signalling domain
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(Preston et al., 1997; Wright et al, 2000). The distribution of CD200 and the CD200 
receptor are similar across species (Wright et al, 2001).
CD200 down-regulates myeloid cell activation through its receptor (CD200R). This 
potentially involves interactions between microglial cells and neurons (Gorczynski et 
al., 2001). The CD200:CD200R interaction regulates microglial activation in the 
murine retina (Broderick et al., 2002) and can prevent damaging autoimmunity during 
retinal inflammation (Dick et al., 2003). However, CD200 knockout mice show 
normal myeloid cell morphology, increased microglial numbers, and increased 
inducible nitric oxide synthase (NOS2) immunoreactivity (Broderick et al., 2002; 
Dick et al., 2003). CD200 interactions are shown in Figure 1.7.
Figure 1.7 The CD200 axis The CD200 axis involves interaction between neurons 
and microglia, as well as microglia:microglia interactions. Disruption o f the CD200 
axis involves dissociation o f the CD200 receptor from the non-signalling ligand. The 
receptor is then free to signal, resulting in microglial activation.
Resting
microgliaCD200
RGC axon CD200L
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microglia
CD200
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1.6.4 Immune cell reaction
Evidence suggests that the immune system is more active in glaucoma patients than 
the normal population (Cartwright et al., 1992; Nagasubramanian et al., 1978; Yang 
et al., 2001a). Due to the indistinguishable phenotypes of active microglia and 
peripheral macrophages, it is difficult to determine the exact roles of these cell types 
during glaucomatous pathophysiology.
Active microglia in the glaucomatous optic nerve are frequently joined by infiltrating 
peripheral T-cells, which exacerbate the immune response (Mo et al., 2003). 
Microglia are involved in antigen presentation to these T cells (Matsubara et al.,
1999). Normally tight junctions in the vascular endothelia (excluding that of the 
prelaminar optic nerve head) would prevent infiltration of peripheral immune cells, 
consequently they are not found in the normal nerve (Hofman et al., 2001). However, 
glaucoma can lead to peripapillary chorioretinal atrophy, which involves compromise 
of the blood-retinal barrier, allowing influx of peripheral cells. Microglial recruitment 
signalling may exacerbate this influx. It is possible that B-lymphocytes are also 
recruited and mature into plasma secreting cells that elicit an immune response in the 
optic nerve.
With a similar function to, and through communication with activated microglia, 
infiltrating immune cells may be neuroprotective or destructive during glaucoma 
(Aloisi et al., 2000, reviewed by Tezel and Wax, 2004). Immune cells may 
indiscriminately phagocytose healthy RGCs to exacerbate neurodegeneration. These 
cells may also secrete neurotoxins possibly as a result of aberrant microglial 
signalling to the infiltrating cells, or lack of tolerance to nervous system antigens. 
While depletion of macrophages reduces peripheral nerve degeneration (Liu et al,
2000), compromise of the immune system elevates neurodegeneration in experimental 
glaucoma. Similarly, immune enhanced rats are more resistant to RGC loss (Bakalash 
et al., 2002). This indicates that the peripheral immune system may have a 
neuroprotective role in glaucoma.
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1.7 Action of Nitric Oxide Synthase: Generic and in the Eve
1.7.1 Nitric oxide synthase
There are 3 major isoforms of the nitric oxide synthase (NOS) enzyme, ranging from 
919 to 1400 amino acids long, and with molecular weights of between 250 to 320 kD 
(Bredt et al., 1991; Nunokawa et al., 1993). NOS functions as a homodimer with a 
wide distribution in diverse organs, from the eye to the heart. NOS catalyses the 
production of nitric oxide (NO) from L-arginine and oxygen in a NADPH-dependent 
reaction. NOS acts on arginine with NADPH and oxygen to produce N-co- 
hydroxyarginine and NADP+. NO is produced in a subsequent reaction, with citrulline 
formed as a by-product. Each NOS subunit contains cofactors that are thought to 
assist in donating 5 electrons to arginine in the formation of NO. These cofactors 
include one each of flavin mononucleotide (FMN), flavin adenine dinucleotide 
(FAD), tetrahydobiopterin, and Fe(HI)-heme per NOS subunit. These reactions are 
summarised in Figure 1.8.
1.7.2 Nitric oxide
NO is a highly reactive and toxic free radical gas produced by NOS. NO has a very 
short half-life of 5 -  10 seconds, before conversion to nitrites and nitrates in the 
extracellular space by oxygen and water (Kotikoski et al., 2002). NO can diffuse no 
further than 200pm from its site of synthesis due to its highly reactive nature 
(Lancaster, 1997). However, the properties of NO mean that it acts as a novel 
transient autocrine or paracrine signalling molecule in several transduction pathways, 
despite its toxicity (Dimmler and Zeiher, 1997).
Following production, NO traverses the lipid bilayer membrane of the cell via rapid 
diffusion by virtue of its small size, and can pass easily into neighbouring target cells 
(Garthwaite and Boulton, 1995). The main target of NO is guanylyl cyclase (GC). NO 
interacts with the heme prosthetic group in the active site of GC to produce 
nitrosoheme which increases the enzymatic activity of GC 50-fold, probably through 
a conformational change (Stamler, 1994). GC then rapidly degrades GTP to produce
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the intracellular second messanger 3’,5’-cyclic GMP (cGMP). Following the rapid 
production of cGMP, it is speedily degraded to GMP by a phosphodiesterase, 
resulting in NO having a rapid (within seconds) effect on the cell. These effects 
depend upon the isoforms of NOS, which has been activated to produce NO.
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Figure 1.8 The structure and reactions o f  nitric oxide synthase NOS is shown 
above with the reactions it catalyses, essential co-factors for NO synthesis and the 
amino acid L-arginine (for details o f these see text). Calcium ions and calmodulin 
(CaM) are shown to represent the activation o f  the inducible NOS isoform (NOS2). 
The NOS enzyme is a homodimer each monomer consists o f a reductase and an 
oxygenase domain. The enzyme catalyses the conversion o f L-arginine into L- 
citrulline and NO (After Boger, 2005; Groves and Wang, 2000).
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1.7.3 The isoforms of NOS
Three isoforms of NOS have been isolated and cloned.
1.7.3.1 NOS-1
NOS1 (also known as brain NOS [bNOS] or neuronal NOS [nNOS]) is constitutively 
expressed and activated via interactions with calcium calmodulin to produce nitric 
oxide (NO) for use as a neurotransmitter (Bredt et al., 1991; Dawson and Snyder,
1994). Inhibition of NOS 1 is achieved by the action of NOS 1 inhibiting protein (PIN), 
which is thought to prevent the formation of dimeric NOS1. Alternative splicing of 
the NOS1 gene can result in 4 variations of the NOS1 enzyme, of which only one is 
ubiquitously expressed. This form of the enzyme localises to skeletal muscle, testis, 
lung, kidney, heat, gastrointestinal tract epithelia (Nathan and Xie, 1994), neutrophils, 
adrenal gland and retina (Koistinado and Sagar, 1995) where it is involved in various 
transduction pathways.
NOS1 is a potent vasodilator involved in the dilation of cerebral and other arteries. In 
these pathways NOS1 is stimulated to produce NO when nerve impulses cause a local 
increase in calcium concentration at nerve terminals. The resulting NO diffuses to 
smooth muscle cells and acts on GC as previously described. cGMP then stimulates 
protein phosphorylation via cGMP-dependent protein kinases within the cell, to 
mediate endothelium-independent neuronal stimulation of smooth muscle relaxation. 
NOS1 has many diverse roles other than vasodilation, such as the reinforcement of 
synaptic strength during the long-term potentiation involved in memory formation 
(Carter and Murphy, 1999).
1.7.3.2 NOS2
NOS2 (or inducible NOS [iNOS]) is only found in cells during abnormal conditions, 
once its production is transcriptionally activated (Lamas et al., 1992). This form of the 
enzyme produces extremely high amounts of NO, which exhibits paracrine toxicity
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during inflammation and degeneration (Lyons et al., 1992). Under these conditions 
NOS1 and NOS3 can also be induced (Dawson and Snyder, 1994).
NOS2 has a role in the immune response, and localises to macrophages and 
neutrophils. NOS2 inhibitors prevent the response of macrophages to immune 
challenge. If these cells are challenged with cytokines or endotoxins such as 
lipopolysaccharide, after a few hours extremely high, sustained levels of NO are 
found during the immune response. These active immune cells can also produce the 
superoxide radical O2', which reacts with NO to form considerably toxic peroxynitrite 
(OONO'). This decomposes rapidly into a hydroxide radical that the cells use in their 
attack on invading “non-self5 substances.
1.7.3.3 NOS3
NOS3 (or endothelial NOS [eNOS]) is localised to the cellular endothelial lining of 
blood vessel walls, as well as nonvascular tissues (Lamas et al., 1992) where it is 
constitutively expressed. NOS3 is similar to NOS1 in terms of sequence homology 
(about 55%) as well as in activation by calcium calmodulin. The actions of certain 
vasodilatory hormones result in increased free intracellular calcium concentration in 
endothelial cells via the phosphinositide signalling pathway. This activates NOS3 
resulting in NO production. The main function of this NO is to act as a physiological 
regulator of blood pressure by acting on smooth muscle cells, via a similar 
transduction pathway to NOS1.
1.7.4 NOS and toxicity
NO released from all forms of NOS can be toxic to cells. Animal models of 
neurodegenerative diseases such as Parkinson’s disease (Santiago et al., 1994), 
Alzheimer’s disease (Resnick et al., 1995) and multiple sclerosis (Bo et al., 1994) 
have suggested a role for NOS in the disease process. During Parkinson’s disease the 
main brain area affected is the substantia nigra, where NOS2 expression is induced in 
reactive glia, resulting in increased NO and degeneration of dopaminergic neurons. 
Endotoxic shock for example, following lipopolysaccharide administration, can be
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mediated by a sustained release of NO following production by NOS2. Similarly, 
inflammation mediated by NO can result in tissue damage. In animal models of 
stroke, NO-producing active NOS1 can damage neurons in the prenumbra, which 
have not been damaged by the stroke itself. Also, experimentally, in NOS1 knockout 
mice ischaemia results in a reduced central nervous system lesion as compared to 
normal mice (Huang et al., 1994), indicating a role for NOS1 in ischaemic nerve 
damage. Glutamate neurotoxicity is also thought to be mediated through NO (Dawson 
et al., 1991).
NO may induce toxicity through anti-apoptotic or pro-apoptotic effects. The anti- 
apoptotic effects of NO production are potentially important in autoimmune disease. 
Prevention of apoptosis may exacerbate the immune response through increased 
numbers of lymphocytes or microglia. It is unknown how NO prevents apoptosis. 
Interactions with transcription factors (Hausladen et al., 1996; Peng et al., 1995; 
Zeiher et al., 1995), heme proteins and enzymes containing iron-sulphur clusters 
(Stamler, 1994) or oxygen radicals (Moncada and Higgs) may all induce the anti- 
apoptotic effects of NO.
NO can induce both necrosis and apoptosis (Figure 1.9). The precise mechanism of 
NO toxicity is not clear, but is likely to be independent of guanylyl cyclase (Brune et 
al., 1996). It is not clear whether NO or peroxynitrite is responsible for apoptotic 
effects on the cell. NO may induce apoptosis through direct DNA damage (Nguyen et 
al., 1992) leading to accumulation of the tumour suppressor protein p53 (Messmer et 
a l , 1994). Consequently, poly(ADP-ribose) polymerase cleavage indicates that 
caspase activation occurs (Messmer et a l , 1996). However, it is also likely that NO is 
involved in a p53-dependent pathway (Messmer and Brune, 1996).
Most importantly, increased levels of NOS in the optic nerve head have been 
associated with the occurrence of primary open-angle glaucoma (Neufeld et al., 1997; 
Quigley and Addicks, 1981). The degeneration of RGC axons in glaucoma can be 
associated with excessive NO production due to elevated NOS. NOS upregulation can 
therefore be held directly responsible for some of the neurodegeneration typical of the 
disease.
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Figure L9 The mechanisms by which NO induces toxicity NO induced toxicity is 
likely to involve p53 and caspase cleavage. However, p53-independent mechanisms 
may also be involved. NO can directly produce DNA damage, which is exacerbated 
through these proapoptotic cascades (adaptedfrom Dimmler and Zeiher, 1997).
1.7.5 NOS in the normal optic nerve
NOS1 is found cytoplasmically in a low number of astrocytes at the prelaminar and 
lamina optic nerve head (Neufeld et al., 1997). This constitutive distribution among 
certain glia means that the NO produced by NOS1 might act as a local mediator 
between these cells, and between glia and neurons. NOS2 cannot be found in normal 
tissue (Neufeld et al., 1997; Shareef et al., 1999). It is expressed only when induced 
by certain physiological challenges. NOS3 is localized to blood vessel walls in the 
prelaminar optic nerve head, where it is found only in the vascular endothelium 
(Neufeld et al., 1997). NOS3 produces NO, which functions as a vasodilator in the 
optic nerve head.
1.7.6 NOS in glaucoma
In the human glaucomatous optic nerve head, all isoforms of NOS are upregulated 
(Neufeld et a l , 1997) and localised to RGC axons, as well as the extracellular matrix. 
However, only NOS2 appears to be upregulated in experimental glaucoma (Shareef et 
al., 1999). The evidence to date points to NOS1 and NOS2 upregulation in astrocytes 
during human glaucoma (Neufeld et al., 1997). Evidence suggests that the role of 
upregulated NOS2 in other central systems is part of a microglial healing response 
that removes damaged nerves and re-wires remaining fibres (Takeuchi et al., 1998).
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NOS3 is believed to be mainly neuroprotective, acting as a vasodilator, thereby 
preventing the tissue from undergoing glaucomatous damage by increasing blood 
flow. This has been proven in NOS3 knock-out mice with ischaemic cerebral 
infarction (Huang et al., 1996).
During human glaucoma, NOS1 expression is upregulated in astrocytes, and this is 
thought to cause the increased toxic levels of NO resulting in neurodegeneration. 
Neufeld (1999) discovered that NOS1 was found in almost all astrocytes in the optic 
nerve head of glaucomatous human eyes. Increases in NOS1 and NOS2 may 
contribute to excessive NO production, which then combines with superoxide to form 
peroxynitrite (Lipton et aL, 1993). This is supported by evidence, which shows the 
accumulation of mitochondria in these astrocytes (Hollander et al., 1995). 
Peroxynitrite is extremely neurotoxic and could contribute to axonal degeneration.
Therefore, it is reasonable to conclude that NOS1- and NOS2-specific inhibitors may 
have a role in the future treatment of glaucoma. For example, by inhibiting the action 
of NOS2 using a specific inhibitor, aminoguanidine, neuroprotection has been 
achieved in rodent ocular hypertension (Neufeld, 1999).
1.8 Strategies for neuroprotection of retinal ganglion cell death
1.8.1 Neuroprotection
Therapies that prevent pathogenesis in neurological disease are considered 
neuroprotective. Neuroprotection involves prevention of the processes involved in cell 
death during disease such as ischaemia (Cheon et al., 2002; Osbome, 1999; Tezel et 
al, 2004'), excitotoxicity (Cakzada et al, 2002; Tezel et al., 20041), oxidative stress, 
free radical production (Yoshioka et al., 2002), and plaque formation (Zhang et al., 
2004). Normally neuroprotection will be applied to a population of neurons that have 
already suffered a primary insult in order to prevent further damage.
Many new glaucoma treatments attempt to decrease neuronal atrophy through direct 
neuroprotection, regardless of effects on IOP (Schlore et al, 2001; Schwarz and
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Yoles, 2000). These novel therapies involve pharmaceuticals, manipulation of 
endogenous proteins and gene therapy. In combination with neuroregeneration 
techniques, neuroprotection may be potentially useful in the restoration of visual 
function during glaucoma.
As more about the mechanisms of cell death in glaucoma become understood, and the 
particular pathways involved are elucidated, it will become clearer how best to protect 
neurons from degeneration. Many neuroprotective strategies for the optic nerve are 
under investigation, but the application of these remains questionable.
1.8.2 Growth factors
Growth factors (GFs) can influence various cellular pathways to induce 
neuroprotection or neurodestruction. GFs can reduce apoptosis, but increase necrosis 
by free radical (for example, NO) induced damage (Haefliger et al., 2000; Klocker et 
al., 1998). Most growth factors produce similar results due to a similar mechanism of 
action, which also causes oxidative stress. However, BDNF, ciliary neurotrophic 
factor and basic fibroblast growth factor have all been shown to have an overall 
positive effect on neuronal survival in RGC cultures and in vivo (Chew and Ritch, 
1997; Rabacchi et ah, 1994).
1.8.3 Calcium channel blockers
Calcium channel blockers, normally used in cardiac conditions, can alleviate 
vasospasm particularly in normotensive glaucoma (Flammer and Orgul, 1998; 
Rojanapongpun et al., 1993). These blockers may decrease visual field loss and optic 
nerve degeneration (Netland et al., 1993).
Nifedipine alleviates symptoms of some normotensive patients, but not others 
(Kitazawa et al., 1989; Lumme et al, 1991). Flunarizine enhances RGC survival, 
possibly through a trophic factor mechanism. Betaxolol is a common p-blocker that is 
thought to function by blocking calcium channels to promote vasodilation and 
neuroprotection.
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The neuroprotective effects of calcium channel blockers may be induced by the 
inhibition of vasospasm (Gasser and Flammer, 1987) or excitotoxicity (Greenberg et 
al., 1990). However, reduction of blood pressure by these agents may decrease optic 
nerve perfusion resulting in ischaemia and axonal damage.
1.8.4 NMD A receptor antagonists
NMDA receptors (NMDAR) are usually activated by glutamate and are thought to be 
involved in RGC death through the enhancement of excitotoxicity (Dreyer et al., 
1996). However, some evidence suggests that vitreal glutamate levels remain normal 
and are therefore not excitotoxic during glaucoma (Carter-Dawson et al., 2002). 
However supporting evidence for glutamate excitotoxicity in glaucoma has recently 
been demonstrated in a rodent model (Moreno et al., 2005).
A putative mechanism for excitotoxicity is glutamate-stimulated NOS activity, 
resulting in toxic NO levels (Kashiwagi et al., 2001). Therefore, NMDAR antagonists 
can decrease excitotoxic and hypoxic damage. Memantine is a commonly used non­
competitive NMDAR antagonist used to prevent Parkinsonian neurodegeneration of 
the substantia nigra (Chen et al., 1992), which also reduces RGC death through the 
prevention of NMDAR activation (Osborne, 1999).
Other neuronal systems can be inhibited to reduce excitotoxic RGC death, for 
example, serotonin receptor antagonism (Inoue-Matsuhisa et al., 2003).
Neuroprotection using systemic neurotransmitter receptor antagonism is undesirable 
due to the wide distribution of most neurotransmitters in the nervous system and the 
potential effects on multiple systems.
1.8.5 NOS inhibitors
RGC neuroprotection during glaucoma and ischaemia can be achieved by preventing 
the production of NO from NOS using A-nitro-L-arginine and A-methyl-L-arginine. 
Indeed, specific inhibition of NOS2 has been investigated during chronic (6 months) 
experimental glaucoma induced via episcleral vessel cautery (Neufeld, 1999).
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Aminoguanidine-induced inhibition of NOS2 reduced neuronal loss from 36% to 
10%. Clearly blocking the action of NOS2 is neuroprotective in the cautery model of 
glaucoma (Neufeld, 1999). However, the induction of NOS expression, as well as 
neuroprotection through NOS inhibition, may be a side effect of vein cautery. It is yet 
to be established whether blocking the other NOS isoforms produces similar effects.
Selective inhibition of NOS isoforms may be more desirable for neuroprotection, 
because though NOS1 and NOS2 products are regarded as neurodegenerative, NOS3 
produces vasodilatory NO, which may help prevent vasospastic glaucoma.
1.8.6 Nitrates
Nitrates such as nitroglycerin release NO, which increases intracellular cGMP levels 
and vasodilation, and are therefore used to treat vascular dysfunction, as well as 
glaucoma (Wizemann and Wizemann, 1980).
Nitrates may increase retinal or optic nerve head (ONH) perfusion and prevent 
ischaemia (Grunwald et aL, 1997), or directly inhibit NMDARs through S- 
nitrosylation of thiol groups at the modulatory sites of the receptor. However, 
increased levels of NO can be neurodestructive through nitrosylation and 
fragmentation of DNA.
1.8.7 Antioxidants
Antioxidants such as trilazad mesylate, a 21 amino acid steroid, can be used to 
neutralise toxic substances in the prevention of apoptosis. Trilazad mesylate acts on 
lipid peroxidation to inhibit apoptosis (Neufeld, 1999). Neutralisation may be 
incomplete, but other compounds can be used as free radical scavengers to enhance 
neuroprotection, including catalase, superoxide dismutase, vitamin C and vitamin E.
Combining the effects of neuroprotection offered by NOS inhibition and free radical 
scavenging enhances the effects of growth factor-mediated protection, suggesting that
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combination therapies are more efficient in neuroprotection of RGCs (Netland et al, 
1993).
1.8.8 Gene therapy
Apoptosis is particularly targeted in potential gene therapies for glaucoma. The 
proteins and genes that inhibit the process are being assessed for possible 
neuroprotective effects in glaucoma.
The Bcl-2 gene is an apoptotic inhibitor, with a potential neuroprotective capacity. 
Bcl-2 expression in rat neurons produces a 50% increase in RGC numbers, and 
overexpression in transgenic mice results in a reduced stroke size. Bcl-2 mRNA 
inserted, via a herpes simplex virus vector, into the murine brain protects cells from 
delayed death following focal ischaemia.
Other compounds that may be neuroprotective through the inhibition of apoptosis 
include deprenyl, a monoamine oxidase inhibitor used in Parkinson’s disease (Leret et 
al, 2002; Maruyama and Naoi, 1999), as well as flumarizene and aurintricardoxylic 
acid.
1.8.9 Immune system modulation
1.8.9.1 Microglia
Due to the uncertain role of microglia in RGC death, the inhibition of microglial 
activity has been tentatively investigated as a neuroprotective strategy in glaucoma 
treatment. Initial studies are contradictory (reviewed by Schwartz, 2003). In some 
cases, inhibition of microglial activation is neuroprotective, whereas in others it 
exacerbates degeneration.
Early microglial activation during central nervous system injury correlates with T-cell 
mediated neuroprotection, suggesting a role in neuroprotective autoimmunity for both 
(Shaked et al., 2004). However, minocycline, a tetracyclic antibiotic can be used to 
inhibit microglial proliferation and activation during many neurodegenerative
46
Chapter I General Introduction
conditions including stroke (Wang et al., 2003), (Arvin et al, 2002), and 
excitotoxicity (Tikka and Koistinaho, 2001). Minocycline is thought to be 
neuroprotective, although the effects it has on RGC survival are unknown.
1.8.9.2 Immuno-protective vaccination
Immune-mediated neuroprotection can be achieved using vaccination with antigens 
that predominate at the site of injury (reviewed by Schwartz, 2004). Copolymer-1 and 
interphotoreceptor retinoid binding proteins can protect RGCs from degeneration 
following glaucoma (Bakalash et al, 2003). Clinical trials are already underway to test 
immuno-protective vaccination of Alzheimer’s disease (reviewed by Vickers, 2002). 
A careful balance needs to be achieved between protective autoimmunity and 
autoimmune disease.
1.8.10 Neuroregeneration
Neuroregeneration can be applied in combination with neuroprotection, when 
neuroprotection alone fails to restore function (reviewed by Schwartz, 2003). 
Neuroregeneration involves using trophic factors to promote the regeneration of 
injured neurons. Until recently this was considered impossible in the central nervous 
system. Now evidence suggests that regeneration is possible following central 
nervous system injury, as damaged axons can generate growth cones (Dickson et al., 
2000). RGC axons have been regenerated in vitro (Negishi et al., 2001).
Nerve growth cone proliferation can be induced through BDNF application to the 
transected optic nerve (Chew and Ritch, 1997). Cell survival and axon regrowth can 
be enhanced by the grafting of a neurolemmal sheath into transected optic nerve 
(Martinou et al., 1994). Neuroregeneration can result in functional synapses (Aguayo 
et al., 1990; Keirstead et al., 1989; Villegas-Perez et al., 1988), with the potential to 
complete the circuits lost during RGC death. Neuroregeneration can also be achieved 
through the introduction of hNT neuronal cells (derived from N-tetra-2 
teratocarcinoma cells) as a retinal graft (Konobu et al., 1998).
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Neuroregeneration following glaucoma may be a very difficult task. The optic nerve 
microenvironment may be adjusted to prevent repair and regeneration of axons 
through changes such as microglial activation during disease. A physical barrier to 
regeneration in the form of the glial scar also exists after disease. Therefore 
regenerative factors will need to be applied to the nerve together with other agents, 
which optimise or promote healing of the nerve.
1.9 Summary of research plan
In order to investigate the effects of IOP elevation on the optic nerve and further 
elucidate the mechanisms that cause RGC cell death, the aims of this project were to:
1) develop the episcleral vessel sclerosis rodent model of glaucoma (Morrison et 
al., 1995)
2) relate IOP elevation to RGC degeneration and death in a rodent model of 
experimental ocular hypertension. Due to the lack of a definitive, practical 
quantification method for assessing neurodegeneration in glaucoma, various 
methods will be established, including some novel approaches.
3) determine the potential roles of glia in glaucoma. Astrocyte and microglial 
changes will be related to IOP elevation and the degree of RGC cell death. In 
particular, the role of microglia will be clarified.
4) clarify the controversial role of NOS in glaucomatous RGC degeneration.
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Chanter II 
General Method Development
2.1 Development of methods used in the animal model
2.1.1 Introduction to animal techniques
All procedures carried out on animals conformed to current Home Office regulations 
concerning the Animals (Scientific procedures) Act, 1986. Experiments were 
performed according to personal license number 30/5874, and under project license 
number 30/1756. The animal model used was developed was based on the episcleral 
drainage vessel sclerosis rodent model of glaucoma (Jia et al., 2000; Johnson et al.y 
1996; Morrison et al., 1997; Morrison et al., 1998).
250-450g 5 to 8 month old male ex-breeder brown Norway rats (Rattus Norwegicus) 
were housed at 21°C and provided with standard laboratory diet and water ad libitum 
(n=75). Animals were maintained on 24 hour 40-901ux light for a minimum of three 
days before experimentation commenced. Rats were handled daily and their weights 
were recorded weekly as an index of health.
2.1.2 Intraocular pressure readings
Intraocular pressure (IOP) was calculated from experimental and control eyes, using a 
factory calibrated Mentor® Tono-Pen™ XL, by taking the mean of 10 readings. A 
sanitised Ocu-film® tip cover was used to shield the tonometer probe from damage. 
Alternatively, a non-static film with a smaller diameter than the Ocu-film® tip cover 
was fixed over the tonometer probe, or the unshielded probe was used in an attempt to 
reduce standard error. 10 readings were taken from each of 3 animals on 3 separate 
occasions using these alternative shields. Eyes were locally anaesthetised using 0.5% 
w/v Benoxinate (Oxybuprocaine) hydrochloride (Chauvin Pharmaceuticals, UK) prior 
to pressure readings.
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Interobserver variation was determined by comparing repeated IOP measurements 
taken by two investigators, between 9am and 6pm, on alternate days (n=66). On no 
occasion were these readings recorded on the same day. On alternate days, one set of 
IOP measurements were taken from both eyes between 7 and 9am or pm. Once it was 
established that circadian changes had been eliminated, readings were taken between 
9am and 6pm. In order to detect any improvements in tonometry with practice of the 
technique, animals were separated into 9 temporal groups dependant upon arrival 
date. IOP readings from these groups were compared.
2.1.2.1 Statistical analysis
All statistical analyses were performed using Microsoft Excel (UK). Average animal 
weight, standard deviation, and standard error were calculated using the Excel 
formulae. Pre-surgical tonometry readings were analysed for statistically significant 
differences between contralateral and ipsilateral eyes. These analyses were performed 
using a two-tailed T-test to generate a P value, as calculated by Excel formula. A P- 
value of <0.05 was taken as statistically significant. The coefficient of variation, 
standard deviation and error were calculated for 9 temporal animal groups in order to 
assess whether tonometry became more reliable with practice. Agreement between 
observers using a standard tonopen cover was tested using Bland and Altman plots 
and also compared via a T-test. A repeated measures test (ANOVA) was used to 
compare alternative tonopen shields as well as alterations in circadian variation of 
IOP.
2.1.3 Principles of ocular surgery
Following initial IOP measurements, animals accustomed to human handling 
underwent surgery under general anaesthetic involving an episcleral microinjection of 
hypertonic saline (1.75 M NaCl, see Appendix 1) into an aqueous vein (n=58). 
Approximately 50 pi 1.75 M NaCl was injected into the episcleral venous system of 
the ipsilateral (left) eye. The contralateral eye (control, right) was not injected.
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2.1.3.1 Microneedle assembly
Disposable microneedles were made from 10 pi borosilicate glass pipettes (Sigma- 
Aldrich, UK) pulled using a pipette puller (David Kopf Instruments, USA). The rough 
microneedle tips were bevelled to avoid excessive tissue damage during injection; the 
needle was lowered onto a flat rotating (14000 rpm) surface attached to an industrial 
rotator and covered with diamond lapping film (World Precision Instruments, UK). 
An example of a bevelled needle is shown in Figure 2.1. Microneedle diameter was 
measured using a DMRA2 microscope (Leica, UK) and Leica QWin image analysis 
software. Initially during the optimisation process all needles, with outer diameters 
from approximately 3 to 70 pm, were cut with a glasscutter under a light microscope 
yielding a length of approximately 6mm. Following optimisation, only microneedles 
with an outer diameter of 10-40 pm were used.
20pm
B1
1
Figure 2.1 A bevelled borosilicate glass microneedle tip The proximal tip (A) was
derived from bevelling as described in section 2.1.3.1. Arrow B indicates the point at 
which bevel starts. Arrows C and D indicate diamond lapping film deposits.
Approximately 3 mm of the rough (cut) end of the microneedle was inserted into a 50 
cm length of polyurethane tubing (Sandown Scientific, UK) with an outer diameter of 
0.038 inches or 0.048 inches, which had previously been tapered by heating and 
stretching by hand over a Bunsen flame. A 23 or 19-gauge needle with the tip broken 
off was inserted into the distal end of the tubing, and all junctions sealed with
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Superglue, UHU, or Araldite over-laid with high viscosity Superglue. In some cases, 
these junctions were additionally sealed with heat-shrink tubing. A small plastic tab 
was positioned along the tubing and held with high viscosity Superglue to mark the 
bevel of the microneedle. This apparatus is depicted in Figure 2.2. After assembly, 
microneedles were stored in either a dry or moist sealed chamber and then sterilised 
before use by applying 100% ethanol to the bevelled tip followed by air-drying.
Microneedle
Glue joint with 
tab attachment
lene
Figure 2,2 Microneedle assembly This diagram shows a 1 ml syringe attached to 
a 23 gauge needle with the tip broken off. This in turn is attached to tapered tubing, 
which has a microneedle inserted into the narrow end. This microneedle can be used 
to inject a single vessel (shown in red and indicated by the arrow), which has been 
isolated from the vessels blocked by the plastic ring around the eye by the narrow slit 
in the ring (adaptedfrom Morrison et al, 1997). The arrow indicates the vessel.
2.1.3.2 Anaesthesia
Before microinjection, rats were anaesthetised via inhalation of 4% isoflurane with 
oxygen in a chamber. For the surgical procedure, they were transferred to a respirator 
consisting of the modified sleeve of a 10 ml syringe connected to a 3% supply of 
oxygenated isoflurane. Animals were monitored throughout the surgery to assess the
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degree of anaesthesia, and the supply of isoflurane adjusted appropriately. The 
operated eye was moistened throughout surgery with drops of 0.9% sterile saline (see 
Appendix 1).
2.1.3.3 Surgical procedure
The conjunctiva was incised under a surgical light microscope (25x to 40x 
magnification, Zeiss, USA). A 5.5 mm inner diameter delrin ring (as shown in Figure
2.3) with a 1mm groove cut into its central internal diameter and a 1mm external gap, 
was fitted around the equator of the eye. The careful placement of this ring excluded 
all aqueous veins, apart from one radial vein in the superior quadrant of the eye, as 
well as preventing injected hypertonic saline from escaping the limbus. The 
experimental setup is shown in Figure 2.4. The eye was positioned downwards by 
applying pressure to the inferior globe using a modified arm held in place with a 
magnetic footplate.
Figure 2.3 A polypropylene ring A ring o f these dimensions was fitted around the 
equator o f the eye during surgery to prevent excessive damage to non-target blood 
vessels during the microinjection o f a mild sclerosing agent (1.75 M NaCl) into the 
episcleral drainage vessel system.
0.228" 7 mm
1.5 mm—•
.0 mm
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Figure 2.4 Surgical set-up used during the microinjection procedure Animals 
were anaesthetised in a chamber before placement on a recovery pad. Anaesthesia 
was maintained via an inhalation mask.
Sclera covering the vessel was micro-dissected with Vannas scissors to expose the 
isolated aqueous vein. The vein was gripped below the site of injection using cupped 
forceps. The microneedle was positioned parallel to the vessel, pointing towards the 
limbus, inserted into the vessel, and 50 pi of filtered hypertonic saline (1.75M) 
injected over 10-30 seconds using a “Genie” syringe pump (Wolf laboratories). This 
force was sufficient to blanch the limbal artery. In some cases, a hand rest was used 
for support.
The plastic ring was removed, and the conjunctiva closed with 8-0 vicryl-rapide® 
absorbable sutures, with a 6 mm micro-point® spatula needle (Johnson and Johnson 
International, UK). Injected eyes were then anaesthetised with benoxinate before 
recovery from the procedure. A drop of 0.5% chloramphenicol (Chauvin 
Pharmaceuticals Ltd, UK) antibiotic was administered, as well as Predsol® (Medeva, 
UK) as a non-steroidal anti-inflammatory. Post-injection intraocular pressure
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measurements were attempted, before consciousness was regained. The same 
procedure, excluding injection of hypertonic saline was performed on sham-operated 
animals (n=8 in total).
2.1.3.4 Post-operative intraocular pressure readings
Following microinjection, IOP was measured (one set of 10 readings per eye) by one 
of two investigators on alternate days and analysed for statistically significant 
differences as described in Section 2.1.2.1. Experimental and control eyes were 
compared. If no significant pressure change (P>0.05) was recorded before day 14 post 
injection, animals were re-injected. IOP was measured for various durations.
2.1.3.5 Methods o f euthanasia and tissue harvesting
Animals were sacrificed at appropriate time points from 0 to 65 days post-induction 
of elevated IOP (n=66). Critical changes occur during experimental glaucoma within 
1 to 14 days post-induction, with few optic nerve changes occurring after 14 days of 
hypertension (Johnson et al., 1997). Tissues were therefore collected from 1 day up to 
14 days post pressure elevation, at frequent end-points. After 14 days of experimental 
hypertension, animals were sacrificed at fewer, more discrete time intervals.
Some animals were euthanised using CO2 overdose in a chamber (n=19). All others 
received a lethal dose of sodium pentobarbital (40mg/kg body weight); in some cases 
this was followed by transcardial perfusion (n=10). The animal’s chest was opened to 
expose the heart and the left ventricle was cannulated with a 19 gauge needle clamped 
into place using an artery clip, and connected to a Cole Parmer (USA) perfusion 
pump. Blood was flushed out using 200 ml of phosphate buffered saline (PBS, see 
Appendix 1) (pH 7.0), followed by fixation with 200 ml of 2% paraformaldehyde 
(PFA) in PBS, both pumped through the system at approximately 120 mmHg. 2% 
PFA was obtained by diluting an 8% frozen stock solution (see Appendix 1). 
Alternatively transcardial perfusion was performed using only 200 ml PBS, 
eliminating the use of fixative. Eyes were removed for analysis, dissected and stored
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in the perfusion fixative or snap frozen in Tissue Tek (Sakura, The Netherlands), 
using liquid nitrogen chilled isopentane, prior to storage at -20°C.
Pre-enucleation eyes were orientated so that an 8-0 silk suture (Ethicon, UK) through 
the sclera marked the superior quadrant. Post enucleation, retrobulbar optic nerves 
were similarly orientated so that a suture distal to the globe marked the superior 
nerve. A scalpel blade was used to incise the sclera, just posterior to the limbus, and 
the anterior and posterior globes were separated with fine Vannas scissors. The 
superior quadrant of the posterior segment was marked using an incision through to 
the optic nerve. The optic nerve head and adjoining sclera were removed through a 
continuation of this incision around the nerve head. The retrobulbar optic nerve was 
separated from the remainder of the nerve using a scalpel.
2.1.3.6 Evaluation o f elevated intraocular pressure
Animals (n=58) with unilateral ocular hypertension were assigned to 5 groups based 
on IOP data. In order to determine the effect of duration of IOP elevation on the optic 
nerve, the number of days that IOP elevation was statistically significant until the date 
of euthanasia (“T”) was calculated. Following the first significant pressure elevation 
the difference in area under the pressure curve (mmHg plotted against days post­
microinjection, “A”), and standard deviation (SD, “S”) of pressure elevation, between 
the ipsilateral and contralateral eyes were calculated. The values for T, A and S were 
used to create indexes to show how optic nerve changes are dependent upon different 
aspects of pressure elevation. These criteria were compared for correlations using 
Pearson’s correlation coefficient (r). Sham-operated animals were excluded (n=8).
2.2 Histology
2.2.1 Source of tissue
Brown Norway rat eyes were obtained from the animal model detailed in previous 
sections. Culled normal Wistar rats from University stock were also used. 
Hypertensive rats were euthanised using the methods detailed in Section 2.1.3.5, 
while normal animals received a CO2 overdose. At all times tissue orientation was
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preserved, using either an appropriately placed suture or scalpel cut. The Corneal 
Transplantation Service provided all human eye tissue samples from donors, for 
which lack of objection for research use had been specifically established. Fresh 
human eyes were processed within 48 hours of cadaver time.
2.2.2 Tissue processing
Rodent ocular tissues were preserved in the perfusion fixative post-enucleation, where 
appropriate, before at least overnight fixation in 10% neutral buffered formalin (NBF, 
see Appendix 4). Tissues from non-perfused animals were fixed immediately in 10% 
NBF following dissection. Human optic nerves were dissected immediately upon 
receiving the eye, using precautions appropriate to the handling of human tissue, and 
preserved in 10% NBF.
2.2.3 Paraffin-Wax Embedding
Fixed human optic nerves and rodent optic nerve head, retrobulbar optic nerve and 
eyecups or posterior segments (both containing whole retinae) were dehydrated 
through increasing concentrations of industrial methylated spirit (IMS, Fisher 
Scientific, UK) diluted in distilled water, and then chloroform in alcohol. The initial 
dehydration step was a 30 minute incubation in 50% IMS, followed by 60 minutes in 
70% IMS. Incubation in 90% IMS was carried out for either one hour or overnight. 
Further dehydration was via a 60 minute incubation in 100% IMS. Tissue was 
prepared for paraffin-wax embedding using a 50:50 chloroform:IMS incubation for 30 
minutes, followed by two 30 minute incubations in 100% chloroform. 10 minutes into 
the last chloroform step, samples were warmed above a 56°C oven. All steps 
involving chloroform were performed under a fume hood. Samples were blotted dry 
on filter paper (Whatman) and incubated at 56°C in molten wax for 60 minutes, and 
then fresh wax for 30 minutes.
Superior and inferior retinae were dissected and embedded using a more gentle 
method. Fixed retinae were orientated on filter paper, and then passed through 
increasing concentrations of ethanol (25%, 33%, 50%, 63%) for 15 minutes each.
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Subsequent washes in more concentrated ethanol were for 30 minutes each (70%, 
80%, 90%). Samples were washed through ethanol containing increasing 
concentrations of chloroform (25% chloroform: 75% ethanol, 33% chloroform: 67% 
ethanol, 50% chloroform: 50% ethanol, 100% chloroform, 100% chloroform) for 15 
minutes each.
A plastic mould was filled to a depth of about 3 mm with molten wax, and partially 
set on a -12°C cold plate. The well was then filled with wax and the sample immersed 
in either a transverse or longitudinal orientation. Wax blocks were cooled on the cold 
plate for 30 minutes and stored at 4°C overnight, or until use.
2.2.3.1 Paraffin-wax sectioning
Wax ribbons, 7 pm thick, were cut from samples using a Microm microtome, and 
individual sections were mounted onto slides. Eye-cup or posterior segment sections 
were taken to include both inferior and superior retinal axes. Sections were floated out 
in a de-gassed water bath at room temperature, then transferred on an uncoated slide 
to a 45°C water bath containing Meyer’s albumin (BDH, UK). Sections were mounted 
on an-remove Histobond slides (Sigma-Aldrich, UK) and incubated for 30 minutes on 
a hot plate at 80°C. Slides were transferred to an oven at 56°C overnight for use the 
next day.
2.2.4 Cryoprocessing of tissue
Fresh rat optic nerve head and human tissue were used for cryoprocessing. The 
sample was snap frozen by immersion in liquid nitrogen chilled isopentane (Sigma- 
Aldrich, UK) for about 30 seconds. Frozen samples were orientated appropriately in a 
foil container containing Tissue-tek (Sakura, the Netherlands), then immersed in 
isopentane until frozen, and stored at -20°C until use.
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2.2.4.1 Cryosectioning
Sections, 7 pm thick, were cut from frozen samples using a cryostat (Leica, UK) and 
mounted onto electrostatically charged Superfrost Plus slides (Surgipath, UK). 
Sections were air dried overnight and used on the subsequent day.
2.2.5 Masson’s trichrome green staining
Masson’s trichrome green stain was used to show connective tissue elements of the 
optic nerve. Wax sections prepared as in section 2.2.3.1 were washed in xylene 
(Fisher Scientific, UK) for ten minutes twice, then rehydrated through graded 
concentrations of IMS (100%;100%;90%;70%;50%) for one minute each. Sections 
from frozen samples (Section 2.2.4.1) were defrosted and then washed in PBS for ten 
minutes before use.
Wax and frozen sections were stained with Harris’ or Meyer’s haematoxylin, 
respectively, for 5 minutes. Staining was developed using a 5 minute wash in tap 
water. Sections were rinsed in 1.3% picric acid for 3 minutes, then washed in tap 
water. Beibrich scarlet solution (1% weight/volume in water) was applied for 2 
minutes. Excess stain was removed under running tap water. Samples were immersed 
in a 1:1 solution of phosphotungstic acid (5% weight/volume in water) and 
phosphomolybdic acid (5% weight/volume in water) for 2 minutes. Fast green 
solution (2g fast green, 100ml distilled water, 2ml glacial acetic acid) was used to 
stain the tissue over 5 minutes and excess stain removed with tap water.
Wax sections were dehydrated through increasing concentrations of alcohol (Section
2.2.3), infiltrated with xylene in two 10 minute washes, then mounted in Histomount 
(BDH, UK). Frozen sections were mounted in Hydromount (BDH, UK).
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2.2.5.1 Light microscopy image capture
Sections were examined using a Leica DMRA2 light microscope at various 
magnifications using 1.6x-100x objectives. Oil immersion was required with 63x and 
1 OOx objectives. Where appropriate, images were recorded using Leica QWin image 
analysis software.
2.2.5.2 Areas o f interest in the optic nerve
For structural staining of the optic nerve, images were captured of the optic nerve 
head and retrobulbar optic nerve, or optic nerve proper from longitudinal optic nerve 
sections. From transverse sections, images of the entire optic nerve were captured. 
Higher magnification images of transversely orientated optic nerves were captured 
from the centre of the nerve, near the retinal vessels.
2.2.6 Haematoxylin and eosin staining
Staining was performed on human and rat optic nerve heads as a morphological and 
structural reference. Wax sections were rehydrated as in Section 2.2.5. Paraffin-wax 
and frozen sections were stained for 5 minutes in Harris’ Haematoxylin (BDH, UK) 
and Meyer’s Haematoxylin respectively. Excess stain was removed with a 10 minute 
wash in tap water. Slides were immersed in eosin for 2 minutes and excess stain 
removed as before. Wax and frozen sections were then mounted as described for 
Masson’s trichrome green staining in Section 2.2.5, and images recorded as 
appropriate using Leica QWin software (see Sections 2.2.5.1 and 2.2.5.2 for details).
2.2.7 Toluidine blue staining
Staining with toluidine blue was carried out as a structural reference similar to 
haematoxylin and eosin staining. Wax sections were brought to water as for 
haematoxylin and eosin staining (Section 2.2.5). Wax and frozen sections were 
stained in 1% toluidine blue (TAAB, UK) for 2 minutes, washed in running tap water
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for 10 minutes, dehydrated and mounted as in Section 2.2.5. Image capture was as for 
Sections 2.2.5.1 and2.2.5.2.
2.3 Electron Microscopy
2.3.1 Tissue fixation
Fixation was used to preserve cellular components and structural details for clarity in 
electron micrographs. Cells were preserved with minimum alteration from the living 
state and in order to protect them from subsequent treatments. All electron 
microscopy reagents were of electron microscopy grade, and purchased from TAAB 
(UK) unless stated otherwise.
Pairs of perfusion-fixed retrobulbar optic nerve samples with a superior orientating 
suture distal to the eye were stored in 2% (n=10) or 4% (n=2) paraformaldehyde 
(PFA) (perfusion and orientation were as described in Section 2.1.1.5). Fresh eyes 
(n=2) and pairs of retrobulbar optic nerves (n=4) were stored in 2.5% glutaraldehyde 
in 0.1 M phosphate buffer overnight. During each step throughout embedding samples 
were agitated at room temperature unless stated otherwise. All PFA was removed 
from fixed samples using a fine-tipped pipette and then samples were fixed for a 
minimum period of two hours at room temperature using 2.5% glutaraldehyde in 0.1 
M phosphate buffer. The glutaraldehyde solution was removed from samples using a 
fine-tipped pipette, and the samples were washed twice for 15 minutes with 0.1 M 
phosphate buffer at room temperature. Samples were post-fixed for one hour in 1% 
osmium tetroxide (diluted from a 2% stock in distilled water). Traces of fix were 
removed using three washes of 15 minutes each in distilled water.
2.3.2 Post-fixation tissue processing and embedding
Samples were dehydrated through increasing concentrations of ethanol 
(50%;70%;90%;100%;100%) for 15 minutes each. A 1:1 ratio of Spurrs medium 
viscosity Epoxy resin (TAAB, UK) and 100% ethanol was added to the sample and 
then incubated for 8 hours. Three 8 hour incubations in increasing concentrations of 
Spurrs medium viscosity Epoxy resin in alcohol (1:1, 1:2, 1:3) followed. Samples
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were then orientated and polymerised in moulds containing 100% resin in an oven at 
70°C for 8 hours.
2.3.3 Semi-thin sectioning and toluidine blue staining
Semi-thin 1 pm transverse optic nerve sections were cut with a glass knife using an 
ultramicrotome. Sections were stained using 1% toludine blue to assess axonal 
damage. Tissue was examined using a Leica DMRA2 microscope under 20x tolOOx 
objectives. Images containing areas of interest were recorded for superior, inferior, 
nasal and temporal nerve quadrants using Leica QWin software (Section 2.2.5.1), as 
well as for the areas described in Section 2.2.5.2 for transverse sections.
2.3.4 Ultra-thin sectioning and labelling for protein
Ultra-thin sections (75 nm) were cut from the same samples using a glass or diamond 
knife and mounted onto the copper side of a grid (TAAB). Three to four samples were 
mounted per grid, and grids stored on filter paper in a parafilm-sealed petri dish until 
use. Samples were stained using 2% aqueous uranyl acetate and lead citrate 
(consisting of 80mM lead nitrate, 120mM sodium citrate, and 160mM sodium 
hydroxide in distilled water). Grids were floated on filtered uranyl acetate, sample- 
size down for 15 minutes. Samples were washed five times in distilled water and then 
dried by gentle dabbing of the grids (sample side up) on filter paper. Lead citrate was 
pippetted onto parafilm, and the samples stained for 10 minutes, before five washes in 
distilled water as previously. Samples were stored on grids in a parafilm-sealed petri 
dish. Nerve sections were examined using a JEOL 1010 transmission electron 
microscope (JEOL Ltd., Japan), and images were recorded of areas of interest.
2.4 Silver staining
Frozen 7 pm retrobulbar optic nerve sections (see Sections 2.2.4 and 2.2.4.1 for 
details) were probed for retinal ganglion cell (RGC) degeneration using a Neurosilver 
staining kit (FD Neurotechnologies, USA). Representative samples of a range of IOP 
elevations were used (n=10). Degenerating nerves can be distinguished by an ability
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to aggregate silver ions. Consequently the agrophylic propensity of degenerating 
nerves was used to assess the degree of neurodegeneration. Staining was performed in 
accordance with kit instructions. In brief, images were captured as described in 
sections 2.2.5.1 and 2.2.5.2, using a Leica DMRA2 microscope and Leica QWin 
software to record images obtained with 1.6x to lOOx objectives.
2.5 Neuronal class III P-tubulin immunolabelling
RGC neurodegeneration was detected immunohistochemically as an inverse measure 
of using neuronal class III p-tubulin (TUJ1) labelling, since TUJ1 specifically labels 
neurons (Pearson et al., 2002; Sergent-Tanguy et al, 2003). Both 7 pm paraffin-wax 
embedded (as in section 2.2.3) and frozen sections (see Sections 2.2.4 and 2.2.4.1) of 
retina (n=5) and retrobulbar optic nerve (n=5) were used, respectively.
Wax sections were brought to water (as described in Section 2.2.5), and frozen 
sections defrosted. Initially the same protocol as developed for immunolabelling of 
the optic nerve with other primary antibodies was used (see Section 2.6.2.2 and Figure
2.5) on both the retrobulbar optic nerve (n=2) and retinal sections (n=2).
Subsequently the protocol developed by Cui et al., (2004) was used (n=3 each for 
both retinae and optic nerve). Sections were incubated for three 10 minute washes in 
PBS, and then treated with 10% normal goat serum (NGS, Dako, UK), 1% bovine 
serum albumin (BSA, Fisher Scientific, UK) and 0.2% Triton X-100 (Sigma-Aldrich, 
UK) in PBS for 1 hour. A 1:500 dilution of monoclonal neuronal TUJ1 antibody 
(Cambridge Biotechnologies, UK) in PBS containing 10% NGS, 1% BSA and 1.2% 
Triton X-100 was used to treat sections overnight. Traces of unbound antibody were 
removed by three washes in PBS as before. Alexafluor 594 (donkey anti-mouse) 
secondary antibody (Molecular Probes, UK) was administered at a 1:1000 
concentration in PBS with 0.002mg/ml bisbenzimide (Sigma-Aldrich, UK) as a 
nuclear counterstain, and reacted for 1 hour. Sections were rinsed in three 10 minute 
PBS washes, mounted in gelvatol (see Appendix 1), and then cover-slipped.
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2.5.1 Control sections
Throughout all immunolabelling experiments, omission of primary antibody 
application to sections was used as a negative control. PBS was added to replace the 
primary antibody. Positive control tissues as recommended by the primary antibody 
manufacturer (for example spleen) were harvested from Norwegian brown rats.
2.5.2 Fluorescent image capture
Representative immunofluorescent images were captured using a Leica DMRA2 
microscope and Leica QFluoro software. Only the lOx, 20x and 40x objectives were 
used. Fluorescence was difficult to distinguish using lower power objectives. Higher 
magnifications were not used, as they did not provide any additional information.
Alexafluor 594 absorbs 522 nm wavelength light and emits red fluorescence at 552 
nm. Bisbenzimide contains a Hoechst fluorochrome, with an excitation wavelength of 
360 nm, producing a colour shift to the blue part of the spectrum at 470 nm. Single 
colour fluorescent images, made up of 264872 pixels, were captured using the 
appropriate Leica fluorescent filters, and composite images were created using Leica 
QFluoro software.
2.5.3 Areas o f interest in the retina
Images were recorded of representative areas of retinal labelling. All retinal layers 
were included in every image. Both the orientation and location of all images were 
recorded.
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2.6 Detection of retinal ganglion cell apoptosis
2.6.1 Tissue and preparation
Duplicate 7 pm thick frozen retrobulbar optic nerve sections were mounted onto 
electrostatically charged slides (section 2.2.4.1), and posterior segment (PS) or retinal 
paraffin-wax embedded sections (section 2.2.3.1) onto Histobond slides for each 
animal (n=25). All sections were then processed for both terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end labelling (TUNEL) and 
active Caspase 3 labelling. Sections of retina contained both inferior and superior 
portions. Positive control slides, consisting of paraffin-wax embedded rat mammary 
gland (Chemicon International, UK), were used as a reference.
2.6.2 TUNEL labelling
TUNEL labelling was performed using the Apoptag® Peroxidase In Situ Apoptosis 
Detection Kit (Chemicon International, UK). All reagents used were included in this 
kit (unless stated otherwise). Paraffin-wax sections were prepared by rehydration 
using three 5 minute washes in xylene, two 5 minute washes in ethanol, then a 3 
minute wash in 95% ethanol, a 3 minute wash in 70% ethanol and a 5 minute wash in 
PBS. Tissue was permeabilised using a 15 minute wash in 20 pg/ml proteinase K 
(PK), and then washed in distilled water twice for 2 minutes each.
Frozen transverse retrobulbar optic nerve sections were fixed in 1% PFA in PBS for 
10 minutes, followed by two 5 minute washes in PBS. Pre-cooled ethanol:acetic acid 
at 4°C was used to further fix the tissue for 10 minutes.
From this point onwards, frozen and paraffin-wax sections were treated similarly. 3% 
hydrogen peroxide obtained via dilution of a 33% stock (Sigma-Aldrich, UK) in PBS 
was used to quench endogenous peroxidase activity. Two 5 minute washes in PBS 
were used to remove residual hydrogen peroxide. Slides were then dried using Kim 
wipes (Fisher Scientific, UK), and sections encircled using a PAP pen (Dako, UK).
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Equilibration buffer (10 pi) was pipetted onto each section, and allowed to react for a 
minimum of 10 seconds. lOpl of TdT enzyme was added to each sample, while 
negative control slides received the same volume of PBS. Slides were covered with a 
plastic hybrislip (Chemicon International, UK) and incubated in moist chambers at 
37°C for 1 hour. Hybrislips were gently removed, and working strength stop-wash 
buffer was applied to the sections to prevent further reaction. Three washes in PBS 
were followed by application of 10 pi per section of antiperoxidase conjugate. After 
30 minutes, unreacted conjugate was removed with four 2 minute washes in PBS. 
Working strength peroxidase substrate, diaminobenzoate (DAB) in the form of Fast 
DAB (Sigma-Aldrich, UK) was applied to each section for 6 minutes. Excess reagent 
was removed by three 1 minute, and then one 5 minute wash in distilled water.
Subsequently, nuclei in the tissue sections were counter-stained with methyl green for 
10 minutes. Excess stain was removed by five 1 second washes in each of two 
distilled water baths, followed by a 30 second wash. Staining was fixed using acetone, 
by washing in two acetone baths (for five 1 second washes each) followed by a 30 
second wash. Sections were dehydrated in two 2 minute washes of xylene and 
mounted in Histomount.
2.6.1.1 Quantification o f TUNEL positivity
TUNEL positivity was assessed by cell counts undertaken in a masked fashion. All 
TUNEL positive and methyl green positive nuclei (i.e. all cells) in the ganglion cell 
layer of the retina were counted for two sections per eye (n=50) by a masked 
observer. The number of TUNEL positive cells was expressed as a percentage of total 
cell number in Microsoft Excel. Average percentage TUNEL positivity was 
calculated for each eye and for each animal group (for group details see Chapter 3, 
Section 2.3.1.6) using a Microsoft Excel formula.
Statistical comparisons were made between ipsilateral hypertensive and contralateral 
normotensive TUNEL positivity at the nasal, superior and overall retina for different 
IOP groups. These comparisons were made using two-tailed T-tests and ANOVA, as 
described in Section 2.1.2.1.
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2.6.3 Active Caspase 3 immunolabelling
Active caspase 3 immunolabelling was performed on the same set of retinae as 
TUNEL labelling (Sections 2.6.1 and 2.6.2) in order to confirm apoptosis in support 
of TUNEL results.
Sections were brought to water as described in Section 2.2.5, then rinsed three times 
for 10 minutes each in PBS and fixed for 10 minutes in acetone. Sections were 
incubated in 0.2% Triton X-100 for 20 minutes, followed by PBS washes as before. 
20 pg/ml PK was applied, and sections incubated for 20 minutes, 40 minutes or 1 
hour in order to optimise labelling conditions. Three PBS washes were performed as 
before. Monoclonal active caspase 3 donkey anti-rabbit primary antibody (Abeam, 
UK) was applied to the sections at a 1:10 dilution in PBS. Two hours later, primary 
antibody was removed via three 10 minute PBS washes. Alexafluor 594 donkey anti­
mouse secondary antibody conjugate at a 1:1000 dilution in PBS was used to 
fluorescently label active caspase 3 tissue antigen. Excess secondary antibody was 
removed by washing three times for 10 minutes each in PBS. Sections were mounted 
in gelvatol (see Section 2.5.2 and Appendix 1). Images were captured as described in 
Sections 2.5.3 and 2.5.4.
2.7 Immunohistochemical staining for NOS, glia and microglial cell markers
2.7.1 Primary and secondary antibodies
Antigens in tissue sections were localised using the primary antibodies described in 
Table 2.1. Initially, single immunolabelling was used in order to optimise techniques 
and to clearly show the tissue localisation of each antigen.
Secondary antibodies were fluorescent Alexafluor 488 donkey anti-rabbit and/or 
Alexafluor 594 donkey anti-mouse.
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Table 2.1 Primary antibodies used in optic nerve immunolablling
Antigen Origin Clonality Supplier
Anti-rat CD200L Mouse Monoclonal Harlan-Sera lab, UK
Anti-rat CD200R Mouse Monoclonal Harlan-Sera lab, UK
Anti-rat CD45 Mouse Monoclonal Harlan-Sera lab, UK
Anti-cow GFAP Rabbit Polyclonal Dako, UK
Anti-rat MHCII Mouse Monoclonal Immunologicals direct, UK
Anti-human NOS1 Rabbit Polyclonal Autogen Bioclear, UK
Anti-human NOS2 Rabbit Polyclonal Autogen Bioclear, UK
Anti-human NOS3 Rabbit Polyclonal Autogen Bioclear, UK
Anti-rat 0X33 Mouse Monoclonal Harlan-Sera lab, UK
Anti-rat OX41 Mouse Monoclonal Harlan-Sera lab, UK
Anti-rat 0X42 Mouse Monoclonal Harlan-Sera lab, UK
2.7.2 Immunohistochemical techniques
2.7.2.1 Optimisation o f paraffin-wax section immunolabelling 
Preparation for immunolablling ofparaffin-wax sections
Wistar rat eye wax sections (7 pm) on Histobond coated slides were rehydrated by 
passing through xylene, decreasing concentrations of alcohol (as described in Section
2.2.5), then fixed for 10 minutes in acetone. Between all subsequent steps, three 10 
minute washes in PBS were used to remove residual reagents.
Antigen unmasking steps
Slides were treated with 20 pg/ml PK in PBS for 20 minutes to aid antibody entry into 
the tissue. Then a 10 minute wash in a 0.2% solution of Triton X-100 in PBS was 
used to permeabilise cell membranes. Subsequently, as PK did not adequately unmask 
antigens, PK was replaced by 0.1% pepsin in 0.01N HC1 administered to the sections 
for 15 minutes. 0.5% normal donkey serum (NDS, Abeam, UK) in PBS was
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substituted for PBS throughout experiments where pepsin was used, to reduce non­
specific binding.
Application o f antibodies
Anti-glial fibrillary acidic protein (GFAP) primary antibody was administered to the 
sections at the following dilutions: 1:100, 1:200, 1:300, 1:400, 1:500, and reacted for 
2 hours at room temperature. Alexafluor 488 secondary antibody diluted to 1:1000 in 
PBS containing 0.002mg/ml bisbenzimide was applied to sections for 1 hour.
2.7.2.2 Development o f an immunolabelling protocol for frozen sections
Preperation for immunolabelling
Fresh and PFA-fixed 7 pm frozen optic nerve sections on Superfrost Plus slides (see 
Section 2.2.4.1 for details) were brought to room temperature for 20 minutes, then 
washed for 30 minutes in PBS. Labelling was improved by removing the PBS wash 
and replacing with an overnight incubation in 30% sucrose at 4°C.
Tissue fixation
Following sucrose treatment, further improvements included fixation in 100% 
methanol for 10 minutes at room temperature. Methanol was substituted with acetone 
for clearer labelling.
Pre-antibody application antigen unmasking and blocking procedures 
Following these initial treatments, the same protocol, as used for wax sections, was 
implemented using PK to unmask tissue antigens (Section 2.7.2.1). Due to excessive 
labelling, and in order to further develop this technique, experiments were run where 
PK and/or Triton X-100 were omitted. Incorporation of a one hour blocking step 
using 5% NDS in PBS did not improve immunolabelling sufficiently. However, 
further optimisation revealed that non-specific tissue antigenicity was eliminated by 
treatment with a 30 minute wash in PBS containing 2% BSA and 0.1% Triton X-100 
(Wash Buffer 1).
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Primary antibody application
Initially primary antibody was added, appropriately diluted (according to 
manufacturers guidelines) in PBS. The addition of 2% BSA and/or 0.1% Triton X-100 
to the primary antibody dilution did not improve labelling. However, by primary 
antibody dilution in PBS containing 0.1% Tween-20 (polyoxyethylenesorbitan 
monolaurate, Sigma-Aldrich, UK), and further by the addition of 0.5% NDS (Wash 
Buffer 2) conditions were optimised. Sections were incubated with primary antibody 
at room temperature for 2 hours or overnight at 4°C.
Removal o f excess primary antibody
Initially excess primaiy antibody was removed by three 10 minute washes in PBS. 
Washing in Wash Buffer 1 as opposed to PBS improved clarity of results.
Secondary antibody application
The appropriate Alexafluor secondary antibody diluted to 1:1000 in PBS containing 
0.002 pg/ml bisbenzimide was applied to the sections for one hour at room 
temperature. Secondary antibody application was optimised as for the primary 
antibody, using Wash Buffer 2. Traces of antibody were then rinsed away using three 
10 minute PBS washes.
Substitution of PBS with Tris-buffered saline (TBS), pH 7.5 (see Appendix 1) did not 
appear to improve immunolabelling, consequently PBS was used in the optimised 
immunolabelling protocol. The final immunohistochemical experimental protocol is 
summarised in Figure 2.5.
2.7.2.3 Control tissue and sections
Control sections were used as described in Section 2.5.1. Two control sections were 
used for each eye. Positive control tissues, as recommended by the primary antibody 
manufacturer, were harvested from Norwegian brown rats.
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4% PFA-fixed frozen sections
________________ i z ________________
Defrost for 20minutes
__________________ i z __________________
Soak in 30% sucrose overnight
_____________iz_____________
Fix in acetone, lOminutes
_______________________________i z _______________________________
Rinse in PBS / 2% BSA / 0.1% Triton-X 100, 30 minutes
_______________________________________ i z ______________________________________
Primary antibody / 0.5% NDS / 0.1% Tween-20, 2 hours or overnight (4°C)
___________________________________i z ____________________________________
Rinse in PBS / 0.5% NDS / 0.1% Tween-20, 3x 10 minute washes
______________________________i z ______________________________
Secondary antibody in PBS / 0.002 pg/ml bisbenzimide
_______ i z ________
Rinse in PBS
‘....II  ,
Mount in gelvatol
, i f
Coverslip
r — E = — iStore in the dark
Figure 2.5 Summary flow chart of immunohistochemical protocol Following 
optimisation o f immunolabelling the same protocol was used consistently on all tissue 
sections. This method is detailed in the flow chart.
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Positive control tissues were brain for GFAP and all nitric oxide synthase (NOS) 
antibodies, as well as lymph and spleen for all macrophage, lymphocyte and 
microglial markers. Additional positive control tissues for NOS-2 and NOS-3 were 
penis and heart, respectively.
2.7.2.3 Non-fluorescent immunohistochemical mountants
During the optimisation procedure, samples were mounted in Hydromount, glycerol 
or gelvatol (see Appendix 1 for details).
2.7.2.4 Primary antibody combinations
Initially, single immunolabelling was used to optimise the protocol for each primary 
antibody in parafin wax and frozen tissue sections. Subsequently, dual labelling was 
performed on two fresh frozen sections from hypertensive (n=25) and normotensive 
(n=25) Norwegian brown rat eyes using combinations of primary and secondary 
antibodies. Dual labelling was required to colocalise NOS antigenicity with astrocyte, 
microglial and immune cell markers. This should provide information on the cell 
types responsible for any alterations in NOS immunolabelling following experimental 
glaucoma. As a general immune and microglial cell marker, major histocompatability 
complex II (MHCII) primary antibody was used in conjunction with each NOS 
isoform primary antibody. MHCII was also used together with GFAP in order to 
ensure there was no colocalisation of microglia or peripheral immune cells with 
astrocytes.
All other cell markers were used in conjunction with NOS2 in order to ascertain 
where potentially neurotoxic nitric oxide (NO) may originate from following ocular 
hypertension. CD200R and CD200L were also used in dual labelling with GFAP. 
Very little is known about the distribution or cellular localisation of CD200 and its 
receptor in the optic nerve, particularly during glaucoma. During dual labelling, 
tissue was incubated in a solution containing both Alexafluor secondary antibodies 
and 0.002 pg/ml bisbenzimide (see Figure 2.5).
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2.7.2.5 Image capture
The orientation and location of fluorescent images captured for each region of interest 
is shown in Figure 2.6. Fluorescent red and blue immunolabelling were examined 
using appropriate fluorescent filters, magnifications and software as described in 
sections 2.5.3. Labelling using the secondary antibody, Alexafluor 488 was visualised 
by excitation at 495nm wavelength light, with green fluorescence emission at 525 nm.
Figure 2.6 Locations in the rat optic nerve o f captured immunofluorescent 
images The rat optic nerve is shown in longitudinal section stained with Masson’s 
trichrome green (x20 magnification). Images were consistently recorded from the 
same locations in the optic nerve following labelling for glial markers and NOS. For 
each optic nerve used, two images were recorded from each region o f interest, namely 
the optic nerve head and optic nerve. The white boxes in the diagram above indicate 
the areas that were imaged.
73
Chapter II General Method Development
All images consisted of 264872 pixels each and were captured using Leica Qfluoro 
software. One optic nerve head and one retrobulbar optic nerve composite image were 
captured per longitudinal section. Each composite image consisted of one each of 
green, red and blue images overlaid. The 40x objective was used, as this enabled 
image capture of the entire optic nerve head width. Optic nerve head images were 
taken from the point of convergence of retinal nerve fibres into the optic cup, while 
retrobulbar optic nerve images were taken from the centre of the nerve immediately 
post-transition zone.
2.7.2.6 Quantification o f immunofluorescence
Immunofluorescence was quantified in optic nerve head and retrobulbar optic nerve 
images. Leica QWin software was used to convert single colour red or green 
(depending on the secondary antibody used) fluorescent images to grey scale. These 
single colour images contained 264872 pixels. For each grey scale image, the 
intensity of every individual pixel was measured. Each pixel was therefore assigned 
an intensity value on a scale from 0 (black) to 255 (white). Pixel intensities were 
recorded and input into Microsoft Excel.
2.1.2.7 Statistical analysis o f  quantified immunofluorescence
All data analysis was performed using Microsoft Excel (n=25). Formulae and 
calculations were input manually unless otherwise stated. Results were separated into 
three animal groups (containing n=25 each) characterised by IOP elevation (see 
section 2.3.1.6). Each of these three groups contained five sub-groups with increasing 
severity of IOP elevation. Each sub-group contained two sets of results for each of 
five animals (n=10 each). Results were normalised by measuring background red or 
green fluorescence from two control (without primary antibody) sections and 
subtracting this from either red or green labelling of the equivalent experimental 
sections from each control and ocular hypertensive eye. Normalisation was performed 
independently for each eye in order to account for variations between eyes. Mean 
numbers of pixels at each intensity (from 0 to 255) were calculated separately for each
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region of interest in contralateral and ipsilateral in each sub-group for every antibody 
used.
Two-sample, two-tailed T-tests were also used to compare the differences in immuno- 
related fluorescence data in contralateral and ipsilateral eyes. The total value, equal to 
the sum of (xy), where x=intensity of a given pixel, and y=the number of pixels at a 
given intensity, was calculated for each intensity. Ipsilateral and contralateral (xy) 
values were compared using a two-tailed T-test. The mean differences were also 
compared for significance between IOP groups, eg T1 and T2, T2 and T3, and so on.
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Chapter III 
Development of a Rodent Glaucoma Model
3.1 Introduction
Histological similarities between the rodent and human optic nerve have led to the 
development of experimental glaucoma models in the rat. Ultrastructural studies of 
the optic nerve head, Schlemm’s canal (van der Zypen, 1977), and the episcleral 
drainage vessels (Morrison et al., 1995) reveal important similarities between the rat 
and human. The rat is therefore potentially useful for modelling glaucoma.
Glaucoma can be modelled in retinal ganglion cell (RGC) culture or co-cultures with 
glia to illustrate pressure-induced cellular alterations at a biochemical level 
(Hernandez et al., 2000; Liu and Neufeld, 2001). However, in glaucoma the entire 
optic nerve head structure and dynamic is altered, involving mechanisms likely to 
affect RGC survival which are still not fully understood. Pressure-induced alterations 
in cell culture can only provide a fraction of the information required for 
understanding the pathogenesis of glaucoma.
Many glaucoma models are available in various experimental animals with conditions 
as diverse as the human disease. Inducible glaucoma models most frequently involve 
manipulation of intraocular pressure (IOP), as IOP elevation is a major risk factor for 
the human disease (Davanger et al., 1991). Experimental animal models of pressure -  
independent glaucoma are available, for example the DBA/2J mouse model of 
pigment dispersion glaucoma (John et al., 1999). During this form of glaucoma, the 
iris pigment disperses and clogs the trabecular meshwork. Hypertension can be 
induced via reduction of aqueous outflow through laser treatment of the trabecular 
meshwork, cauterisation of episcleral drainage vessels, and most recently a
spontaneously occurring glaucoma model has been discovered (Thanos and Naskar, 
2004).
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The most common form of human glaucoma, primary open angle glaucoma (POAG), 
can be closely emulated in some forms of experimental glaucoma. Glaucomatous 
changes homologous to primary open angle glaucoma (POAG) can be induced in the 
Norwegian brown rat by a direct injection of a mild sclerosant into the episcleral 
drainage system (Johnson et al., 1995). By virtue of direct links between the episcleral 
venous system, and Schlemm’s canal (Morrison et al., 1995), aqueous drainage vessel 
sclerosis directly results in elevation of IOP. Variation in technique, such as amount, 
concentration and injection rate of sclerosant can produce different degrees of IOP 
elevation sustainable over chronic periods.
IOP should be monitored on a regular basis during experimental glaucoma. Accurate 
assessment of IOP elevation can allow direct correlation between IOP and optic nerve 
changes. Daily tonometry causes artefactual reduction of IOP, therefore less frequent 
readings are more accurate (Moore et al., 1995). IOP measurements are highly 
sensitive and can be affected by many variables including ocular rigidity and 
pathology (Damji et al., 2003). General anaesthesia can reduce IOP up to 60% (Jia et 
al., 2000). Therefore, measurement is best obtained via awake tonometry using a local 
anaesthetic. Indications are that the hand-held Mentor® tonopen can be used on small 
rodents to obtain reliable IOP readings (Danias et al., 2003; Moore et al., 1995).
IOP shows circadian variation under the control of suprachiasmatic nucleus (SCN) 
oscillator neurons (Quintero et al., 2003). Human IOP peaks during the day, with a 
trough during the night (Asrani et al., 2000; Pointer, 1997). However, most rodents 
are nocturnal, and therefore experience peak ocular tension during the night (Krishna 
et al., 1995; Nii et al., 2001). Maintenance on a 12:12 lightrdark cycle results in a two 
hour peak or trough in IOP one hour into the dark or light cycle, respectively (Jia et 
al., 2000). In order to avoid the effects of circadian control on IOP animals can be 
exposed to constant low levels of non-neurotoxic 60 -  90 lux light.
Many fundamental characteristics of IOP elevation via episcleral drainage vessel 
sclerosis in the rat render this model and species the most convenient for experimental 
glaucoma studies. Similarly, due to our current understanding of IOP (including the
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effects of anaesthesia and circadian control), glaucoma can now be reliably induced 
by the experimental elevation of IOP.
The aim of this chapter was to develop a reliable animal model of pressure-dependent 
glaucoma similar to that developed by Morrison et al., 1995. Analysis of aspects of 
hypertension in order to relate these to other glaucomatous pathological changes was 
also essential.
3,2 Methods used to develop experimental glaucoma
All methods used in the development of an experimental glaucoma model are 
described in Chapter II, Section 2.1 inclusive. Objectives included determination of an 
accurate method to measure IOP (including the minimisation and control of circadian 
IOP), as well as optimisation of surgical techniques of IOP elevation.
Adult male Norwegian brown rats were used (n=75), animal heath was measured as 
an index of health throughout experimentation. IOP was measured using 10 readings 
taken from both eyes using a Mentor Tonopen ® tonometer.
Tonometric techniques were developed pre-surgery by the use of alternative probe 
shields. Two observers took all tonometry readings, and interobserver analysis was 
used to ensure consistency. Low lighting levels (60 to 90 lux) were used to minimise 
circadian variation in IOP. These methods were developed to ensure that multiple 
investigators could perform the most accurate method of tonometry, and reliable IOP 
readings could be recorded at any time.
Surgical elevation of IOP involved ipsilateral retrograde microinjection of a single 
episcleral drainage vessel with 1.75M hypertonic saline. Contralateral eyes were used 
as controls. Optimisation of surgical methods involved may fine adjustments to 
published technique (Morrison et al., 1995). In particular, the structure of the 
microneedle used to inject hypertonic saline was adapted to improve success rate of 
IOP elevation.
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Following surgery to elevate ocular pressure, IOP was measured consecutively for the 
first five days. Tonometry was then performed on alternate days until euthanasia. 
Duration of IOP elevation (T), area under the pressure curve (A) and standard 
deviation of pressure elevation (S) were calculated for all animals with a significant 
pressure elevation (P<0.05) in ipsilateral versus contralateral eye. Five groups were 
created within each of T, A and S, to represent the wide variation in aspects of IOP, 
and to allow pathological alterations of the optic nerve to be ascribed to the different 
aspects of pressure elevation. Correlation between these groups were assessed using 
Pearson’s correlation coefficient.
3.3 Results
3.3.1 Animal health during experimentation
Mean animal weight increased from 383 g on initiation of licensed procedure to 395 g 
at euthanasia (Figure 3.1). All animals appeared healthy and infection, irritation or 
inflammation of the operated area was not observed. 10.9% of animals experienced 
bladder infections both pre and post-procedure and were treated with veterinary 
prescribed systemic antibiotics. One animal suffered from a skin irritation treated by 
daily swabbing with dilute Betadine. Irreversible weight loss was recorded from 2 
animals due to circumstances unrelated to husbandry or procedure.
3.3.2 Development of tonometric techniques
Initial pre-surgical tonometry readings from the first group of experimental animals 
suffered from high variability due to experimenter inexperience. For all animal groups 
other than the first, standard deviation was low and sustained. Over time standard 
deviations became significantly reduced for both experimenters, in both eyes. More 
reliable tonometry readings were obtained with practice of the technique (Figure 3.2).
Standard deviation of tonometric techniques were not significantly reduced by use of 
alternative tonopen probe shields (P>0.05). The naked probe produced the minimum
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standard deviation (7.11), which increased with the thickness of the shield (i.e. 7.74 
with non-static film and 8.42 with a Mentor Ocu-film cover).
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Figure 3.1 Animal weight as an index o f health (n=75) Weekly animal weight is 
shown post-microinjection. Animal number reduced over time due to euthanasia. 
Mean animal weight did not reduce as a result o f the microinjection procedure. 
Microinjection appears to have no adverse effects on animal health. Standard 
deviation (bars) indicates a high variability o f animal weight.
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Figure 3.2 Increased reliability in IOP reading over time IOP readings from 
animals (n=75), grouped depending on the start date o f IOP measurements proved 
that initial (group 1) measurements o f IOP suffered from high deviation (columns), 
standard error (bars) and coefficient o f variation (dots). White represents 
contralateral measurements, while ipsilateral measurements are shown in grey. In 
subsequent groups, deviation, variation and error decreased.
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On comparison, interobserver variation was not significantly different with the 
unshielded probe (P=0.62) or the Ocu-film cover (P=0.35). However, interobserver 
tonopen readings using non-static film were significantly different (P=0.0059). 
Contralateral and ipsilateral lOPs were not significantly different with the unshielded 
tip, non-static film, or Ocu-film cover (P=0.95, 0.72 and 0.99, respectively). These 
data are summarised in Figure 3.3.
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Figure 3.3 Pre-operative IOP readings with different tonopen tip covers IOP
readings (n=3) did not differ significantly in standard deviation or error with the use 
o f different tonopen tip covers according to ANOVA testing (P>0.01). Interobserver 
differences in IOP were also not significant with alternative tip covers (P>0.1). Error 
bars show the range o f standard deviation.
3.3.3 Inter-investigator tonometry readings
Inter-investigator variations in pre-surgical tonometry readings were not statistically 
significant for contralateral (P=0.32) or ipsilateral (P=0.41) eyes. Mean contralateral 
pre-surgery readings for investigator 1 and 2 were 25.42 mmHg and 24.99 mmHg, 
respectively (figure 3.4). Investigator 1 obtained a mean ipsilateral IOP of 26.36 
mmHg, while investigator 2 obtained an ipsilateral IOP of 24.77 mmHg (Figure 3.4).
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Figure 3.4 Inter-investigator comparison o f IOP readings Pre-surgical 
contralateral and ipsilateral IOP were not significantly different between 
investigators (p>0.05, n=75, Investigator 1, grey and Investigator 2, white). Bars 
indicate standard deviation. Difference in IOP and average IOP are indicated by 
circles. There was good agreement between investigators (k=0.61, kappa is the 
measure o f inter-rater agreement according to Bland and Altman testing).
3.3.4 Minimisation of circadic control of IOP
Circadian peaks and troughs in aqueous outflow and secretion were eliminated by 72 
hour exposure to low levels of constant light. Under normal lighting conditions, a 
peak during the dark phase (7-9pm) and a trough during the light phase (7-9am) of the 
light cycle would be expected. Comparison of readings, taken during these time 
points, with readings taken during the day, demonstrated that circadian control of IOP 
had been eliminated by exposure to constant lighting (Figure 3.5).
Mean contralateral IOP was 25.16 mmHg during “day” readings. A reduction of only 
0.11 mmHg was observed with readings taken during the “dark” phase of the light 
cycle, when IOP mean was 24.31 mmHg. A slight IOP increase of 0.35 mmHg was 
observed during the “light” phase, with a mean IOP of 25.36 mmHg. Similar 
discoveries were made using the ipsilateral IOP, which increased by 0.83 mmHg and 
reduced by 0.4 mmHg during the “dark” and “light” phases respectively. Day 
ipsilateral IOP was recorded as 25.10 mmHg.
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Figure 3.5 Exposure to constant light eliminated the circadian control o f IOP
IOP recorded at time points with circadian relevance were not significantly different 
according to ANOVA testing (n=75, P>0.1). Light readings were performed during 
the circadian trough, while dark readings were taken during the peak in aqueous 
outflow. Day readings were recorded at any time point between these peaks and 
troughs. Therefore reliable tonometry readings can be recorded at any time over a 
24-hour period.
Slight IOP differences were recorded from each eye at all time points. Ipsilateral IOP 
was higher than contralateral IOP both during the “dark” (0.68 mmHg) and “light” 
(0.09 mmHg) phases. However, during the day, contralateral IOP was slightly above 
ipsilateral by 0.06 mmHg. None of these differences were significant (P>0.1). These 
changes are opposite to those produced by circadian flux. Constant lighting eliminated 
the circadian control of IOP. Therefore, IOP measured at any point would not be 
artificially elevated or reduced.
3.3.5 Microneedle adaption
Some adhesive agents were highly electrostatic and attracted dust particles in the form 
of a white deposit. Capillary action allowed entry of adhesive into the needle due to 
low viscosity. Successful microinjection was not achieved using these needles due to 
blocked fluid outflow. Storage in a moist chamber prevented successful
□  DARK ■  DAY □  LIGHT
Ipsilateral Contralateral
Time point
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microinjection through softening of the adhesive bond resulting in leaking. Needles 
where high viscosity Superglue™, dried for 10 minutes before application were found 
to be optimal for successful IOP elevation. The application of heat shrink tubing 
around the blunted needle and tubing attachment overlaid with high viscosity 
Superglue™ produced even more durable needle assemblies. Application of this 
tubing to secure the microneedle limited accessibility to the episcleral vasculature.
Heat-stretched tubing used to deliver sclerosant was highly elastic, and reduced 
resistance to pressure resulted in uncontrollable fluid outflow. Consequently the 
volume of hypertonic saline delivered into the episcleral drainage system could not be 
measured. Slightly tapered small (0.038 inch OD) diameter tubing was found to be far 
more accurate and safe for episcleral fluid delivery.
Initial surgeries using 50 pm diameter microneedles, supplied by the Morrison 
laboratory were unsuccessful. The superior episcleral drainage vessels were too small 
for successful cannulation with a needle of this diameter. Significant pressure 
fluctuations were recorded from the 10 animals microinjected with these needles, 
relating to either IOP reduction (Figure 3.6) or unsustained elevation (Figure 3.7). 
Microneedle diameters of less than 15 pm often blocked with dust particles. Increased 
resistance to fluid outflow due to a small inner diameter resulted in leakage from the 
adhesive joints and lack of fluid delivery. Microneedles of between 20 and 30 pm 
outer diameter were optimal for cannulation. Insertion of approximately 2 mm of the 
needle length was sufficient to occlude the vessel, produce a successful microinjection 
and elevated IOP (Figure 3.8).
3.3.6 Development of surgical techniques
Ergonomics of surgery were an issue, as it necessary to insert then maintain a 
microneedle in a small aqueous drainage vessel for almost a minute. The hand rest 
designed specifically for this purpose assisted in successful microinjections. After 
some time it was found that this rest interfered with accessibility to the tissue, and that 
practice had increased hand stability sufficiently for rest-free microinjections.
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Figure 3.6 An example of IOP reduction Reduction o f  IOP during optimisation o f
microinjection is shown (n=l). IOP elevated only at day 1 post-microinjection. IOP 
returned to normal by day 3, and no further elevations were recorded up to 62 days 
post-microinjection. Bars indicate standard deviation.
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Figure 3.7 Fluctuation of experimental eye pressure In some cases fluctuation o f
experimental eye pressure was recorded, as shown above (n=l). This deviation can 
be accounted for by optimisation o f  the microinjection procedure, and the variability 
between individual animals. Bars indicate standard deviation.
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Figure 3,8 Consistent IOP elevation Following optimisation o f  the microinjection 
technique it was possible to secure a consistent IOP elevation. However, this 
elevation could become unstable, producing extremely high pressure as shown (n=l). 
In the majority it was possible to avoid this pressure response by reducing the force o f  
hypertonic saline injection. Bars indicate standard deviation.
3.3.7 IOP elevation
IOP elevation was successfully sustained in the majority of animals (n=57). Post- 
surgical mean contralateral IOP was 25.34 mmHg, while ipsilateral was 31.25 mmHg, 
an increase of 5.89 mmHg. Sham-operated animals (n=8) did not experience a 
sustained significant pressure elevation under any circumstances.
Mean daily ipsilateral IOP elevation for all animals was 6.55 mmHg. IOP was 
elevated for between 1 and 65 days. Standard deviation of elevated IOP ranged from
1.05 to 13.56 depending on whether the IOP elevation was sustained, or fluctuated. 
The average standard deviation of all readings was 3.76. Sham-operated animals 
(n=8) did not experience a sustained significant pressure elevation under any 
circumstances. Ocular hypertensive animals were separated into groups with 
increasing pressure duration, area under the pressure curve or standard deviation. The
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table shown in Figure 3.9 illustrates the boundaries of these IOP sub-groups. Group 
boundaries were set based upon the available range of animals, post-mortem. Figures 
3.10 to 3.12 show the full range of duration of pressure elevation (T1 to T5), area 
under the IOP curve (A1 to A5) and standard deviation of elevated pressure (SI to 
S5). These groups can be used to correlate pathological optic nerve changes with 
changes in IOP.
Level GROUP “T”
Duration of IOP 
elevation (days)
GROUP “A”
Area under the pressure 
curve (mmHg)
GROUP “S”
Standard deviation
1 1 - 7  (n=10) 0.9 -  22.7 (n=8) 0-1.511 (n=6)
2 1 1 -1 9  (n=19) 24 .3 -96 .8  (n=16) 1.52 - 2.96 (n=13)
3 20-27  (n=l 1) 97.2-151.1 (n=15) 3.20 - 3.75 (n=9)
4 3 3 -4 6  (n=10) 165.3-256.1 (n=8) 3.81 - 5.57 (n=16)
5 47 - 65 (n=7) 271.9-469.3 (n=10) 6.02 -12.76 (n=12)
Figure 3.9 Attributes of IOP used to categorise experimental IOP elevation
Animals (h=57) falling between the values shown for each variable were assigned to 
the relevant group. The number o f  animals within each group is shown.
Area under the IOP curve is equal to IOP multiplied by number of days of pressure. 
Area under the IOP curve and duration of pressure elevation covary, with a 
correlation coefficient (r) of 0.602 (p<0.001). There is a trend towards an increase in 
both factors. This correlation would increase if all pressure elevations were similar. 
There is variation in the magnitude of pressure elevation, which is independent of the 
duration of IOP elevation in some cases. However, in the majority longer durations of 
pressure elevation produce a higher area under the curve (Figure 3.10). Standard 
deviation of IOP elevation correlated negatively with the duration of pressure 
elevation at r = -0.0784 (p<0.001, Figure 3.11). Longer pressure durations resulted in 
the lowest standard deviations. IOP may stabilise at longer durations or as familiarity 
with and tameness of the animal increase. Area under the pressure curve and standard 
deviation of pressure elevation elevated together and correlated with a coefficient of r 
= 0.17 (p<0.001, Figure 3.12).
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Figure 3.10 Duration o f IOP elevation and area under the IOP curve Duration o f 
IOP elevation (shown as bars) was over a wide range from 1 to 65 days (n=58). 
Duration o f elevated pressure increased with area under the pressure curve (r = 
0.602). Outliers indicate generation o f very low or very high-pressure elevations in 
combination with particularly short or long durations o f elevated pressure.
Figure 3.11 Standard deviation o f IOP elevation with duration o f elevation
Overall standard deviations o f IOP elevation (black points) covaried with duration o f 
IOP elevation (grey bars) for individual animals (n=58). There was a low correlation 
between these sets o f values (r = -0.0784).
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Figure 3.12 Standard deviation o f IOP elevation with area under the curve
Standard deviation o f IOP elevation (black points) correlates at a low level with area 
under the IOP curve (grey bars, r = 0.17). As area under the curve increases, there is 
a slight trend for standard deviation to elevate (n=58).
3.4 Discussion
3.4.1 Animal health and constant illumination
The assessment of animal health during experimental studies is vital in terms of 
producing good quality data. Animal weight is the most convenient method of making 
such measurements. No reduction in animal weight was recorded following the 
initiation of procedure. Therefore it is unlikely that animals were adversely affected in 
any way other than that intended by the procedure.
The few anomalous cases of weight loss and illness recorded here might be expected 
in any normal population of animals. However, failure to thrive may be the 
consequence of a number of experimental variables, including infection, anxiety, or 
procedural side effects. Many studies have investigated the effects of constant light, 
which may have a profound effect on ability to thrive. Constant lighting was included 
in these experiments in order to minimise the circadian control of IOP fluctuation.
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The evidence suggests that circadian fluctuation of IOP no longer occurred under 
constant light. IOP was relatively constant throughout all time points expected to have 
circadian relevance. This corresponds with other experiments involving constant low 
levels of lighting (Moore et al., 1995; Morrison et al., 1995). Similarly the animals 
used in this study (and others) did not experience adverse effects from the 
experimental conditions.
Slight weight increases may be a consequence of growth, however the effects of 
constant light on feeding may also be shown through the elevation of animal weight. 
It possible that other circadic processes controlled by SCN oscillation were disrupted 
by constant light exposure. Visible light exposure can produce neuroendocrine 
alterations leading to changes in hormone levels, which contribute to immune 
response and feeding (reviewed by Roberts, 2000). In particular, the hypothalamo- 
pituitary-adrenal (HPA) axis, normally involved in maintaining homeostasis during 
chronic inflammation though adrenal glucocorticoid release can be disrupted by 
exposure to constant light (reviewed by Harbuz, 1999). Therefore animals exposed for 
long periods to constant light would be more likely to develop autoimmune disease.
The elimination of circadian control may result in more reliable tonometry readings 
(Moore et al., 1995; Morrison et al., 1995), however, the effects may be more far 
reaching. For example, through compromise of the immune system which may affect 
neurodegeneration in glaucoma (Bakalash et al., 2002).
3.4.2 Validity of tonometric techniques
Tonometry was used to identify experimental glaucoma via elevation of IOP. IOP 
readings are most commonly recorded from experimental animals via a hand-held 
Tonopen. This is an extremely reliable method, and is much more convenient for 
studies on small animals than other methods such as Goldmann which may require 
general anaesthesia.
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Many studies use an unshielded tonopen to measure IOP in experimental glaucoma. 
The use of Mentor Ocu-film tip covers, non-static film, or the absence of a cover does 
not improve tonometiy readings. It is therefore best practice to use the manufacturers 
recommended method, as this is not significantly worse than other methods. This also 
avoids unnecessary damage to the tonopen, and voiding of the warranty. This small 
study suggests that use of an unshielded tonopen may be an unnecessary precaution.
3.4.3 The elevation of IOP
In order to successfully elevate IOP it was necessary to make various improvements 
and adjustments including a reduction in microneedle diameter and taper of 
microneedle tubing. The techniques used by Morrison et al. (1995) were found to be 
inappropriate due to the small sized aqueous drainage vessels of our animals. 
Inaccuracies in hypertonic saline delivery resulting from the use of tapered 
microneedle tubing were also eliminated by our study. These alterations should 
improve success rate and ease of the microinjection procedure during future studies.
Several problems were encountered during the development of the glaucoma model. 
During optimisation of the microinjection procedure, surgery sometimes resulted in 
reduction of IOP. Hypertonic saline injection causes reduction in the size of the ciliary 
body, which may account for this low IOP (Chanis et al., 2003). It is also possible that 
fitting a constrictive equatorial band around the eye during surgery in order to limit 
vessel sclerosis may affect IOP. The pressure from this band may have forced 
aqueous to exit the eye resulting in IOP reduction. There is also no evidence to 
suggest that this band did not have adverse effects on RGC survival through physical 
damage of the retina. However, lack of IOP elevation or adverse effects of surgery in 
sham-operated animals indicated that surgical techniques other than hypertonic saline 
delivery were unlikely to cause IOP fluctuations that induce RGC damage.
3.4.3.1 Elevation o f IOP in other rat models
Many laboratories have reported difficulties in developing the episcleral drainage 
vessel sclerosis glaucoma model identified by Morrison et al. (1995). These groups
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often resort to either the episcleral drainage vessel cautery model (Garcia-Valenzuela 
et al., 1995; Sawada and Neufeld, 1999), or translimbal laser photocoagulation of the 
trabecular meshwork (Levkovitch-Verbin et al., 2002). Episcleral vessel cautery 
disrupts blood flow, and it is unknown whether optic nerve alterations are produced 
by reduction of aqueous drainage, or from congestion of ocular blood flow. Similarly, 
the effects of laser treatment on the ocular system may not be localised to just the 
trabecular meshwork. Damage to other ocular tissues may result from laser treatment, 
for example the iris or the cornea may become damaged.
These alternative models may be representative of secondary or vasospastic 
glaucoma. However, they do not convincingly represent POAG, the most common 
form of the human disease. The elevation of IOP via sclerosis of an aqueous drainage 
vessel is more representative of the human condition. The changes suggested here to 
the techniques used by Morrison et al. (1995) may improve the success rate of this 
model in other laboratories.
3.4.3.2 Comparisons between basal and elevated IOP
IOP has been used to define many glaucoma models, and is a major diagnostic factor 
in the human disease. As a result there is a wealth of information available regarding 
IOP elevation during glaucoma.
In comparison with data collected by Johnson et al. (2000) from the same breed and 
strain of rat, mean control IOP used in the present study is relatively high. Johnson et 
al., (2000) found mean control IOP was 19.5 mmHg, as compared to our value of 
25.34 mmHg. Norwegian brown rats have been shown to exhibit a control IOP of 25.1 
mmHg (Grozdanic et al., 2003) similar to IOP values achieved in this study. The high 
number of readings recorded, and the use of two separate investigators limits the 
possibility of tonometric error produced from experimental technique. It is possible 
that similar to discrepancies in vasculature of the episcleral drainage vessels, there are 
discrepancies in IOP between the rats used in this study, and those used by Johnson et 
a l  (2000).
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Other glaucoma models use different breeds of rat. Both the vein cautery (Garcia- 
Valenzuela et al, 1995; Sawada and Neufeld, 1999) and the laser photocoagulation 
(Lekovitch-Verbin et al., 2002) models involve Wistar rats. While the spontaneously 
glaucoma model recently discovered by Thanos and Naskar (2004) occurs in Royal 
Collage of Surgeons rats. Unfortunately the use of different breeds and frequent 
aneasthesia before tonometry means it is difficult to draw comparisons between the 
ocular pressures in these and the present study. The control IOP levels of these 
animals appears to be much lower than the Norwegian brown, with reports of 11.6 
mmHg (Garcia-Valenzuela et al, 1995; Sawada and Neufeld, 1999), 19 mmHg 
(Lekovitch-Verbin et al., 2002) and 15.1 mmHg (Thanos and Naskar, 20043). It is 
likely that these differences are due to breed of rat and anaesthesia.
As in the human population, the IOP of the rat will vary. The majority of studies 
indicate that control IOP of the rat is lower than that of the human. However, in this 
study the Norwegian brown IOP is higher than the human upper limit of 21 mmHg. 
This is not relevant to the present study as it is impossible to draw interspecies 
comparisons due to the effects of ocular rigidity, corneal surface and corneal thickness 
on IOP readings. Not all ocular hypertensive patients will develop glaucoma, and 
some glaucoma patients have IOP within the normal range. Therefore the important 
factor in the development of glaucoma is degree of pressure elevation and not the 
actual pressure. Therefore, despite a higher than expected control IOP (as compared to 
other rat studies), the model used here provides a reliable mild pressure elevation.
Episcleral vessel sclerosis can result in much higher pressure elevations than the 5.6 
mmHg with average pressure of 31.24 mmHg produced here. Pressure was elevated 
by 19.5 mmHg to 36 mmHg by Johnson et al. (2000) despite use of the same 
techniques. However vein cautery in the Norwegian brown can result in a milder 
pressure elevation of 9 mmHg (Grozdanic et al., 2003) while in Wistar rats cautery 
elevates pressure by 10.6 mmHg to a value of 22 mmHg (Garcia-Valenzuela et al, 
1995; Sawada and Neufeld, 1999). Laser photocoagulation of the trabecular 
meshwork produces IOP elevations of 25.5 to 49 mmHg in Wistar rats depending on 
experimental conditions and duration of elevation (Lekovitch-Verbin et al., 2002). In
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the spontaneously hypertensive rat model IOP elevates unilaterally to 35 mmHg 
(Thanos and Naskar, 2004 ), an increase of 19.9 mmHg.
Severe IOP elevations are normally induced in experimental glaucoma. Mild pressure 
elevation such as that achieved in the present study may be more representative of 
human glaucoma. Degeneration typical of very high pressures, which appears as a 
porous appearance of the optic nerve, is rarely seen in human glaucoma, and has only 
been documented in the most serious conditions (Quigley et al., 1981). This 
degeneration is often found in experimental glaucoma.
3.4.3.3 Attributes o f IOP elevation
No other published studies have examined the attributes of raised IOP in experimental 
glaucoma in the detail described here. Other studies calculate average daily IOP 
elevation, together with the duration of this increase. Peak IOP as well as average IOP 
elevation have also been measured (Levkovitch-Verbin, et al., 2002). Daily IOP 
elevation and average IOP are not representative of the overall IOP elevation. An 
average or peak IOP may be maintained over a wide range of time points or may vary 
considerably throughout. As glaucoma is a progressive disease, during which IOP can 
vary the most informative method of describing IOP should combine both duration 
and magnitude of elevation. Standard deviation of IOP elevation may also be useful. 
Therefore the direct effects of duration of pressure elevation, area under the pressure 
curve and standard deviation of pressure elevation on RGC survival can be measured.
Standard deviation varied considerably during different cases of experimental 
glaucoma. Long durations of pressure elevation can be sustained at consistent 
pressures, while higher pressures are less consistently maintained. Duration of IOP 
elevation and degree of pressure elevation are both crucial attributes of the area under 
the pressure curve. Area under the curve will enable the association of a combination 
of IOP elevation and duration of elevation with any alterations following experimental 
glaucoma. Future results can now be correlated with specific and relevant aspects of 
the pressure curve.
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3.4.4 Conclusions
In order to develop a representative glaucoma model, IOP was manipulated and 
measured as accurately as possible. Attributes of IOP elevation during experimental 
glaucoma that have never previously been examined were assessed and compared 
during this study. These investigations should improve understanding of the IOP 
changes involved during experimental glaucoma. These IOP changes can then be 
related specifically to biochemical, cellular and pathological disease alterations.
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Chapter IV 
Comparative Optic Nerve Histology and Neurodegeneration
4.1 Introduction
In order for an animal model to be a good glaucoma model, optic nerve tissue 
morphology should be similar to that of the human. Glaucomatous structural and 
cellular optic nerve alterations, which are likely to play a role in retinal ganglion cell 
(RGC) death (Lam et al., 2003b; Naskar et al., 2002; Varela and Hernandez, 1997; 
Quigley and Addicks, 1981; Wang et al., 2002b), should also be comparable.
Following glaucoma, detectable morphological alterations such as excessive optic cup 
excavation, bowing of the lamina cribrosa and reduction in nerve fibre bundle density 
occur. These can be used to identify successful elevation of IOP and the induction of 
experimental glaucoma. Alterations in the content of optic nerve connective tissue 
(Johnson et al., 1996) and cellular changes have also been reported (Ahmed et al., 
2004; Naskar et al., 2002; Neufeld, 1999; Quigley et al., 1981; Varela and Hernandez, 
1997; Wang et al., 2002b; Yucel et al., 1999).
It is essential to correlate degree of RGC death and degeneration with IOP in 
glaucoma models. Glaucomatous RGC degeneration begins at the site of injury, 
where axons traverse the lamina cribrosa (Quigley et al., 1981) and frequently results 
in axonal loss (Shou et al, 2003; Weber et al., 1998). Therefore, glaucomatous 
neurodegeneration can be reliably quantified using optic nerve proper axon counts 
(Ogden and Miller, 1966; Potts et al., 1972; Levkovitch-Verbin et al., 2002). 
However, these are impractical due to the technique’s labour-intensive nature and 
expense. Unfortunately, retrograde labelling used in many glaucoma studies is 
inaccurate due to the effects of glaucoma on retrograde transport. Grading axonal 
degeneration on a scale following histological staining is possible as large pores or 
vacuoles remaining following axon loss (Johnson et al., 2000). While of limited
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quantitative use, this technique can be used to reproducibly classify the degree of 
damage in a qualitative approach.
Distinctive morphological alterations are displayed by degenerating RGC axons. 
These include dilation, inclusion of large intracellular vesicles and Wallerian 
degeneration (Marques et al., 2003; Quigley et al., 1981). However, the changes that 
occur during rodent experimental glaucoma have not been explored at this level of 
detail. This information would enhance the knowledge of the degeneration process 
during ocular hypertension.
Axonal degeneration is known to enhance the accumulation of silver ions. Silver 
staining methods have been relied upon in the study of nervous system anatomy and 
pathology for some time (Grimelius, 2004). Silver staining has not been investigated 
for the assay of glaucomatous neurodegeneration, and may prove to be a novel, 
practical and accurate method for assessing neuronal degeneration.
Initial degeneration of the RGC axon spreads retrogradely to the soma, possibly, 
through loss of neurotrophic support amongst other factors. Subsequently, RGC 
bodies die mainly through the process of apoptosis and rarely via necrosis (Garcia- 
Valenzuela et al., 1995) at a rate of around 4% per week (Laquis et aL, 1998).
A popular method for quantifying RGC apoptotic death is cell counts of TUNEL 
positivity in the retinal RGC layer, reinforced with detection of apoptosis-associated 
enzymes such as active caspase 3. However, these studies are limited by the transient 
nature of apoptosis and restriction to the RGC body in the retina. Consequently the 
quantification of axonal degeneration, together with that of RGC apoptosis counts, 
may be more reliable.
In this chapter, morphological aspects of the normal and glaucoma optic nerve will be 
examined from a superficial histological level, through to the high-resolution electron 
microscopy level. Rat optic nerve head morphology will be compared to that of the 
human. New techniques for quantitative and qualitative assessment of
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neurodegeneration will be developed and compared with existing standards. The 
effects of IOP elevation on cell death and degeneration will be investigated.
4.2 Methods
Various methods were used to compare optic nerve structure and illustrate 
glaucomatous cell death and neurodegeneration. These included some novel 
techniques as well as established methods.
Normotensive human (n=2) and rat eyes (n=6) were compared histologically for 
similarities. See Chapter II, Section 2.2 for the histological methods, including 
haemotoxylin and eosin, Masson’s trichrome green, and toluidine blue staining, 
developed and used during this chapter.
Following the induction of unilateral experimental ocular hypertension, contralateral 
control (n=6) and ipsilateral hypertensive rat eyes (n=6) were also compared using the 
histological techniques described above in order to show glaucomatous 
degeneneration of the optic nerve at various levels of pressure elevation.
Details of all techniques used to detect neurodegeneration can be found in Chapter II, 
Sections 2.3, 2.4 and 2.5. These included electron and light microscopy, used to 
investigate nerve fibre loss in retrobulbar optic nerve samples (n=5). Silver staining 
was used to detect degenerating neurons in the retrobulbar nerve by virtue of the 
agrophillic propensity of degenerating nerves. Two samples were taken from each 
group of duration of IOP elevation (T1 to T5, n=10). TUJ-1 immunofluorescence 
labelling of neurofilament protein in the retinal ganglion cell layer of the retina was 
also used to detect neurodegeneration (n=3) during intermediate durations of ocular 
hypertension (T3).
Cell death was detected using TUNEL positivity and immunolabelling for active 
caspase 3, as described in Chapter II, Section 2.6. These methods were used to label 
the apoptosing retinal ganglion cell body in the retina (n=25), as well as any glial cell
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death occurring in the optic nerve head (n=5). Retinae used were representative of the 
15 different groups of IOP elevation created by dividing the retinae depending on 
duration of IOP elevation (T1 to T5), area under the IOP curve (Al to A5), and 
standard deviation of IOP elevation (SI to S5). The number of TUNEL positive cells 
per retina were counted twice each in a total of 5 pairs (contralateral control and 
ipsilateral hypertensive) of retinae per group and groups compared using ANOVA 
followed by T-testing. Consequently, RGC degeneration as a function of IOP 
variables (T, A and S) were monitored to assess the effect of IOP on optic nerve 
degeneration over time.
Table 4.1 Experimental animal groupings according to pressure elevations
Level GROUP “T”
Duration of IOP 
elevation (days)
GROUP “A”
Area under the pressure 
curve (mmHg)
GROUP “S”
Standard deviation
1 1 - 7  (n=10) 0 .9 -2 2 .7  (n=8) 0-1.511 (n=6)
2 1 1 -1 9  (n=19) 24 .3 -96 .8  (n=16) 1.52 - 2.96 (n=13)
3 20-27 (n=ll) 97.2-151.1 (n=15) 3.20 - 3.75 (n=9)
4 3 3 -4 6  (n=10) 165.3-256.1 (n=8) 3.81 - 5.57 (n=16)
5 47 - 65 (n=7) 2 7 1 .9 -4 6 9 3  (n=10) 6.02 -12.76 (n=12)
4.2 Results
4.2.1 Histology of the human and rat optic nerves
4.2.1.1 Histology o f  the human optic nerve
Human optic nerve histology was similar to that described in the literature (Figure 4.1 
and 4.2). As the RGC axons leave the retina they become grouped into nerve 
fascicles, separated by cells, in the prelaminar region. At this level the optic nerve 
nerve head is narrow. Connective tissue elements first appear in the underlying lamina
99
Chapter IV Comparative Optic Nerve Histology and Neurodegeneration
50
20>un
Figure 4.1 Histology o f the normal human and rat optic nerve in longitudinal
section Images show Masson ’s trichrome green staining o f the normotensive human 
(a-e) and rat (f- j) optic nerve. Areas o f green staining represent connective tissue 
elements. Cytoplasmic elements are stained pink, while cell nuclei are blue-black. 
Low magnification longitudinal images (a-e) show details o f structure from the nerve 
head to the retrobulbar or postlaminar optic nerve. The human optic nerve head and 
lamina cribrosa are shown at higher magnifications in images b and c, with the 
equivalent areas for the rat in g and h. The postlaminar human optic nerve is shown 
at higher magnification in images d and e, and the rat retrobulbar optic nerve in 
images i and j. * ** *** denote areas discussed in text.
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Figure 4.2 Histology o f the normal human and rat optic nerve in transverse section
Masson’s trichrome green stained images o f the normotensive human (a-c) and rat 
(d-f) optic nerve in transverse section are shown. Colours represent tissue 
components as described for Figure 4.1. Magnification increases from images a-d for 
the human nerve, and d- f  for the rat.
cribrosa at the level of the sclera (Figure 4.1 a, *). Then in the postlaminar region, the 
nerve diameter widens into the optic nerve proper (Figure 4.1 a, **).
Connective tissue beams were found throughout the human optic nerve (Figure 4.1 a 
to e, * and **). These elements have a dense well-organised horizontal distribution at 
the nerve head (Figure 4.1 a, b and c). Beams were interspersed with pores containing 
axons fascicles. A few cell nuclei were detectable within the nerve head fascicles 
(Figure 4.1 b and c), but were packed around the collagenous beams (Figure 4.1 c). 
Connective tissue elements were also present throughout the optic nerve proper 
(Figure 4.1 a, d and e). These elements stained less intensely than those of the lamina 
cribrosa, and were not of uniform organisation or orientation. Vertical septae were
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joined occasionally by horizontal septae (Figure 4.1 d and e, **), the latter occuring 
with more frequency along the course of the nerve (Figure 4.1 d and e, *). More 
nuclei were visible than in the nerve head, localised around connective tissue 
elements (Figure 4.1 d), with some dispersed among the nerve fibre bundles (Figure
4.1 e).
The human optic nerve was round in cross section and surrounded by connective 
tissue sheaths (the meningeal sheaths, Figure 4.2 a). The central retinal vessels were 
surrounded by connective tissue sheaths in the optic nerve head. Nerve fibre fascicles 
were surrounded by green connective tissue in transverse section of the optic nerve 
(Figure 4.2 b and c). Glial nuclei were again proximal to these columns. Transverse 
sections revealed some glia that appeared to be separating the nerve into fascicles 
independently of connective tissue. Other glial nuclei were observed within the nerve 
bundle.
4.2.1.2 Histology o f the rat optic nerve
In comparison with the human, the rat optic nerve reveals a much simpler structure 
overall. The rat optic nerve begins at the narrow optic nerve head (Figure 4.1 f, Figure
4.3 a and f, *), followed by a slightly wider transition zone (Figures 4.1 f, **), which 
widens further into the retrobulbar nerve (Figure 4.1 f, ***).
The connective tissue beams of the human lamina cribrosa were replaced in the rat by 
sparse connective tissue islands with horizontally orientated septa. Septae were 
located throughout the nerve head and transition zone (Figure 4.1 h and i, *). Optic 
nerve head connective tissue stained less densely. Transition zone septae appeared 
more densely stained and fewer in number. The rat nerve head and transition zone 
appeared to contain less connective tissue with opposite orientation than the human 
equivalents. Similar to the human, this connective tissue is surrounded by few glial 
nuclei (Figure 4.1 h and i, 4.3 a, b, c, f, g and h), between which, the nerve axons 
appeared in fascicles (Figure 4.1 h and i, Figure 4.3 b, c, g and h).
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Figure 4.3 Haematoxylin & Eosin and Toluidine blue stained normal rat optic 
nerve in longitudinal section Longitudinal rat optic nerve sections were stained with 
haematoxylin and eosin to produce images a-e. Nuclei were stained blue-black, and 
all other tissue elements were stained pink by this method. Images f-j are the 
equivalent sections stained with toluidine blue. In f  to j  nuclei are stained blue. 
Images a- e and f-  j  show from the optic nerve head through to the retrobulbar optic 
nerve. Images b, c, g and h show the nerve head in more detail. The retrobulbar optic 
nerve is shown in more detail in images d, e, i and j.
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The connective tissue of the rat retrobulbar optic nerve is also less, compared to the 
postlaminar human optic nerve (Figure 4.1 f, g and h, *). Retrobulbar connective 
tissue elements appear to maintain the orientation of those in the transition zone 
(Figure 4.1 i * and j,). Compared to the human optic nerve there were far more glial 
nuclei in the retrobulbar optic nerve of the rat (Figure 4.1 i and j, Figure 4.3 d, e, i and 
j). These nuclei form glial columns, which are more prominent than connective tissue 
in this area of the nerve (Figure 4.1 i).
The rat optic nerve proper appeared horizontally oval in transverse section (Figure 4.1 
n, Figure 4.4 a and d), in contrast to the human nerve. Meningeal sheaths surrounded 
the rat nerve. The nerve fibres and glial nuclei did not appear organised into or around 
regularly arranged fascicles when viewed in cross section (Figure 4.2 a-f), Figure 4.4 
a-f). The central retinal vessels of the rat optic nerve were not clearly identifiable. 
However transverse sections contained a large element of connective tissue in the 
central inferior portion (Figure 4.2 d and e) likely to mark the equivalent of these 
vessels.
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Figure 4.4 Haematoxylin & Eosin and Toluidine blue stained normal rat optic 
nerve in transverse section Transverse sections o f optic nerve are shown at 
increasing levels o f detail following haematoxylin and eosin staining in images a to c, 
and for toluidine blue staining in images d t o f  Colours represent tissues as described 
in Figure 4.3.
104
Chanter IV Comparative Optic Nerve Histology and Neurodegeneration
4.2.2 Histological alteration of the optic nerve following glaucoma
The rat optic nerve following ocular hypertension is shown in Figures 4.5a-j. The 
nerve shown is of T5 pressure duration. The most notable alteration in the nerve was 
excessive retrograde bowing of the nerve head (Figures 4.5a, d and g, *) to produce a 
large physiological cup. The entire optic nerve head region was retrogradely 
displaced. The optic cup extended to the transition zone and terminated were the 
nerve widens. The retrobulbar nerve appeared much wider than controls perhaps 
through retrodisplacement of nerve tissue rather than fibre myelination.
Islands of connective tissue were sparse in the hypertensive optic nerve. Very few 
lightly stained beams of connective tissue with no detectable organisation can be 
observed in Figure 5.4b. No retrobulbar connective tissue was identified following 
glaucoma (Figure 4.5c). Connective tissue appeared to decrease throughout the optic 
nerve following experimental glaucoma.
Staining of cytoplasmic elements, including nerve fasicles appeared less dense 
following hypertension. Loss of tissue appeared as large vacuoles or holes in the 
nerve. These holes were mostly round in shape and were prominent in the nerve head 
becoming less evident in retrobulbar regions (Figures 4.5a-i) with no regular 
arrangement. Tissue loss was not associated with glial columns or connective tissue, 
but was preferentially located in the optic nerve head or transition zone.
The nuclear elements of the optic nerve appeared to have lost their columnar 
organisation at the nerve head and transition zone probably due to retrodisplacement 
of nerve tissue (Figures 4.5a, b, d, e, f  and g). Retrobulbar nuclei retained their 
columnar organisation (Figures 4.5c, f  and i). However, these columns were not as 
uniform or parallel in arrangement as those of control nerves. Nuclei also appeared 
enlarged, indicating aggregation of cells, or glial hypertrophy.
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Figure 4.5 Ocular hypertensive rat optic nerve histology Longitudinal sections o f 
the rat optic nerve were stained with Masson’s trichrome green (a-c), haematoxylin 
and eosin (d-f) and toluidine blue (g-i) following experimental glaucoma. Images a, f  
and k show the optic nerve head and retrobulbar regions following glaucoma. The 
optic nerve head is shown at higher magnifications for the three stains in image b 
(Masson’s trichrome green), e (haematoxylin and eosin) and g (toluidine blue). 
Higher magnification retrobulbar optic nerve is shown in images c (Masson’s 
trichrome green) f  (haematoxylin and eosin) and i (toluidine blue). * denotes 
retrograding bowing o f the optic nerve head.
Many important alterations induced by IOP elevation were observed by simple optic 
nerve histology. Alterations in connective tissue, nerve fibre density, and nuclear 
elements as well as the shape of the optic nerve head were observed.
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4.2.3 Semi-thin sections of the rat optic nerve
Untreated control eyes and dissected retrobulbar optic nerves, fixed post-dissection in 
2.5% glutaraldehyde overnight at 4°C, revealed normal retrobulbar optic nerve 
morphology. Minimal degenerative characteristics were observed by semi-thin 
sectioning, followed by toluidine blue staining and light microscopy (Figure 4.6 a and 
b).
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Figure 4.6 Toluidine blue stained semi-thin sections o f rat retrobulbar optic 
nerves following a mild degree o f  pressure elevation over a relatively short period o f 
time. Control images (a and b) show a normal optic nerve morphology, while images 
following hypertension (c and d) contain alterations typical o f neurodegeneration. 
This includes the appearance o f  vacuoles in the optic nerve (d, arrows). Dark patches 
o f staining indicate macroglia, most likely to be oligodendrocyte cell bodies (b and d).
The quality of sectioning was superior to thick sections, cut for histological 
processing, resulting in the observation of very clear differences in contralaral control 
and ipsilateral hypertensive retrobulbar optic nerve.
Normal nerves were structurally dense with few irregular shaped vesicles (Figures 
4.6a and b). Oligodendrocytes were identifiable throughout the nerve. Ocular
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hypertension reduced nerve density, and predominantly rounded vesicles appeared 
increased in number and size (Figures 4.6c and d). Glial elements were as described 
for control nerve.
4.2.4 Silver staining of optic nerve axon neurodegeneration
Silver staining of control retrobulbar optic nerve did not produce any detectable 
indication of neurodegeneration. Background appeared as tiny silver grains, even in 
control optic nerve sections (Figure 4.7a), and could not be removed due to the use of 
electrostatically charged slides.
Figure 4.7 Silver staining o f  rat optic nerve Control retrobulbar optic nerve 
revealed no signs o f neurodegeneration (a). As duration o f hypertension increased 
through images b to f  (T1-T5), signs o f  neurodegeneration also became greater. 
Dark brown silver aggregates were first visible (b). These were then replaced by 
more diffuse aggregates (c). Dark brown aggregates were again visible in d with a 
less ramified morphology, together with gold coloured patches. In images e and f  
dark brown aggregates were replaced by discrete black aggregates, while gold- 
coloured patches were still evident.
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Initially, at short durations of hypertension (3 days, T l, Figure 4.7b) silver labelling 
of degenerating axons was detectable using light microscopy. Accumulation of silver 
grains appeared as discrete dark brown patches within the optic nerve. Staining 
appeared as rounded areas, as well as more elongated shapes (Figure 4.7b).
Following 14 days (T2, Figure 4.7c) of ocular hypertension, silver labelling did not 
identify neurodegeneration as clearly as in earlier time points. Silver accumulation 
appeared discrete, but not as dense due to the lighter colour of labelling (Figure 4.7c). 
This indicated that following an initial wave of neurodegeneration and axonal 
damage, there was an intermediate period where this damage was alleviated or 
delayed. Damage was barely detectable at the 14 day time point.
The accumulation of dark silver grains appeared to increase during subsequent stages 
of ocular hypertension (T3, Figure 4.7d). Many discrete areas of stain were visible 
here as fairly round dark brown areas. The nerve stained light brown, and gold 
coloured irregular-shaped patches were present throughout (Figure 4.7d).
In more severe cases of hypertension (T4, Figure 4.7e) silver accumulation was 
present as rounded black deposits with a reduced size (Figure 4.7). Some fairly large 
granules were still evident, however, the majority of staining appeared as very small 
black deposits. These areas were present within the light brown stained nerve, as well 
as in gold-coloured patches.
A further lean toward this trend for smaller accumulations of silver was seen in 
staining of T5 (Figure A.If) nerves. It was not possible to distinguish by eye whether 
there was more or less staining between groups T4 and T5.
4.2.5 Electron microscopy of the rat optic nerve
Electron micrographs revealed normal retrobulbar optic nerve morphology including 
a regular round/oval closely packed axonal arrangement, minimal myelin 
degeneration and slightly granular ordered cytoplasm (Figures 4.8a-d). Optic nerve
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Figure 4.8 Electron micrographs o f  control and hypertensive retrobulbar optic 
nerves High magnification electron microscopy shows the effect o f IOP on the 
retrobulbar optic nerve. The control optic nerve (a to d) showed normal morphology, 
whereas the hypertensive optic nerve (e to I) showed signs o f degeneration. Major 
morphological changes included irregular axonal arrangement (e and f), organelle 
accumulation (g, arrow), damaged myelin sheaths and debris (h and i), large 
intracellular vesicles (j and k, arrows), and watery degeneration (I, arrow).
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degeneration was revealed following IOP elevation (Figure 4.8e-l). Axonal shape 
altered to an appearance typical of “watery” degeneration (described by Narciso et al., 
2001; Marques et al., 2003; Sefton and Lam, 1984), cytoplasmic shrinkage away from 
the myelin sheath, as well as inclusion of large intracellular vesicles were evident. 
Dark cytoplasmic inclusions likely to be organelle accumulations were also present. 
Myelin damage and fragmented debris were widespread, evident as dark granules 
throughout the sheath as well as an “unravelled” appearance (Figure 4.8e-l). Some 
axons appeared qualitatively enlarged (Figure 4.8j) compared to controls (Figure 
4.8b).
4.2.6 Alterations in neurofilaments following experimental glaucoma
Neuronal class III P-tubulin (TUJ-1) was present in the retinal ganglion cell layer 
(GCL) of the normal rat retina (Figure 4.9a). Bright red labelling of RGCs was 
observed. These cells appeared to be fairly dendritic and were regularly spaced along 
the GCL. A few TUJ-1 positive cells were also found in the other retinal layers. This 
is likely to be due to cross-reactivity with neurofilament components of other 
neuronal or glial cells in these layers.
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Figure 4.9 TUJ-1 immunolabelling o f  the retinal ganglion cell layer (a) Red
TUJ-1 immunolabelling appeared mainly to be localised to the retinal ganglion cell 
layer (GCL). Some TUJ-1 positivity was observed in other layers, (b) TUJ-1 
immunoreactivity was reduced following experimental ocular hypertension. Blue 
labelling denotes Hoechst stained nuclei.
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Following hypertension, the intensity of TUJ-1 labelling appeared to be reduced 
(Figure 4.9b). Fewer cells were labelled in the GCL, with less intense labelling also in 
the other retinal layers. TUJ-1 labelled cells were irregularly spaced and occurred less 
frequently. TUJ-1 positive RGCs also appeared less dendritic following ocular 
hypertension.
4.2.7 Retinal ganglion cell apoptosis
Labelling of apoptotic RGC bodies in the retina increased following hypertension 
(Figure 4.10c-e). Qualitative observations of active Caspase 3 immunoreactivity 
revealed similar results (Figure 4.1 lc-e).
In the control retinae (Figure 4.10c and Figure 4.11b) and retrobulbar optic nerve 
sections (Figure 4.1 Of and Figure 4.11a), no TUNEL or active caspase 3 
immunoreactivity was observed. Results of TUNEL positive RGC counts are detailed 
in the following sections in relation to ocular hypertension (see Chapter III, Figure 
3.9 for details of IOP groups).
Overall significant elevations in superior, inferior and total number of apoptotic 
RGCs (P<0.001, n=25) were found following hypertension. The mean percentage of 
apoptotic RGCs following hypertension was 3.47%, while control levels were 0.70% 
(n=25). Similar apoptotic percentages were found between superior and inferior 
retinal portions (n=25). Mean superior apoptosis was 3.25%, while inferior was 
3.70% following hypertension. The equivalent control values were 0.85% (superior) 
and 0.70% (inferior).
4.2.7.1 The effects o f duration ofpressure elevation on RGC apoptosis
Figure 4.12 shows how duration of hypertension affects retinal TUNEL positivity. 
Low durations of hypertension (T l) did not significantly elevate RGC apoptosis 
(P>0.05). Tl apoptosis was slightly increased in superior (1.46%), inferior (2.62%) 
and overall retina (2.04%) as compared to controls.
1 1 2
Chapter IV Comparative Optic Nerve Histology and Neurodegeneration
a Positive contro
Retina
3 > m
\  
b Fositme control
Retiobulbai optic neno
2) llii
f Control
3} I'n
S Hypertension
e Hyper teimon
23 i « i i
h Hypertension
Figure 4.10 TUNEL staining in the rat retina and optic nerve TUNEL positivity is 
shown as brown-stained areas in the retina, nuclei were counterstained using methyl 
green (n=25). Images a and b show positive control (rat mammary gland) with clear 
brown TUNEL positive cells. Negative controls o f  contralateral retina (c) infrequently 
contained TUNEL positive cells, while retrobulbar optic nerve sections (f-h) did not 
show any TUNEL positivity (c). At relatively short durations o f hypertension few 
TUNEL positive cells were present in the RGC layer (d). Longer durations resulted in 
an elevation o f TUNEL positivity (e).
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Significant elevation of apoptosis was initiated at T2 durations of hypertension in the 
inferior retina (P<0.05) at a rate of 2.06%. Overall retinal apoptosis was also 
significantly elevated (P<0.05) at 1.89%, while superior RGC apoptosis was not 
(P>0.05).
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Figure 4.11 Active caspase 3 immunoreactivity No active caspase 3 
immunoreactivity was found in negative control sections o f (a) retrobulbar optic 
nerve or (b) retina. Representative images o f  active caspase 3 immunoreactivity in the 
hypertensive retina are shown (c to d). Active caspase 3 immunoreactivity appeared 
as discrete red nuclear labelling in the ganglion cell layer (d), that colocalised with 
Hoechst stained blue nuclear labelling (e). These images confirmed retinal ganglion 
cell death via apoptosis following ocular hypertension.
Significant elevations extended to both superior and inferior retinal axes, as well as in 
the overall retina, in longer duration groups T3 and T4 (P<0.05). Apoptotic rates for 
T3 durations were 5.29%, 5.47% and 5.38% for the superior, inferior and overall 
retina respectively. T4 values were slightly reduced at 3.38%, 5.56% and 4.47%
20 twi
a Hypertension (optic nerve)
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respectively. The slightly higher apoptotic rates in the inferior retinal portion were 
not significant for T3 or T4 (P>0.05). Following the longest durations of ocular 
hypertension (T5), a more diffuse significant level of apoptosis at 1.46% was found 
throughout the ipsilateral retina (P<0.05), while neither superior (P>0.1) nor inferior 
(P>0.05) axes appeared to be specifically affected.
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Figure 4.12 RGC TUNEL positivity as a function ofduration o f hypertension.
% TUNEL positivity increased in all ocular hypertensive retinae, compared to 
normal controls. The difference between control and ocular hypertensive percentage 
apoptotic cells is shown for the retina overall (black), superior retina (grey and 
inferior retina (white). TUNEL positivity significantly altered between groups 
(p<0.01, ANOVA testing) and significantly increased for groups T2, T3 and T4 (T- 
testing, n=25). Bars show standard deviation. */**/*** indicate increasing levels o f  
significance.
4.2.7.2 RGC apoptosis with area under the IOP curve
RGC apoptosis appeared to consistently increase with area under the pressure curve 
(A), (Figure 4.13). For group A l, diffuse (not localised to a particular area of retina) 
RGC death was indicated through significant elevation (P<0.05) of overall RGC 
apoptosis by 1.71%. In A2, significant elevation of superior (P<0.05), inferior 
(P<0.05) and overall retinal (P<0.001) apoptosis to 2.29%, 3.27% and 2.78% 
respectively resulted. Apoptosis significantly increased in A3 retinae overall
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(PO.OOl) at 3.27%, as well as in inferior regions (P<0.05) at 3.45%. Overall RGC 
apoptosis significantly increased to 3.75% by A4 (P<0.05), this was localised to the 
inferior retina (PO.Ol). In highest area under the pressure curve group (A5), RGC 
apoptosis elevated to 4.65% in the overall retina (PO.OOl). Superior and inferior 
axes were also significantly affected with increases of 3.75% and 5.56% respectively 
(PO.Ol).
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Figure 4.13 RGC TUNEL positivity as a function o f area under IOP curve.
% TUNEL positivity increased with increasing area under the IOP curve in groups 
Al to A5 (n=25) these changes were significantly different according to ANOVA 
testing (p<0.01). Normalised percentage apoptotic RGCs following hypertension are 
shown for the retina overall (black), superior retina (grey and inferior retina (white). 
Increasing levels o f significance according to T-testing (p<0.05, p<0.01, p<0.001) 
are indicated by * ** and ***.
/
4.2.7.3 RGC apoptosis with standard deviation o f IOP elevation
Pressure elevation resulted in increased RGC apoptosis in the overall retina in all 
groups of standard deviation. Elevation of apoptosis was very significant for groups 
SI to S4 (PO.OOl) with a slight reduction in S5 (PO.05). Percentage apoptosis 
fluctuated with increasing standard deviation from between 1.48% to 5.28%.
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Even at low levels of standard deviation of pressure elevation (SI) significant increase 
of apoptosis was found in the superior (3.11% P<0.05) and inferior (3.20% PO.Ol) 
retina. Apoptotic rates significantly increased to 1.51% and 1.45% in superior and 
inferior S2 retina (PO.05). These rates significantly increased further to 4.57% and 
3.91% in S3 (PO.05). S4 conditions significantly elevated the number of apoptotic 
RGCs in inferior (PO.05) retina by 3.59%. Under S5 conditions significant elevation 
of inferior and superior RGC apoptosis was found (PO.05) at 4.20% and 6.36%. 
These changes are shown in Figure 4.14.
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Figure 4.14 RGC TUNEL positivity as a function o f standard deviation o f IOP.
The effect o f increasing standard deviation o f pressure elevation throughout groups 
SI to S5 (n=25) are shown on RGC apoptosis in the retina overall (black), superior 
retina (greyj and inferior retina (white). The difference in % TUNEL positivity in all 
ipsilateral hypertensive retinae as compared to contralateral controls was plotted. 
Overall TUNEL positivity significantly increased for all groups o f standard deviation 
o f pressure elevation (p<0.05, ANOVA). * (p<0.05), ** (p<0.01) and ***(p<0.001) 
denote increasing levels o f statistical according to T-testing.
4.4 Discussion
The detection of neurodegeneration and changes in optic nerve structure are a vital 
indication of both experimental glaucoma and the human disease. Excessive optic cup
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excavation, as well RGC axonal loss, is crucial in the detection of clinical glaucoma. 
Optic nerve head alterations can contribute to degeneration of the retinal RGC body 
and axon in the optic nerve. Many new exciting techniques, in addition to more tried 
and tested methods, are available for the detection of neurodegeneration.
4.4.1 Histology of the normal optic nerve
General histology of the rat and human optic nerves demonstrated the structural 
features and organisation of the nerves as well as alterations following experimental 
ocular hypertension. The presence of cell nuclei, presumably microglial and 
astrocytic, between the cribriform layers of the lamina cribrosa and collagenous 
beams in the distal nerve was particularly important, as assessment of these cells 
under experimental conditions will be determined out in future chapters.
The human and rodent optic nerve head were found to have a similar structural 
organisation, vital in an animal model of human disease, which affects this very area 
to produce its symptoms. The rat optic nerve has a much simpler structure, but of the 
same basic organisation as the human equivalent (Morrison et al, 1997). The 
difference in lamina cribrosa structure between species should be taken into account 
when relating experimental glaucoma to the human equivalent. The less pronounced 
connective tissue organisation of the rodent optic nerve head is important in 
experimental glaucoma studies. Increased ocular tension can result in pressure- 
dependent glaucoma whereby laminar beams are weakened through genetic mutation 
or disease (Gonzalez et al, 2000). The rat optic nerve head inherently contains less 
structural support, but may be more suited to studies of this type of human disease 
than other animal models that do not have a lamina cribrosa, as this tissue plays such 
a crucial role in protecting the human optic nerve from pressure within the eye.
The rat optic nerve head compares more favourably to the human, in terms of 
morphology, than the murine optic nerve. Some glaucoma models use the murine eye 
in which to develop disease despite a complete absence of lamina cribrosa in the 
mouse. Layers of elongated astrocytes and an external ring of collagenous material 
replace the lamina cribrosa (May and Lutjen-Drecoll, 2002). Therefore essential
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alterations in the optic nerve head that arise in glaucoma cannot be investigated in 
murine models.
Correlation in density and distribution between glial nuclei in the human and rat optic 
nerve head indicate that these elements may react similarly to ocular hypertension 
across species. The prominence of glial columns in the rat retrobulbar nerve may 
indicate that astroglial columns rather than connective tissue beams support this area 
in the rat. It is not known what effect this may have on initial or chronic nerve 
damage. Prominent glial columns may also accentuate any glial alterations following 
hypertension beyond their significance in human glaucoma.
It is important to recognise the limitations of using the rat optic nerve. The structure 
of the rat optic nerve is far simpler than the primate. However, in terms of connective 
tissue elements and glial organisation, the rat is far more similar to the human than 
many other mammals. Other advantages of studying the rat nerve include potentially 
high animal numbers and a quick tissue turnover, meaning fast generation of many 
experimental results.
4.4.2 Optic nerve histology in experimental glaucoma
The rat optic nerve head appears to react to IOP elevation with significant retrograde 
displacement, similar to human glaucoma. However, the lack of connective tissue 
observed in the rat optic nerve following glaucoma does not correspond with other 
human or animal data. Speculatively, it more likely that this reduction may have 
occurred due to phagocytosis or changes in active astrocyte secretion profiles, and 
may indicate that the severity of induced hypertension was excessive. Histological 
staining, carried out in this study, to identify structural components of the optic nerve 
was superficial. Other studies using immunolabelling (Johnson et al, 1996), western 
blotting (Hernandez et al., 2000) and electron microscopy techniques (Quigley et al., 
1981; Quigley, Dorman-Pease and Brown, 1991) have closely examined these 
components in disease (reviewed by Morrison 2005). It is possible that the 
histological stains used here do not show the dynamic effects of ocular hypertension 
on structural components of the optic nerve.
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Histological loss of axonal material following experimental glaucoma is supported by 
electron microscopy studies (Quigley and Addicks, 1981). The presence of large 
pores replacing axoplasmic material is only recorded from post-mortem glaucoma 
eyes in the most severe disease cases. The time-course of glaucoma is artificially 
accelerated in experimental animals. Changes that would normally occur over several 
years are induced to occur over weeks in the laboratory. These pores may therefore 
indicate that experimental glaucoma induced in this study is representative of only the 
most severe human conditions, or that the disease is indeed experimentally 
accelerated.
Temporal alterations following experimental glaucoma can be used to determine how 
human glaucoma might progress, for example by using the duration of hypertension 
(T) groups created in this study. Tl is representative of human glaucoma before the 
onset of symptoms. T2 shows the initial stages of disease when a glaucoma sufferer 
may begin to loose the peripheral visual field. The condition then progresses from T3 
to T5, where chronic glaucoma is represented in the animal model. This indicates that 
our model may cover the full time-course of disease. However, this hypothesis has 
severe limitations due to the presence of a porous nerve even at T2 durations of ocular 
hypertension, indicating a far more advanced disease state than should occur after 
only 10 days of hypertension. This then raises the question as to the state of a truly 
chronic rat glaucoma nerve.
We do not know how the rat optic nerve would appear after a more chronic disease 
situation, perhaps one year of hypertension using our model. However, it is likely that 
disease would be far more advanced than for a relative time in a human study. This 
data strongly suggests that correlation of specific time points between experimental 
and human glaucoma is not practical. However, in examining the initiation and 
maintenance of a human disease it is necessary to ascribe the human disease stages to 
the animal equivalent, which is not necessarily exactly the same. Certainly in this 
study, there would be nothing gained by developing rats with severe ocular 
hypertension of months duration, as the chronic human disease is represented by T5.
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It appears as though in experimental glaucoma, as is common in the human disease, 
the number of glial nuclei increase. It is not known whether glia are proliferating or 
migrating in an effort to neuroprotect the axons, or whether this effect is deleterious to 
the nerve.
Not all optic nerve alterations following experimental glaucoma were as described in 
the literature. A loss of connective tissue may be important in the overall reaction of 
the optic nerve to ocular hypertension. Alterations in glia are of particular interest in 
this study, therefore conservation of their reaction to hypertension between human 
and rat is essential. Excessive excavation of the optic disc (Rahman et al, 2002; 
Spaeth et al., 2002), a paucity of optic nerve axons (Chauhan et al., 2002; Johnson et 
al., 2000; Levkovitch-Verbin, 2002) and proliferation of glial nuclei (reviewed by 
Neufeld and Liu, 2003) are widely documented. Axonal or RGC loss is a major 
attribute of glaucoma and is essential in order to quantify nerve damage in 
experimental glaucoma.
4.4.3 Neurodegeneration of the RGC axon
Neurodegeneration was identified via optic nerve and axon morphology, as well as 
the accumulation of silver ions. Ultrastructural studies of nerve morphology were 
particularly informative with regard to the specifics of degeneration i.e. myelin 
damage and organelle accumulation. Due to the time consuming nature of electron 
microscopy and the qualitative nature of morphologically grading damage, new more 
quantitative measures are required. Silver staining is a useful and reliable technique 
used extensively throughout neuroscience to identify degeneration. This study showed 
that silver staining can be used to identify neurodegeneration following glaucoma. 
Due to the nature of the silver stain (black dots in the tissue), further method 
development is required to develop an accurate quantitative measure of the 
degenerating axon count, perhaps through computer assisted counting of stained 
areas.
In order to detect the extent of neurodegeneration semi-thin sections of optic nerve 
can be compared for integrity. This idea was introduced in the first automated fibre
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counts of axon number in the primate optic nerve (Ogden and Miller, 1966; Potts et 
al., 1972). Subsequently reliable quantitative optical density measurements of stained 
optic nerve and qualitative grading scales of axonal damage have been developed. 
Qualitative comparisons of semi-thin optic nerve sections were used to reveal typical 
signs of axonal loss following ocular hypertension in the present study. Other similar 
studies have shown cell shrinkage or selective loss of large diameter axons through 
reduction in axonal size during early stages of experimental glaucoma (Levkovitch- 
Verbin et al., 2002).
This type of experiment has been used extensively to ascertain the number of optic 
nerve fibres in normal experimental animals, and following disease. Levkovitch- 
Verbin et al. (2002) used such a system to show the axon count of Wistar rats at 
around 87,318 axons. Progressive axonal loss was recorded up to 9 weeks of ocular 
hypertension, where 51.6% of axons remained. However, axon counts can be prone to 
sampling errors, are time consuming and require extensive resources. Due to 
variability in the number of axons counted, other methods may be more informative in 
quantification of degeneration. In current assessment of experimental glaucoma the 
arbitrary classification of semi-thin sections on a damage grading scale by masked 
observers is generally accepted as an accurate method. Alternatively counts of 
apoptotic RGCs are a more quantitative widely accepted method of assaying damage.
However, studies on the axonal size and distribution, such as those performed by 
Bennis et al. (2001), Levkovitch-Verbin et al. (2002), Ogden and Miller (1966) as 
well as Potts et al. (19722) require sampling and quantification techniques similar to 
axon counts. No other techniques can currently quantify all these aspects of 
degeneration or compare the extent of axonal loss with changes in axonal size and 
distribution. However, qualitative assessment of nerve damage via electron 
microscopy can be useful in determining the attributes and time-course of axonal 
damage. For example, electron microscopy of the optic nerve has revealed 
demyelination, axonal swelling, and peripheral immune cell infiltration following 
experimental optic neuritis (Guy et al., 1992).
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Studies of ocular hypertension generated through episcleral vessel sclerosis have 
shown axonal swelling and myelin debris (Johnson et al., 2000). We can now confirm 
that myelin debris takes on the form of granular deposits, as well as an unravelled 
disorganised appearance of the sheaths. These are changes typical of the human 
disease (Quigley et al., 1981), and are normally combined with an accumulation of 
intracellular organelles associated with a reduction in retrograde transport (Tsukita 
and Ishikawa, 1980). Unlike normal optic nerves with uniformly distributed axonal 
contents (Forrester and Peters, 1967), granular intracellular deposits thought to be 
organelle accumulations were found following hypertension in this study. These 
results demonstrate for the first time that axonal transport may be disrupted following 
episcleral vessel sclerosis.
Silver staining of the retrobulbar optic nerve has not previously been used to qualify 
experimental glaucoma. This study demonstrates that silver staining can show a 
pressure-dependent pattern and increase in glaucomatous neurodegeneration. This 
type of labelling is ideal for the development of a qualitative damage grading scale, or 
indeed computerised quantification. Hopefully in the future this technique will be 
used to quantify RGC axon degeneration.
This study confirms loss of optic nerve material and degeneration of RGC axons 
following experimental glaucoma using both light and electron microscopy. Pores 
remained in the nerve in regions o f axonal loss. Optic nerve degeneration involved 
many morphological alterations some of which can be related to functional deficits. 
Degeneration of the RGC axon would be expected to result in reduced neurotrophin 
supply to the RGC body in the retina, and consequently cell death. These studies do 
not confirm whether this degeneration leads to RGC loss in the retina.
4.4.4 RGC degeneration in the retina
The use of labelling neurofilament components of the axon has long been examined 
as a method for quantification of RGC loss, not only degeneration. The neurofilament 
proteins represent a potential target for the assessment of neurodegeneration as well as 
regeneration. In general, loss of neurofilament protein is indicative of disease or
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degeneration. Rather than a measure of cell death, these studies are more indicative of 
RGC stress which does not necessarily lead to death (Schlamp et al., 2001). Loss of 
TUJ-1 can be used to indicate glaucomatous RGC damage in the cell soma, or 
ganglion cell layer of the retina. Other neurofilaments are also thought to decrease 
before the onset of cell loss in glaucoma (Schlamp et al., 2001).
Since Cui et al (2003) demonstrated that TUJ-1 selectively labels RGC in the GCL, 
TUJ-1 could be used to monitor RGC counts. This study is the first to successfully 
label normal and ocular hypertensive RGCs with TUJ-1. Similar to other cytoskeletal 
components of the axon, TUJ-1 did appear decreased following ocular hypertension.
TUJ-1 studies of the retina indicated that experimental glaucoma affects the RGC 
body as well as the axon. Reduction of neuron-specific tubulin labelling implicates 
loss of postmitotic RGCs (Lee et al., 1990) in ocular hypertension. Immunolabelling 
of purified astrocytes identifies a low percentage of TUJ-1 positive cells despite the 
high specificity of TUJ-1 immunopositivity to differentiated neurons (Mellough et al., 
2004; Pimental et al., 2000; Sergent-Tanguy et al., 2003; Snow and Robson, 1994; 
Watanabe et al., 1991). This slight overlap in immunoreactivitiy is supported in this 
study where other non-GCL cells are TUJ-1 immunopositive. It is likely therefore that 
these cells are astrocytes with TUJ-1 immunoreactivity.
Identification of RGC degeneration at the level of the retina benefit from an 
independence from retrograde transport elements. Therefore quantification of damage 
should be far more accurate with these techniques than retrograde labelling. Cell 
morphology can also be examined for a better understanding of neurodegeneration in 
the retina. Immunolabelling studies of neurofilament proteins are particularly 
amenable to this. Initial studies using these new methods have far reaching 
implications, not just for the study of glaucoma but also, for investigations into other 
forms of neurodegeneration.
Despite the suitability of TUJ-1 immunoreactivity for the assessment of nerve 
damage, there are some drawbacks. Immunoreactivity for TUJ-1 is very specific for 
post-mitotic neurons (Sergent-Tanguy et al., 2003). However, a small proportion of
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cultured astrocytes are also TUJ-1 immunopositive (Sergent-Tanguy et al., 2003). 
These cells may express TUJ-1 as a result of neuro-glial interactions. Therefore some 
astrocytes can be expected with TUJ-1 positivity in retinal tissue sections. This is 
supported by the present study where TUJ-1 immunoreactivity was found to be 
present in the retinal ganglion cell layer, as well as in other layers of the retina. 
Therefore TUJ-1 immunoreactivity may also be present in retinal glia. Co-localisation 
studies, for example using GFAP and 0X42, may be used for the future investigation 
of TUJ-1 retinal cell specificity.
TUJ-1 immunolablling clearly identifies morphology of RGC soma and processes 
(Mellough et al., 2004). TUJ-1 studies of the glaucoma retina have the potential to 
elucidate size and shape alterations in the RGC dendritic field, following these initial 
investigations. TUJ-1 studies have been used to co-localise RGCs with calcium 
signalling in the retina (Pearson et al., 2002). Tuj-1 has also been used to quantify cell 
survival in retinal whole-mounts after axotomy (Cui et al., 2003). However, TUJ-1 
labelling has not been used with the episcleral vessel sclerosis model of glaucoma 
before. These findings indicate that loss of TUJ-1 immunoreactivity may provide a 
new quantification method for the assessment of neurodegeneration and nerve loss in 
the RGC layer. RGC loss was also examined by quantification of apoptosis in the 
RGC layer.
4.4.5 RGC apoptosis
Upregulation of apoptotic retinal cell death and degeneration in glaucoma occurs 
throughout all retinal layers (Wang et al., 2002). The number of apoptotic RGCs 
occurring in the retina is commonly used as a quantitative measure 
neurodegeneration. RGC numbers also decrease with severity of pressure elevation in 
experimental glaucoma (Hanninen et al., 2002).
Apoptosis occurs at a low rate in the normal retina in order to sustain cellular turnover 
(Hanninen et al., 2002). Low levels of apoptosis in control retinae were indicated in 
the present study by TUNEL positivity, and confirmed by active caspase 3 
immunoreactivity.
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4.4.5.1 Caspases
Apoptosis can be indicated by caspase activation. Activation of caspase 3 indicates 
that effector caspases are activated following episcleral drainage vessel sclerosis, 
consistent with limbal vessel sclerosis (McKinnon et al., 2002). Episcleral vessel 
sclerosis also activates caspase 9 and the intrinsic caspase pathway regulated by 
intracellular or mitochondrial signals (Hanninen et al., 2002). Laser photocoagulation 
of the trabecular meshwork similarly activates retinal effector caspases (caspase 3) as 
well as the extrinsic (caspase 8) pathway (McKinnon et al., 2002). The extrinsic 
caspase pathway (caspase 8) regulated by cell surface receptor-ligand binding is 
therefore involved in glaucoma, and is followed by activation of effector caspases 
(caspase 3) and apoptosis. The present study indicated effector caspase activation 
following experimental ocular hypertension. Therefore it is likely that extrinsic and/or 
intrinsic caspases are also upregulated. These data support a role for apoptosis in RGC 
death.
Caspase activation is a useful method of determining the extent of nerve damage, as 
well as a potential point for therapeutic intervention. The application of caspase 
inhibitors may reduce RGC death during glaucoma (Kermer et al., 1998; Kugler et al, 
1999). Ocular development studies show that macrophages can induce target cell 
apoptosis (Lang et al., 1994). It is possible that activated macrophagic microglia are 
involved during RGC apoptosis, and may exacerbate neuronal loss. This however is 
yet to be determined.
4.5.5.2 TUNEL
Apoptosis measured by TUNEL positivity increases with duration and magnitude of 
IOP elevation (Garcia-Valenzuela et a l , 1995). Apoptosis is thought to initiate at 4 
days post-initial injury (Hanninen et al., 2002). The present study confirmed that 
ocular hypertension does not induce apoptosis in the first 4 days following RGC 
insult, and extends this to 7 days under conditions of mild pressure elevation. 
Significant elevation of RGC apoptosis was not recorded until 11 days post-induction 
of hypertension, where low levels of RGC death were localised to the inferior retina.
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In the present study, initially very low levels of apoptosis were recorded; this 
increased between days 20 to 46, and then began to reduce after day 47 of ocular 
hypertension. Mild pressure elevation appeared to produce a peak in apoptosis during 
intermediate disease time points, with a lag during initiation, and late disease stages. 
Apoptosis appeared to follow a different course over time with more severe pressure 
elevation. Apoptosis progressed at around 5 to 8% per week up to 6 weeks following 
the doubling of IOP via episcleral vein cauterisation (Garcia-Valenzuela et al., 1995). 
Increasing the magnitude of pressure elevation 4 to 6 times resulted in 20% RGCs 
becoming apoptotic after only 7 days. Lower IOP elevations are therefore expected to 
produce a smaller effect on RGC apoptosis. However, episcleral vessel sclerosis 
produced apoptotic levels as low as 0.14% including high pressures and long 
durations of pressure (Johnson et al., 2000), and may therefore affect RGC death in a 
different manner than other glaucoma models.
Elevation of area under the IOP curve produced a consistent increase in the number of 
apoptotic RGCs. Indicating that a combination of magnitude and duration of IOP 
elevation and RGC death show a positive correlation. These factors are important 
therefore in inducing and maintaining conditions of cell death.
The effects of standard deviation of IOP elevation were not as clear. Small pressure 
fluctuations in the lower standard deviation groups did not seem to have a direct effect 
on cell death, indicating that lower levels of standard deviation are not important in 
inducing death. However, high levels of standard deviation (S5) produced the highest 
levels of apoptosis seen in any group. This indicates that the consistency of elevated 
IOP is an important factor in the amount of cell death. Therefore a combination of 
duration and magnitude of pressure elevation is likely to affect cell death, while only 
the highest level pressure deviation will produce a definite increase in apoptosis. It is 
likely that other studies would produce similar results, however, these attributes of the 
IOP curve have remained uninvestigated until now.
Neurotrophin studies indicate that loss of neurotrophic factors initially localises to the 
superior retina, which may therefore be worse affected in experimental glaucoma 
(Johnson et al., 2000). In contrast the present study indicated that RGC death was
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initiated in the inferior retina. Localised deprivation of neurotrophins occurs when 
IOP is doubled for only one week (Johnson et al., 2000), a much higher IOP elevation 
than achieved here. However, at the longest durations of pressure elevation, RGCs in 
the present study preferentially apoptosed in the superior retina. This indicates that the 
localisation of neurotrophic deprivation and cell death to the superior retina only 
occurs under severe IOP elevations or long durations of elevation. The implications of 
these findings are twofold. Firstly, moderate pressure elevations may not follow the 
same pattern of apoptosis in the retina as more severe elevations. Secondly, at lower 
pressures neurotrophin deprivation may not be involved in the initiation of RGC 
death.
TUNEL positivity correlates with RGC number following hypertension (Garcia- 
Valenzuela et al., 1995) and is therefore likely to provide a good measure of cell loss. 
Although identification of apoptotic RGCs is useful in determining the degree of IOP 
induced damage, there are drawbacks to this technique. The main failure is the short 
time that fragmented cellular DNA is free to bind exogenous TdT. This may only be a 
few hours, and as a result measurements of apoptosis may underestimate neuronal 
damage (Wyllie et al., 1980; Darzynkiwicz et al., 1992; Garcia-Valenzuela et al., 
1995). RGCs are not the only cell type present in the ganglion cell layer of the retina. 
Supportive glia in the form of Muller cells may also become affected by elevated IOP, 
and respond through apoptosis or proliferation. These cells are difficult to distinguish 
from neurons in the type of study presented here, and may therefore affect results.
4.5.6 Conclusions
Neurodegeneration following ocular hypertension can be qualified and quantified in 
many ways. All of these methods have various drawbacks. However, as in this study a 
combination of techniques can used successfully to show RGC degeneration and 
death following hypertension. Generally, identification of apoptotic RGCs was used, 
in combination with axonal counts and qualitative retrobulbar optic nerve grading, in 
the assessment of nerve damage in glaucoma. This study supports others which have 
indicated that RGC death by apoptosis occurs with ocular hypertension. Cell death 
occurs at a lower rate at more moderate pressure elevations. Data regarding apoptosis
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was supported by retrobulbar optic nerve studies, which indicated extensive axonal 
degeneration following the induction of elevated IOP. Techniques measuring 
apoptotic RGC death were valuable in the assessment of disease progression. 
Apoptotic cell counts appear relatively quick and non-subjective as compared to 
axonal counts and nerve grading respectively.
Morphological alterations, analogous to that in human glaucoma, were shown from 
the level of the optic nerve tissue, through to the degeneration of single axons as a 
result of experimental ocular hypertension. All of the findings presented here should 
enhance the understanding of RGC death in experimental glaucoma, and draw further 
parallels with the human disease.
In conclusion, the rat is a good model for the evaluation of the effects of ocular 
hypertension on the expression of glia and microglia. These will be described in 
future chapters.
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Chapter V
Glial Activation Following IOP-Induced RGC Death
5.1 Introduction
Primary open angle glaucoma (POAG) usually initiates when elevated intraocular 
pressure (IOP) causes retrodisplacement of the lamina cribrosa associated with 
reduced retrograde neurotrophic support and pathological cellular changes (Quigley 
and Addicks, 1981). Retinal ganglion cell (RGC) loss continues after reduction of 
IOP to normal levels, indicating attenuated secondary neurodegeneration during 
which microglia activate and proliferate (Bakalash et al., 2002).
There is considerable evidence that macroglia, particulary optic nerve head 
astrocytes, are involved in initiation and maintenance of cell death (Wang et al. 
2002). The role of microglia is less clear, despite their potential influence over 
damage (Tezel and Wax, 2004). The temporal response of retinal microglia to ocular 
hypertension is known (Lam et al., 2003b; Wang et al., 2000), however, chronic 
optic nerve responses have yet to be elucidated. Clarification is also needed on the 
neuroprotective and/or destructive role of microglia during glaucoma (reviewed by 
Schwartz, 2003; Tezel and Wax, 2004).
Microglial activation influences RGC survival (Raibon et ah, 2002). Production of 
toxins including nitric oxide (NO), implicate activated microglia in 
neurodegeneration (Chao et al., 1992; Neufeld et al., 1997; Siu et al., 2002). Th-1 
type cytokine (IL-2 and IFN-y) stimulation of microglia can generate chronic 
neurodestructive immune response (Abbas et al., 1996; Matsubara et al., 1999; 
Mosmann and Sad, 1996) during disorders such as stroke and multiple sclerosis.
130
Chapter V Glial Activation Following IOP-Induced RGC Death
The temporal relationship between neuroretinal cell death and microglial activation 
suggests a scavenger function for microglia (Naskar et al, 2002; Schuetz and 
Thanos, 2004). Evidence also suggests a neuroprotective function for microglia and 
T-cells via secretion of potent anti-inflammatory factors, which limit damaging 
autoimmunity (Bakalash et al., 2002; Morris et al., 1997; Parra et al., 1997).
Microglia may mediate neuroprotection only when in contact with neurons (Zeitlow 
et al., 1999). Neuroglial contact or communication may become compromised 
during glaucoma similarly to conditions of axotomy (Schuetz and Thanos, 2004) or 
stress, where the retinal CD200/CD200L axis is disrupted (Broderick et al., 2002). 
Microglial CD200R interacts with myeloid and RGC CD200 (Dick et al., 2001) to 
downregulate retinal microglial-induced autoimmunity and may have similar effects 
in the optic nerve (Dick et al, 2003).
Determining the temporal relationship between immune response and chronic RGC 
death in the glaucoma optic nerve will help elucidate the microglial role in 
pathophysiology. The relationship of neuroglial signalling with microglial activation 
may uncover mechanisms of secondary degeneration with possible relevance to 
other neurodegenerative diseases. Consequently astrocyte, microglial and immune 
cells as well as neuroglial interactions via the CD200 axis were measured from the 
initiation of experimental glaucoma through to more chronic time points.
5.2 Methods
Methods developed and used in the chapter are described in full in Chapter II, 
Section 2.7. The final immunolabelling protocol summarised in Chapter II, Section
2.7, Figure 2.5 produced acceptable results for all primary antibodies in dual 
labelling and was used to produce all results for quantification.
Experimental ocular hypertension was induced in Norwegian Brown rats, using 
episcleral drainage vessel sclerosis. Ocular hypertension was maintained as described 
in Table 5.1, to various durations, area under the IOP elevation/duration curve and
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standard deviation of IOP elevation. These aspects of ocular hypertension were then 
examined for astroglial and microglial alterations.
Table 5.1 Experimental animal groupings according to pressure elevations
Level GROUP“T”
Duration of IOP 
elevation (days)
GROUP“A”
Area under the pressure 
curve (mmHg)
GROUP “S”
Standard deviation
1 1 - 7  (n=10) 0.9 -  22.7 (n=8) 0-1.511 (n=6)
2 1 1 -1 9  (n=19) 2 4 .3 -9 6 .8  (n=16) 1.52 - 2.96 (n=13)
3 20-27 (n=l 1) 97 .2-151.1  (n=15) 3.20 - 3.75 (n=9)
4 3 3 -4 6  (n=10) 165.3 -  256.1 (n=8) 3.81 - 5.57 (n=16)
5 47 - 65 (n=7) 271.9-469.3  (n=10) 6.02 -12.76 (n=12)
Quantification involved subtraction of control immunofluorescence (without the 
addition of primary antibody) from contralateral (control, normotensive) and 
ipsilateral (hypertensive) optic nerves. The number of pixels at each intensity were 
measured on a brightness scale of 0 to 255. Each intensity was multiplied by the 
number of pixels at that intensity to give a value, the pixel (xy). This value was used 
in T-tests to test for significant differences between contralateral and ipsilateral eyes.
Immunolabelling was used to detect alterations in astrocytes (GFAP) and 
haematopoetically derived peripheral cells and/or microglia (CD45 and MHCII). The 
pan-microglial cell marker 0X42 was used to label all optic nerve microglia, 
regardless of activation state, while the macrophage marker, 0X41, was used to 
identify activated (and therefore macrophagic) microglia.
Due to inseparable differences between the microglia of the CNS and cells of the 
peripheral immune system, it was necessary to use an additional marker, 0X33. This 
marker was used to identify infiltrating peripheral lymphocytes, the presence of 
which would indicate compromise of the blood-brain-barrier (BBB), and therefore 
the possible infiltration of peripheral immune cells. Due to the nature and similarities 
between both the central and peripheral immune response, and the role of recruitment 
signalling it was necessary to use this panel of markers to clarify the cell types 
involved in the reaction to hypertension at the optic nerve head.
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5.3 Results
5.3.1 Quantification of immunofluorescence
Immunofluorescence quantification graphs for peaks in pixel number and intensity 
results were improved through subtraction of control immunofluorescence (Figure 
5.1). Control immunofluorescence, present in the absence of primary antibody, can 
be regarded as “noise” or “background fluorescence”, and is commonly subtracted 
from fluorescence results in terms of both data analysis, as in the present study, and 
images.
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Figure 5.1 Quantification o f immunolabelled pixel intensity Quantification o f 
T4 duration CD200 ligand immunolabelling pixel intensity are shown at the optic 
nerve head (n=5). Black plots represent pixel intensity following hypertension 
(ipsilateral eye), while grey plots represent control (contralateral eye) pixel 
intensity. Raw data is shown in graph 1. Clearly changes in results were produced 
by subtraction o f control immunofluoresence (2).
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5.3.1 Astrocytic reactivity
5.3.1.1 GFAP distribution in the normal and hypertensive optic nerve
A summary of astroglial changes as aspects of IOP elevation increase during 
experimental glaucoma is shown in Table 5.2 and Figure 5.1. Alterations in GFAP 
are also shown with respect to area under the pressure curve and the standard 
deviation of IOP (Table 5.2). These figures also show summaries of the relevant data 
for all other markers probed.
GFAP was distributed throughout normal optic nerve head astrocytic processes in a 
transverse orientation. Columns of astrocytes could be identified, with dense 
processes distributed within optic nerve head columns (Figure 5.2). GFAP 
immunopositivity appeared sharp throughout (Figure 5.2). Following hypertension 
denser labelling was discovered with brightly labelled thick astrocytic processes 
(Figure 5.2, T1-T4, A1-A5 and S1-S5). Alternatively GFAP reduction was observed 
as disrupted low intensity labelling, processes were thinner and fragmented (Figure 
5.2, T5).
5.3.1.2 Effects o f pressure elevation on optic nerve head astrocyte reactivity
The intensity distribution of fluorescent labelling for GFAP increased, but not to a 
significant level during initiation of experimental glaucoma at T l, and became 
consistently significantly elevated until T3 (P<0.05, Table 5.1 and Figure 5.3). Later, 
reduction of GFAP to normotensive levels occurred during T4. GFAP was further 
reduced during T5.
Area under the IOP curve and standard deviation affected the distribution of GFAP 
fluorescence intensity in a similar manner. In groups Al to A5 and SI to S5 there 
was not significant change in GFAP immunofluorescence excluding A3 and S3. 
Intermediate area under the IOP curve and standard deviation were most likely to 
produce a significant GFAP elevation. Both low and high area under the IOP curve 
and standard deviation did not result in significant GFAP elevation.
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Marker Duration of pressure elevation Area under IOP curve j Standard deviation of pressure elevation
T1 T2 T3 T4 T5 Al A2 A3 A4 A5 | SI S2 S3 S4 S5
CD200L | +++ — + -
CD200R +++ - +
CD45 + + +++ +++ +++ + ++ 1 + +++ +
MHCII
0X33 + 1
0X41 +++ ++ -
0X42 ++ +++ ++ +++ + + +
GFAP + +++ +++ +
CD200L . . . —
CD200R +++ -- +
CD45 +
MHCII
0X33 + +++
0X41
0X42 +++ . . . . . . +++ ++ ++ ++
GFAP . . . - “f
Table 5.1 Quantification o f immunolabelled pixel intensity This table summarises how duration o f  elevated IOP (T1 to T5), area under the IOP curve (A l to A5) 
and standard deviation o f  pressure elevation (SI to S5) can affect optic nerve head cell markers (n=25). Significant increases in fluorescence distributions following 
hypertension were found by comparing average pixel (xy) between and within T, A and S groups following T-testing at significance levels o f P<0.05 (+), P<0.01 (++) and 
PO.OOl (+++).
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ControlControl Control
Figure 5.2 GFAP immunolabelling at the optic nerve head Control GFAP 
immunolabelling (green) was highly organised into astroglial columns. Elevated 
immunolabelling at the optic nerve head is shown in T1-T4, A1-A4 and S1-S5. 
Reduction o f GFAP immunolabelling following hypertension is shown in T5 and A5. 
White bar represents 50pm.
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Figure 5.3 Effects o f pressure elevation on optic nerve head GFAP Groups T1 
to T5, A l to A5 and SI to S5 inclusive are shown (n=25). The difference in overall 
distribution as calculated by multiplying the number o f pixels at each intensity and 
subtracting contralateral controls from ipsilateral hypertensives is shown in grey. 
Significance was measured at levels o f  P<0.05 (*), P<0.01 (**) and P<0.001 (***) 
using a T-test. Significant inter-group differences are indicated by over-plot bars.
5.3.2 Infiltration of peripheral lymphocytes
5.3.2.1 Distribution o f 0X33 immunolabelling
Contralateral control optic nerve heads did not show any 0X33 immunoposititvty 
(Figure 5.4, Control). Sharply labelled 0X33 positive cells appeared to infiltrate the 
nerve under hypertensive conditions (Figure 5.4, T1-T4, A1-A5, SI-S3 and S5). 
0X33 used to identify infiltrating peripheral lymphocytes localised to large amoeboid 
cells, occasionally in astroglial columns, usually just within the nerve border at the 
level of the optic nerve head (Figure 5.4 T1-T4, A1-A5, SI-S3 and S5).
As duration of ocular hypertension increased from T1 to T4, 0X33 immunopositivity 
also increased, and appeared organised into a columnar distribution by T4 (Figure 5.4,
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T1-T4). At the highest durations of IOP elevation 0X33 immunopositivity appeared 
to return to control levels (Figure 5.4, Control and T5).
As area under the IOP pressure/time curve increased, so did 0X33 immunoallabelling 
(Figure 5.4, Al to A5). By A4 0X33 immunolabelling localised to columns within 
the optic nerve head, this distribution was also observed in A5, during which these 
columns appeared thicker, and contained more 0X33 positivity (Figure 5.4, A4 and 
A5).
Increasing standard deviation of pressure elevation induced fluctuations in 0X33 
immunolabelling (Figure 5.4, S1-S5). SI immunolabelling was increased as compared 
to controls, and appeared as a number of amoeboid 0X33 positive cells (Figure 5.4, 
Control and SI). 0X33 immunopositivity was also increased during S2, when 
labelling appeared localised to columns in the optic nerve head (Figure 5.4, S2). S3 
immunolabelling was similar to SI (Figure 5.4, SI and S3), while S4 
immunolabelling appeared to return to control levels (Figure 5.4, Control and S4). 
0X33 positivity had returned to elevated levels by S5, and regained a columnar 
distribution (Figure 5.4, S5).
5.3.2.2 Changes in optic nerve head 0X33 immunolabelling with elevated pressure
0X33 labelling for B lymphocytes although increased during all durations of pressure 
elevation (T1 to T5) did not achieve statistical significance as compared to controls 
via T-testing (Table 5.1 and Figure 5.5). However, on inter-group comparison, a small 
significant increase in 0X33 positivity was found between groups T3 and T4 
(P<0.05). Subsequently 0X33 immunopositivity was significantly reduced between 
T4 and T5 (PO.OOl).
In both area under the IOP curve and standard deviation of IOP elevation groups, only 
following high area under the IOP curve in group A5 were 0X33 immunolabelling 
levels increased significantly (P<0.05) as compared to controls. Elevation of area 
under the IOP curve, and standard deviation did not produce a consistent effect on 
0X33 immunolabelling.
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Figure 5.4 0X33 immunolabelling at the optic nerve head Representative images o f 
optic nerve head immunolabelling from control and all hypertensive groups T1-S5 are 
shown. Red labelling indicates 0X33 immunoreactivity, which appeared localised 
mainly to rounded amoeboid cells (C), and occasionally elevated following induction 
of ocular hypertesion (T4, A4, A5, S2 and S5). White bar represents 50/jm.
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Figure 5.5 Effects o f  pressure elevation on optic nerve head 0X33
Quantified optic nerve head 0X33 varied depending on pressure elevation on 
statistical comparison. The difference between ocular hypertension and control pixel 
(xy) is shown. Intra-group comparisons are shown in black, inter-groups comparisons 
are in red. Significance was measured at levels o f P<0.05 (*), P<0.01 (**) and 
P<0.001 (***) using two sample, two tailed T-testing.
5.3.3 Microglial changes
5.3.3.1 Qualitative observations o f microglial activation
Few MHCII and CD45 positive dendritic cells were found in control optic nerve, 
indicating a lack of microglia and haematopoetically derived peripheral cells under 
normal ocular pressures (Figures 5.6 and 5.7). Following ocular hypertension few 
alterations in MHCII were found, while CD45 labelled cells with both amoeboid and 
dendritic morphologies (Figures 5.6 and 5.7) at the nerve head.
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MHCII
Duration of IOP elevation did not appear to alter the level of MHCII 
immunopositivity in the optic nerve head (Figure 5.6, T1-T5). Throughout all stages 
of ocular hypertension MHCII immunopositivity appeared sharply defined (Figure 
5.6). However, MHCII labelling did identify increasingly amoeboid cells as duration 
of ocular hypertension increased (Figure 5.6, T1-T5).
As area under the IOP elevation/duration curve and standard deviation of IOP 
elevation increased, MHCII positivity appeared to decrease (Figure 5.6, A1-A5 and 
S1-S5). Initial elevation of area under the IOP elevation/duration curve resulted in 
MHCII positivity identifying more amoeboid-shaped cells than under control 
conditions (Figure 5.6, Control and A l). A2 conditions resulted in a return to a more 
dendritic MHCII positive labelling pattern (Figure 5.6, A2), while an amoeboid 
distribution was regained by A3 (Figure 5.6, A3). Both A4 and A5 MHCII 
immunopositivity appeared amoeboid in distribution, but was reduced as compared to 
controls (Figure 5.6, Control, A4 and A5).
Groups SI and S2 were similar in MHCII positivity to Al and A2. Intermediate 
standard deviation of IOP elevation (S3) resulted in an amoeboid CD45 labelling 
pattern which identified very few cells (Figure 5.6, S3). CD45 immunolabelling 
returned to increased levels by S4, when positivity appeared fragmented (Figure (5.6,
S4). At the highest conditions of standard deviation of IOP elevation (S5) CD45 
immunopositivity again became reduced, and appeared less than control levels 
(Figure 5.6, Control and S5).
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Figure 5.6 MHCII immunolabelling at the optic nerve head MHCII 
immunolabelling was used to identify optic nerve myeloid cells including dendritic 
microglial cells (arrow, T2, A2 and S2) as well as amoeboid peripheral infiltrating 
myeloid lineage cells (arrow, T5). Labelling appeared to fluctuate following ocular 
hypertension (T1 to T5, A l to A5 and SI to S5). White bar represents 50pm.
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CD45
Under control conditions CD45 sharply labelled few fairly amoeboid cells (Figure
5.7, Control). CD45 positivity was increased at all stages of duration of IOP elevation 
(Figure 5.7, T1-T5).
Elevated duration of ocular hypertension appeared to increase the number of 
amoeboid, sharply-labelled CD45 positive cells (Figure 5.7, Tl). CD45 
immunopositivity identified larger cells at T2 (Figure 5.7, T2), while by T3, cells 
appeared even larger (Figure 5.7, T3).
CD45 immunlabelling appeared more diffuse at T4, labelling appeared localised to 
both large and small cells (Figure 5.7, T4). Increased diffusion of label was observed 
by T5, possible indicating localisation o f label to cell of a more dendritic morphology 
(Figure 5.7, T5).
Throughout increase of area under the IOP elevation/duration curve increased CD45 
immunoreactivity appeared localised to sharply-labelled large amoeboid cells (Figure
5.7, Al to A5). At A2 and A5 labelling appeared more fragmented, and may have 
loclalised to smaller cells (Figure 5.7, A2 and A5). By A5, CD45 positivity appeared 
slightly more dendritic than at other stages of hypertension (Figure 5.7, A5).
Similarly, CD45 imunolabelling appeared elevated and localised to large amoeboid 
cells in all standard deviation of IOP elevation groups (Figure 5.7, S1-S5). S3 and S5 
labelling also appeared more fragmented, and similarly to A2 and A5 (Figure 5.7, A2, 
A5, S3 and S5).
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Figure 5.7 CD45 immunolabelling at the optic nerve head CD45 
immunolabelling (red), was used to identify all leukocytes as well as microglia in the 
optic nerve head. More optic nerve cells appeared CD45 positive in relation to 
MHCII positivity. Following induction o f  ocular hypertension CD45 immunolabelling 
appeared elevated in the optic nerve head (T1-S5). White bar represents 50pm.
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0X42
In control nerve head and retrobulbar regions, many cells sharply labelled with 
0X42. In the majority these cells had diffuse dendritic fields (Figure 5.8, Control). 
Ocular hypertension was associated with elevated 0X42 positive cell number, as well 
as labelling intensity (Figure 5.8). These 0X42 positive cells appeared less dendritic 
with fewer, thicker processes.
Initially ocular hypertension induced brighter, sharper labelling of less dendritic cells 
(Figure 5.8, T l, Al and SI). The number of cells labelled did not appear to differ 
from controls during the initial stages of hypertension (Figure 5.8, Control, T l, Al 
and SI). T2, A2 and S2 labelling appeared similar to T l, A l and SI, however, 
labelled cells were of an elongated morphology (Figure 5.8, T l, T2, A l, A2, SI and 
S2).
The third group of duration of ocular hypertension, area under the IOP 
elevation/duration curve and standard deviation of IOP elevation indicated a peak in 
0X42 immunoreactivity (Figure 5.8, T3, A3 and S3). In these third stage groups 
many 0X42 positive cells were sharply labelled, all appeared completely amoeboid 
in morphology (Figure 5.8, T3, A3 and S3). 0X42 immunoreactivity was 
subsequently reduced in more severe hypertensive groups, appearing as sharply 
labelled, bright, but few amoeboid cells (Figure 5.8, T4, T5, A4, A5, S4 and S5). In 
summary the effects of severity of IOP variables investigated here produced similar 
effects on 0X42 pan-microglial labelling.
In general the myeloid cell markers CD45, MHCII and 0X42 appeared to change in 
distribution and density following ocular hypertension.
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Control ControlControl
Figure 5.8 0X42 immunolabelling at the optic nerve head 0X42
immunolabelling identified dendritic microglial cells at the optic nerve head in 
controls. 0X42 immunoreactivity is shown in red. 0X42 immunolabelling appeared to 
elevate as a consequence o f  ocular hypertension (T1-S5 inclusive). Many optic nerve 
head cells were 0X42 positive in all images. White bar represents 50pm.
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5.3.3.2 Quantification o f  optic nerve head MHCII at different pressure elevations
No significant changes in distribution of MHCII fluorescence intensity were found 
following hypertension when examining duration of pressure elevation or area under 
the IOP curve (Table 5.1 and Figure 5.9). Therefore MHCII positive myeloid cells 
including resident microglia and possibly peripheral immune cells were not affected 
by increasing duration of IOP elevation or area under the IOP curve. One significant 
elevation was found between groups T3 and T4, where MHCII immunoreactivity 
significantly elevated (P<0.05). High standard deviation of pressure elevation 
induced a mildly significant MHCII elevation between groups T4 and T5.
MHCII
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Figure 5.9 Effects o f  pressure elevation on optic nerve head MHCII A two
sample t-test was used to compare MHCII optic nerve head immunolabelling at 
different pressure elevations (n=25). The differences between these data values are 
represented by a grey bar fo r  duration, area under the curve and standard deviation 
o f pressure elevation. Significant differences between groups are shown in red 
(P<0.05).
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5.3.3.3 CD45 immunolabelling with increasing elevated pressure
During initial (Tl and T2, PO.OOl) and chronic (T4 and T5, PO.OOl) durations of 
pressure elevation CD45 fluorescence distribution and pixel (xy) significantly 
increased as compared to controls. Pixel (xy) was also significantly elevated between 
groups T3 and T4 (P<0.05). Similarly significant elevation of optic nerve head CD45 
immunoreactivity occurred in groups of high (A4, P<0.05 and A5, PO.Ol) as well as 
low (Al, PO.OOl) area under the IOP curve (Table 5.1 and Figure 5.10). CD45 
immunoreactivity was also significantly elevated when standard deviation was low in 
groups SI (PO.05), S2 (PO.OOl), and S3 (PO.05).
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Figure 5.10 Effects o f  pressure elevation on optic nerve head CD45 Optic nerve 
head CD45 immunofluorescence was quantified and compared following ocular 
hypertension using a two sample t-test (n=25). The difference between data sets are 
shown in grey. Significant differences between control and hypertensive nerves are 
shown by the black stars (P<0.05, P<0.01, P<0.001). Differences between.groups 
are shown in red (P<0.05).
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Statistical comparisons indicated that CD45 levels were most likely to elevate at 
chronic IOP elevations with low area under the curve and standard deviation. 
However, initial disease stages, or higher area under the IOP curves were also likely 
to elevated CD45 levels. CD45 upregulation did not appear to correlate directly with 
elevation of any other markers described in this chapter.
5.3.3.4 0X42 positive microglial alterations with elevation o f IOP
The intensity distribution of labelling for 0X42 significantly elevated during T2 
(P<0.05), T3 (PO.OOl) and T4 (PO.Ol, Table 5.1 and Figure 5.11). Pan-microglial 
elevation indicated, during T2 to T4, that microglial cells were increased due to 
proliferation or migration. Inter-group analysis revealed that there were significant 
differences (PO.OOl) between each group (Tl to T5).
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Figure 5.11 Effects o f pressure elevation on optic nerve head 0X42 All
hypertensive groups are shown (n=25). Grey bars indicate overall differences in 
distribution (pixel xy). Significance was measured at levels o f P<0.05 (*), P<0.01 
(**) and P<0.001 (***) using a T-test. Red over plot bars indicate significant inter­
group differences.
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By examining area under the IOP curve it was possible to determine specifically that 
A3 area under the pressure curve was more likely to produce 0X42 upregulation 
(PO.OOl) than any other. 0X42 significantly elevated during the high standard 
deviation of pressure elevation achieved in groups S3 (PO.05), S4 (PO.05) and S5 
(PO.05).
Elevation of microglia corresponded with increase of CD45 positive myeloid cells. 
Both 0X42 and CD45 were significantly elevated (PO.05) from S2 to S4 inclusive. 
Increased microglial labelling also corresponded with elevation of the macrophage 
marker, 0X41, at T4, A3 and S4. This will be described and discussed in more detail 
later (Chapter V, Section 5.3.4.2). Briefly, the elevation of microglial markers 
appeared to occur before microglial activation.
5.3.4 Macrophagic cell changes
5.3.4.1 Distribution o f  0X41 immunolabelling
0X41 positive cells appeared rounded, but not devoid of processes (Figure 5.12). 
Throughout all experimental conditions 0X41 labelled sharply defined amoeboid­
shaped cells. These activated cells were present in high numbers throughout the optic 
nerve head, whereas control nerves were normally devoid of 0X41 positive 
macrophages (Figure 5.12).
Infiltration by 0X41 positive cells appeared to occur with increase of all ocular 
hypertension variables in a similar manner (Figure 5.12 T1-S5 inclusive). 0X41 
positivity increased via greater number of 0X41 positive cells, all of which had a 
similar morphology throughout. Eventually a uniform distribution was reached 
throughout the optic nerve by T3, A3 and S4 (Figure 5.12, T3, A3 and S4). These 
peaks in 0X41 positive cell number were followed by a reduction in labelling (Figure 
5.12, T4, T5, A4, A5 and S5). Overall, 0X41 positive macrophages appeared to be 
present in increased numbers following experimental glaucoma.
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1
Figure 5.12 0X41 immunolabelling at the optic nerve head Control optic nerves
were virtually devoid o f  macrophage positivity (Control, red). Ocular hypertension 
induced elevation o f optic nerve head 0X41 immunoreactivity, (T1-S5 inclusive) 
Peaks in macrophage activity are shown in images T3, A3 and S4. White bar 
represents 50pm.
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5.3.4.2 Changes in optic nerve head 0X41 with pressure elevation
Increased immunofluorescence distribution of optic nerve head 0X41 positive 
macrophages was recorded at T3 (PO.OOl) and T4 (PO.Ol, Table 5.1 and Figure 
5.13). These elevations were also consistently significantly different between 
ipsilateral experimental eye groups.
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Figure 5.13 Effects o f  pressure elevation on optic nerve head OX41 Optic nerve 
head OX41 immunolabelling at different durations o f  pressure elevation (n=25) were 
compared using a two sample t-test, the difference in distribution o f  pixel intensity 
(xy) is shown in grey. Significant differences within (black stars) and between groups 
(red bars and stars) were found at levels o f  P<0.05 (*), P<0.01 (**), and P<0.001 
(***)■
Intermediate are under the pressure curve induced significantly increased OX41 
positivity (A3, PO.Ol) which was also significant elevated as compared to other 
hypertensive ipsilateral optic nerves (PO.OOl). High standard deviation of pressure 
elevation induced OX41 upregulation in groups S4 (PO.05) and S5 (0.05). S4 
OX41 was also significantly elevated as compared to S3 levels. As no labelling of 
peripheral cells was found (0X33), it can be assumed that any immune cell markers
OX41
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in the optic nerve are those o f resident microglial. 0X41 upregulation occurred 
following increase of microglial (0X42) labelling according to duration of pressure 
elevation groups. Data indicates that microglial proliferation or infiltration preceded 
microglial activation. Proliferation / infiltration occurred throughout T2 to T4, with 
activation occurring later at T3 and sustaining until T5.
Activation (0X41) and proliferation / infiltration also coincided at A3 (intermediate) 
are under the pressure curve. At low standard deviations (S2) the microglial response 
was initiated (0X42), and maintained until S4. Only at the highest standard 
deviations were both the proliferative / infiltrative and macrophagic responses 
induced together.
5.3.5 Disruption of neuroglial interactions
5.3.5.1 Distribution o f  the CD200 ligand and receptor
Under control conditions, CD200 ligand labelling was sparsely distributed throughout 
the optic nerve head (Figure 5.14, Control). It was not possible to identify any axonal 
labelling. CD200 receptor was dispersed similarly to CD200 ligand under ocular 
normotension, however, more cells appeared to be labelled (Figure 5.15, Control). 
Following ocular hypertension elevations in both receptor and ligand were evident as 
increased labelling intensity of a greater number of cells.
CD200 Ligand
As duration of ocular hypertension increased, many amoeboid-shaped areas of sharp 
CD200 ligand immunopositivity appeared in the optic nerve head (Figure 5.14, Tl). 
This labelling pattern progressed into fewer, brightly-labelled sharp CD200 ligand 
positive areas (Figure 5.14, T2). Labelling was similar to T2 at T3 and T4, with fewer 
areas of CD200 ligand positivity (Figure 5.14, T2-T4). At the highest durations of 
ocular hypertension (T5) labelling distribution was similar to previous groups, but 
very few areas of positivity were identified (Figure 5.14, T1-T5).
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Figure 5.14 CD200 ligand immunolabelling at the optic nerve head CD200
ligand (red labelling) identified very few  cells. In the majority labelled cells were o f  
an amoeboid morphology. Elevated labelling following ocular hypertension appeared 
in the majority as brighter labelling o f  a greater number o f cells with amoeboid 
morphology (Tl, T2, A l, A2, SI and S5). White bar represents 50pm. S4).
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Initially, increased area under the IOP duration/elevation curve (Figure 5.14, A1-A3) 
had similar effects to increasing duration of ocular hypertension (Figure 5.14, T1-T3). 
The highest areas under the IOP duration/elevation curve (A4 and A5) resulted in 
reduced CD200 ligand positivity to bellow control levels (Figure 5.14, Control, A4 
and A5). Throughout increased area under the IOP curve, labelling appeared sharp 
and amoeboid in distribution (Figure 5.14, A1-A5).
Increased standard deviation o f IOP elevation resulted in sharp, brighter labelling of a 
similar number of areas as controls (Figure 5.14, Control, SI). Further elevation of 
standard deviation resulted in reduction o f CD200 ligand labelling very few areas of 
positivity (Figure 5.14, S2). CD200 ligand labelling under S3 and S4 conditions 
identified few, amoeboid sharp and bright areas of positivity (Figure 5.14, S3 and 
S5 conditions produced many areas o f more diffuse, dendritic labelling (Figure 5.14,
S5).
CD200 Receptor
The labelling pattern produced by CD200 receptor immunopositivity did not change 
throughout experimental conditions. Immunopositivity appeared as discrete, sharp 
labelling in an amoeboid distribution. (Figure 5.15). Elevation of ocular hypertension 
induced a reduction in the number o f CD200 receptor-positive labelled areas (Figure
5.15, Tl). Further elevation resulted in increased labelling, appearing as more 
discrete and amoeboid areas o f CD200 receptor labelling (Figure 5.15, T2 and T3). 
The highest levels of hypertension (T4 and T5) resulted in a return o f CD200 receptor 
similar to control labelling (Figure 5.15, Control, T4 and T5).
A1 and A2 area under the IOP elevation/duration curve reduced CD200 receptor 
immunopositivity in the optic nerve head, as compared to controls (Figure 5.15, 
Control, A1 and A2). Immunopositivity increased to the highest level during 
intermediate area under the IOP curve (A3), this increase, sustained throughout to the 
highest levels of area under the IOP curve (A4 and A5), appeared as a higher number 
of CD200 receptor positive areas in the optic nerve head (Figure 5.15, A4 and A5). 
Standard deviation o f IOP elevation produced the same alterations in optic nerve head
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Figure 5.15 CD200 receptor immunolabelling at the optic nerve head CD200
receptor immunolabelling (red) distribution was similar to the CD200 ligand. A 
representative example o f optic nerve head labelling is shown in control images. 
Hypertension induced mild elevation o f CD200 receptor labelling (T3 and A3). 
Increased immunoreactivity appeared as brighter labelling o f amoeboid cells 
exemplified in images T3 and A3. White bar represents 50jam.
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CD200 receptor labelling as area under the IOP elevation/duration curve (Figure
5.15, SI to S5).
5.3.5.2 Correlation o f nerve head CD200 ligand and receptor with IOP elevation
CD200 ligand significantly elevated at T1 levels of ocular hypertension (P<0.001) 
(Table 5.1, Figures 5.16 and 5.17). However, CD200 receptor was significantly 
reduced (PO.OOl) at this time point. These changes are supported by inter-group 
comparisons (PO.OOl).
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Figure 5.16 Effects o f  pressure elevation on optic nerve head CD200 ligand
Immunofluorescence varied with each group o f elevated IOP (T1 to S5 inclusive, 
n=25). Differences shown via two sample T-testing between hypertensive and control 
are indicated by grey bars. Inter-group differences are shown in red. Significance 
was measured to a level o f  P<0.01 (*) and P<0.001 (***).
Significant (PO.OOl) upregulation of CD200 receptor also occurred transiently 
during T3, this was a significant elevation as compared to ipsilateral T4 data 
(PO.01). At T5 significant reduction of CD200 ligand occurred. CD200 axis
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alterations according to area under the IOP curve mirrored those of duration of 
pressure elevation. During A l, CD200 ligand was significantly elevated (P<0.05) as 
compared to controls, while the receptor was significantly reduced (P<0.05). Later, at 
T3 CD200 receptor became significantly increased, subsequently at higher area under 
the pressure curve (A4) the ligand became significantly reduced (P<0.05).
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Figure 5.17 Effects o f  pressure elevation on optic nerve head CD200 receptor
Optic nerve head CD200 receptor immunoreactivity was compared at different 
pressure elevations and aspects o f  elevation (T1 to S5 inclusive, n=25) using pixel xy 
values (grey) generated by two-sample T-testing. Inter-group differences are shown 
in red. Significance was measured to a level o f P<0.01 (*), P<0.05 (**), and 
P<0.001 (***)■
Grouping of hypertensive changes by level of standard deviation indicated that 
CD200 axis alterations were not specific to any particular range of standard deviation 
of IOP elevation produced in this study.
Significant alterations in the CD200 axis did not appear to correspond well with 
changes in the other markers used. Changes of CD200 ligand at T1 occurred while
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CD45 positivity / myeloid cells were also elevated. At T3 CD200 receptor 
upregulation coincided with pan microglial (0X42) and macrophage (0X41) marker 
elevation. These associations were similar during area under the IOP curve associated 
CD200 axis changes. As CD200 axis alterations occur before microglial changes, the 
axis is implicated in the microglial response to injury.
53.6 Retrobulbar optic nerve changes
Retrobulbar optic nerve alterations were assessed in order to show whether microglial, 
immune cell and astrocyte alterations were typical to the site of primary damage in 
glaucoma, or could be extended to include regions other than the nerve head. In the 
majority control and hypertensive labelling appeared qualitatively similar to the optic 
nerve head. However, microglial/myloid cell markers appeared more pronounced in 
retrobulbar sites as compared to the optic nerve head (data not shown).
The first significant retrobulbar optic nerve changes following the initiation of ocular 
hypertension were elevation of CD200 receptor at T1 (P<0.01). Retrobulbar CD200 
axis dissociation preceded any other retrobulbar optic nerve changes, and also 
occurred at more chronic disease time points of T4 and T5 duration (P<0.001).
MHCII and 0X42 positive myeloid cells and microglia responded to ocular 
hypertension at the same time in retrobulbar and nerve head regions. Significant 
elevations of 0X42 initiated at T2 (P<0.01), with lack of MHCII elevation. The 
retrobulbar 0X42 response was maintained until T3 (P<0.01) indicating an attenuated 
microglial response similar to the optic nerve head. In the retrobulbar nerve 0X41 
positive macrophages significantly elevated in advance of the optic nerve head 
reaction with significant elevation at T2 and T3 (P<0.001 >.
0X33 positive B lymphocyte labelling was similar to the optic nerve head, without 
significant elevation. Retrobulbar CD45 did not correspond with optic nerve head 
labelling, indicating a lack of CD45 positivity throughout disease. GFAP was also not 
elevated at retrobulbar sites.
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5.3.7 Co-localisation studies
Dual immunolabelling studies revealed little correlation between the cell markers 
probed. GFAP immunoreactivity identified cells within astroglial columns, similar to 
MHCII immunopositivity. However, the distribution patterns of these two markers 
were very different aside from this similar origin in the optic nerve head astroglial 
columns. GFAP labelling was far more widespread throughout the nerve, while 
MHCII was localised around cell nuclei. Lack of cross-reactivity was observed 
between GFAP and MHCII positive cells (Figure 5.18). This positive control 
indicates therefore that astrocytes and microglia are spatially and morphologically 
distinct in all regions of the optic nerve.
Figure 5.18 GFAP and M HCII colocalisation Immunohistochemistry did not 
identify colocalisation o f  GFAP (green) and MHCII (red) in the optic nerve head. 
These two markers are clearly separated in distribution. Nuclei are labelled blue. 
White bar represents 50pm.
Dual labelling studies of GFAP and CD200 ligand and receptor revealed lack of 
colocalisation of these markers (Figure 5.19). CD200 ligand and receptor did not 
appear to be expressed on astrocytes at the optic nerve head (Figure 5.19 and 5.20) or 
retrobulbar regions (not shown). It can be assumed therefore that the CD200 axis 
involves neuroglial optic nerve interactions that are microglia-neuron in nature.
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Figure 5.19 GFAP and CD200 Ligand colocalisation CD200 ligand did not exhibit 
a similar labelling pattern to GFAP at the optic nerve head. Green labelling indicates 
GFAP, CD200 ligand is shown in red, while nuclei are labelled blue. White bar 
represents 50pm.
Figure 5.20 GFAP and CD200 Receptor colocalisation CD200 receptor is shown in 
red, while a clearly different labelling pattern shown in green represents GFAP 
immunopositivity. Nuclei are labelled blue. White bar represents 50pm
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5.4 Discussion
Neuroglial interactions and regulation of the central immune response are critical in 
many neurodegenerative central nervous system disorders such as Alzheimer’s and 
Parkinsons disease as well as glaucoma (Vickers et al., 19951; Vickers, 1997). 
Although glaucoma is not generally regarded as an inflammatory disease, it is 
becoming increasingly clear that immunomodulatory mechansisms are involved in the 
pathophysiology of retinal ganglion cell death.
Microglial activation has been reported in both human and experimental glaucoma but 
only the relationship of optic nerve head microglial activation to initiation of damage 
has been previously reported (Lam et al, 20032). The present report confirms the role 
of microglial activation in chronic experimental glaucoma.
5.4.1 Development of a method for immunolablling quantification
Quantification of immunolabelling using QWin to measure pixel intensity produced 
results that were difficult to interpret. Partially this was caused by the spread of 
fluorescence across 256 pixel intensities. Had this number of pixel intensities been 
reduced, perhaps by using a positive control to create a measurement scale, results 
would have been more precise and clearer. In current literature there is a deficit in 
clear fluorescence quantification methods, as well as the statistics used on fluorescent 
data. This study shows that Leica QWin can be used to measure raw fluorescence 
from images, however, the techniques developed could be refined further for clarity of 
results.
Parametric two-sample t-testing used the sum value generated by multiplying pixel 
number at each intensity by total pixel numbers, which were then compared for 
significance. This is particularly conservative in comparison with other techniques, 
such as non-parametric Kolmogorov-Smimov testing, and therefore suitable to 
analyse data which can vary according to distribution in terms of pixel number and 
intensity. A large peak in pixel number at low intensity was normally present in the 
contralateral plot, while peaks in ipsilateral pixel number were much smaller, but at 
higher intensities. This means that the consistency of the data may have affected the
162
Chapter V Glial Activation Following IOP-Induced RGC Death
results using other tests. Subtraction of background fluorescence was a vital step and 
is commonly used to enhance clarity of results in fluorescence analysis.
5.4.2 Correlation of cellular marker upregulation with apoptosis data
In order to ascertain the importance of upregulation of cellular markers in the optic 
nerve head, it is necessary to compare immunofluorescence data with data on retinal 
ganglion cell apoptosis following ocular hypertension. Correlation of optic nerve 
markers with apoptotic rates described in Chapter IV, Figures 4.12, 4.13 and 4.14 
should clarify the role optic nerve head components play during glaucomatous 
neurodegeneration.
5.4.2.1 GFAP levels and apoptosis
Initial significant elevation of GFAP coincided with significant elevation of RGC 
death. Later, reduction of GFAP to normotensive levels during T4 occurred following 
an RGC cumulative apoptotic rate of 13.78%. GFAP was further reduced during T5, 
as was the apoptotic rate. Astrocyte reactivity appeared to be involved in experimental 
glaucoma following initiation of RGC death. Reactivity was then reduced at more 
severe hypertensive levels when the cumulative apoptotic rate was high. Both low and 
high area under the IOP curve and standard deviation did not result in significant 
GFAP elevation. Apoptosis in these groups was raised to an intermediate level, 
indicating that GFAP elevation was primarily related to aspects of pressure elevation 
as opposed to the resultant apoptosis
5.4.2.2 0X33 levels and apoptosis
Lack of 0X33 upregulation indicates that cumulative RGC apoptosis over time did 
not induce significant infiltration of 0X33 positive peripheral cells following ocular 
hypertension as compared to controls.
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5.4.2.3 MHCII levels and apoptosis
The RGC damage and cumulative apoptotic rate of up to 15.24% produced in this 
study were not sufficient to induce elevation of MHCII positivity in ipsilateral as 
compared to contralateral eyes.
5.4.2.4 CD45 levels and apoptosis
CD45 elevation occurred before apoptosis was significantly increased, and was 
consistently elevated at all apoptotic rates excluding the highest at T3 (5.38%). 
Similarly, these elevations correspond with the lowest rate of apoptosis during Al 
(1.71%, P<0.05), as well as the highest during A4 (3.75%, P<0.05) and A5 (4.65%, 
P<0.05). The apoptotic rate varied without consistency during CD45 elevation with 
standard deviation of IOP elevation from 1.48% (P<0.05) at S2 to 4.24% (P<0.05) 
during S3. Consequently it appears unlikely that CD45 levels are involved with RGC 
apoptosis. Increased CD45 levels were correlated with the highest and lowest 
apoptotic rates.
5.4.2.5 0X42 levels and apoptosis
Significant elevation of 0X42 corresponded with the initiation of significant levels of 
RGC apoptosis at 1.89%, which focused at inferior retinal regions. 0X42 was 
consistently elevated until the cumulative apoptotic rate reached 13.78%. When the 
apoptotic rate became reduced at T5 (1.46%, P<0.05), 0X42 also reduced to 
normotensive levels. This data indicates a direct link between microglial upregulation 
and apoptotic rate. Cumulative apoptosis had only reached 3.27% at A3 0X42 
elevation. This shows that despite a low apoptotic rate, 0X42 was induced as a 
function of increased area under the pressure curve. Cumulative apoptotic levels were 
greater in groups S3-S5, co-incident with 0X42 upregulation, than in lower standard 
deviation of pressure elevation groups, indicating as association between 0X42 level 
and apoptotic rate.
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5.4.2.6 0X41 levels and apoptosis
0X41 upregulation at both T3 and T4 were associated with the highest apoptotic rate 
at 5.38% and 4.47%, respectively. This suggests that macrophages may be involved 
in the increased apoptotic rate present in the RGC layer following the induction of 
chronic experimental glaucoma. A3 0X41 upregulation corresponds with a moderate 
cumulative apoptotic rate of 7.76%, and a significant elevation in apoptosis specific 
to the inferior retina (P<0.05). Therefore, while increased duration of pressure 
elevation and a high apoptotic rate were likely to produce elevation of 0X41 
positivity, so was an intermediate area under the pressure curve combined with a 
moderate apoptotic rate. S4 0X41 elevations occurred after a cumulative apoptotic 
rate of 8.87%, with S5 reductions after 12.00% RGC apoptosis. Significantly elevated 
(P<0.05) apoptotic rate at these time points, though were at both moderate and high 
levels (3.13% and 5.28%, respectively). Inducation of 0X41 upregulation, or increase 
of macrophagic cells at both intermediate and high apoptotic rates indicates that 
macrophages may not have directly increased the apoptotic rate of glaucomatous 
RGCs.
5.4.2.7 CD200 axis levels and apoptosis
Initial upregulation of CD200 ligand occurred at T l, preceding significant increase of 
apoptotic rate. However, reduction of CD200 receptor at Tl indicated loss of receptor 
preceding significant RGC loss. Upregulation of CD200 receptor also occurred at T3 
when apoptosis peaked (5.38%). Meanwhile T5 CD200 ligand down-regulation 
occurred with a drop in the apoptotic rate to 1.46%, and a cumulative rate of 13.78%, 
again this implicates the CD200 axis in glaucomatous pathophysiology. A low 
apoptotic rate (1.71%) at A l occurred with significant CD200 ligand elevation 
(P<0.05). Following a cumulative apoptotic rate of 3.93% at T3, CD200 receptor 
became significantly elevated (P<0.01). CD200 ligand then became reduced at the 
cumulative apoptotic rate of 7.76% (A4). This data is a good indication that the 
CD200 axis was involved in the induction of RGC death.
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5.4.3 The astroglial reaction in ocular hypertension
GFAP is a molecular marker for astrocytes which is used extensively to identify these 
cells (Eclancher 1996). GFAP immunoreactivity within the optic nerve shows that 
astrocytes and their processes make up an extensive network, around and within the 
nerve fibre bundles. Other research indicates that in both animal models and human 
glaucoma, GFAP at the optic nerve head is augmented. The astroglial stress response 
incorporates prolonged metabolic and morphological changes, which produce a glial 
scar (Norenberg, 1994). GFAP upregulation may indicate glial scarring and 
prevention of axonal regeneration (Fawcett and Asher, 1999), or alternatively 
astrocytic promotion of neuronal plasticity and repair (Goss et al., 1998; Ridet et a l , 
1997).
GFAP elevation has been detected using ELISA and RT-PCR techniques in the 
glaucoma rat retina following 8 and 35 days of ocular hypertension. However, 
immunolabelling techniques do not detect any early changes in optic nerve head 
GFAP expression (Johnson et a l , 1996; Lam et al., 2003b). Our study reinforces this 
immunolabelling data, and localises the time frame of optic nerve head glial activity 
during initiation at the onset of significant cell death, as well as at some more chronic 
disease stages. We can also conclude that astrocytic activation is not affected by 
conditions of particularly mild and severe pressure elevations or standard deviation. 
The astroglial response is not induced in the retrobulbar optic nerve following 
glaucoma, indicating that it does not have a role to play in clearing RGC debris.
GFAP elevation indicates that the astrocyte response to elevated IOP may be an 
essential and potential target for therapeutic intervention. Neuroprotective strategies 
for glaucoma treatment combined with targeting the glial scar may prevent further 
RGC damage and promote neuronal regeneration (Fawcett and Asher, 1999). Some 
neurons also express GFAP due to the close coupling between neural and glial 
elements in the nervous system (Ling, 1989), therefore neuroglial interactions at this 
level may also be involved in the disease.
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5.4.4 Infiltration of peripheral immune cells
The central and peripheral immune systems share inseparable similarities. Lack of 
correlation between optic nerve head 0X33 upregulation and macrophage (0X41) 
upregulation means that we can rule out the possibility that we are observing 
infiltration of blood-borne immune cells as well as activation of resident optic nerve 
microglia, as B lymphocyte immunoreactivity was not recorded. A lack of correlation 
between B lymphocyte infiltration and the microglia/macrophage response indicates 
that in the retrobulbar nerve neither peripheral cell proliferation or migration occur in 
concordance with microglial activation. Peripheral immune cells are not elevated in 
the retrobulbar nerve
Lack of 0X33 positive peripheral B lymphocytes indicates integrity of the blood- 
retina-barrier (BRB) without peripapillary atrophy during disease. Normal lamina 
cribrosa, retrobulbar optic nerve and brain vascular endothelia contain tight junctions 
(Rapaport, 1976), with blood-brain barrier (BBB) markers. However, the prelaminar 
optic nerve lacks these characteristics, and represents a weak point in the BRB 
(Hofman et al., 2001). B lymphocyte optic nerve entry through the prelaminar BRB 
may be exacerbated by recruitment signalling. It is possible that optic nerve head 
astrocytes and microglia, both elevated during experimental glaucoma, produce 
lymphoid chemokines, which attract peripheral immune cells including B 
lymphocytes (Columba-Cabezas et al., 2003). However, it is unlikely that B-cell 
recruitment occurred in this glaucoma model, and BRB integrity was maintained.
We assume that lack of 0X33 signal indicates correct function of the BRB, however, 
a lack of B cell response may indicate that peripheral B-lymphocytes invade optic 
nerve sites, but do not proliferate and mature into antibody secreting cells during 
glaucoma. CD40 signalling has been implicated in B lymphocyte maturation and 
proliferation as well as T cell differentiation during Alzheimer’s disease (reviewed by 
Town et al., 2001) and CD45-mediated inhibition of microglial activation (Tan et al., 
2000). Following B lymphocyte infiltration, interactions with microglia via the CD40 
axis including CD45 may prevent lymphocyte proliferation and maturation. 
Interaction with this axis may account for upregulation of CD45 positivity following 
ocular hypertension.
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As infiltration does not occur either during or subsequent to microglial 
proliferation/activation and the initiation of RGC death, B lymphocytes are unlikely to 
influence initiation of microglial responses or neurodegeneration during glaucoma. 
Also, immune cell responses can be ascribed to the resident cells of the CNS, rather 
that infiltrating peripheral immune cells.
5.4.5 Microglial activation during ocular hypertension
The microglial response to central nervous system injury typically occurs early in 
disease onset, and may be neuroprotective, or destructive (Soares et al., 1995). This 
response is characterised by an alteration in cell morphology from a dendritic 
phenotype to an activated amoeboid state, when microglia become motile, 
macrophagic and proliferative. Under conditions of prelaminar BRB compromise 
resident active optic nerve microglia and peripheral macrophages are virtually 
indistinguishable by cell surface marker expression. However, activation of microglia 
has been measured throughout retinal and optic nerve pathologies using 0X41 and 
0X42 as markers (Lam et al., 20032; Raibon et al., 2002; Rao et al., 2003; Wang et 
al., 2000), as well as the more general immune cell markers MHCII and CD45 
(Neufeld, 1999).
Increased CD45 and 0X42 positive optic nerve head microglia indicated that 
microglial proliferation or recruitment occurs early during glaucoma, while activation 
occurs later. Simultaneous activation and proliferation or recruitment occurs early in 
retrobulbar regions. Microglial markers are upregulated in the initial stages of disease 
coincident with the onset o f IOP induced cell death. Macrophages are induced later 
and the response is sustained. Microglia therefore may exacerbate the initiation of 
RGC death in glaucoma.
During microglial activation RGC apoptosis peaks, followed by a trough when 
activation abates. This is consistent with a role for optic nerve head microglia in 
glaucoma pathophysiology, which may be either degenerative or reparative (Lam et 
al., 20032; Wang et al., 2000). Due to increased apoptosis during activation microglial 
exacerbation of cell death is likely. However, reduction of apoptosis immediately 
following microglial activation suggests that microglial-mediated neuroprotection
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may also occur. Retrobulbar microglia are likely to share a similar role to their nerve 
head counterparts.
Increase of optic nerve head microglia before macrophages indicates that microglia 
may influence macrophage recruitment during glaucoma. However, this study 
establishes that macrophage-mediated neurodegeneration is a result of microglial 
activation and not the result of recruited peripheral cells. Recruited macrophages have 
been shown to increase axonal degeneration following nerve injury (Liu et al., 2000). 
Macrophages can interact with myeloid and neuronal signal-regulatory proteins to 
induce neurotoxic NO production (Adams et al., 1998) via a CD8 (0X8) mediated 
mechanism (Hiiji et al., 1997). NO has been implicated during RGC pathophysiology, 
however this is controversial. It is likely that resident activated microglia serve a 
similar role.
Activated microglia are potent regulators of the immune response themselves. 
Activation involves upregulation of immune-stimulatory molecules, such as tumour 
necrosis factor (TNF) a  and interleukin (II) 12. These molecules signal to other 
microglia and infiltrating cells to regulate, for example differentiation of T cells, and 
maturation of B-lymphocytes. T-cell differentiation into Th-1 and Th-2 types may 
influence autoimmunity and neuroprotect during glaucoma (Bakalash et al., 2002). 
Microglial restriction of the Th-1 mediated immune response may be neuroprotective 
in experimental glaucoma.
The evidence suggests a role for microglia during initiation of RGC death. Microglial 
activation is likely to occur at high levels of RGC apoptosis, and therefore may have a 
role to play in cell death. This study was unable to ascertain whether this role is in 
active initiation of cell death, or in bystander damage. However, reduction of 
apoptosis following the microglial response may implicate microglia in 
neuroprotective pathways during glaucoma.
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5.4.6 Neuorglial interactions during glaucoma
Neuroglial signalling via the CD200 axis appears to be involved during initiation of 
ocular hypertension induced nerve damage and modulation of optic nerve head 
microglia. Retrobulbar optic nerve CD200 ligand and receptor also appear to be 
involved during the initiation of disease, as well as at more chronic time points. 
During early disease stages, the CD200 receptor and ligand dissociate, and may 
upregulate subsequent microglial activation.
The present study confirms the role of the CD200 axis during the microglial 
interactions of glaucoma. Glaucoma, not normally thought of as an immune disease, 
may involve microglial cells. Regulation of these cells may also be involved in 
disease via the CD200 axis. The role of this axis in other disease models makes it an 
ideal candidate for investigation during glaucoma. For example, CD200 has a role in 
immunosupression during transplant rejection (Chen et al., 1997; Gorczynski et a l , 
1999; Gorczynski et al., 1998) as well as susceptibility to collagen-induced arthritis 
and experimental allergic encephalomyelitis (Chen et a l,  1997; Gorczynski et a l, 
1998; Hoek et a l, 2000). Numbers of retinal microglia are elevated and tonically 
activated in CD200-/- mice (Broderick et a l,  2002).
Our data supports a role for changes in the optic nerve head CD200 axis during the 
initiation of retinal ganglion cell death. Disruption of this axis is found at initial stages 
of disease in the optic nerve, and therefore may play an important role in 
neurodegeneration.
It is possible that due to RGC death RGC-expressed CD200 ligand is reduced during 
glaucoma. The free receptor may then bind an alternative ligand to signal microglial 
activation. The receptor-ligand interaction normally serves to prevent receptor- 
mediated intracellular signalling and microglial activation. However, binding of an 
alternative ligand may enhance this signalling and prevent immunological detection of 
CD200 receptor. The evidence from other studies suggests that this in not the case, 
and that free receptor induces microglial activation, however no other studies have 
examined alternative CD200 interactions in the optic nerve. It is unlikely that 
reduction of the type 1 cytokines IL-2 and IFN-y, and an elevation of type-2
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cytokines, IL-10 and IL-4 due to CD200 receptor activation (Gorczynski et a l, 1999; 
Gorczynski et al., 2001) are involved in glaucoma pathophysiology.
It seems likely that microglial upregulation is important during initiation of retinal 
ganglion cell death and that microglial activation has a role during later stages. These 
observations may explain why clinical glaucoma can often progress despite reduction 
of IOP to normal levels, as microglia may continue to support neuronal damage. 
Other neuroglial signalling pathways are likely to be responsible for the initiation of 
microglial activation during glaucoma.
5.4.7 Conclusions
This study demonstrates the involvement of microglia, B lymphocytes and astrocytes 
in experimental glaucoma. The data support involvement of the CD200 axis in the 
initiation of glaucoma and in chronic regulation of microglial activation at the primary 
site of damage, the optic nerve head. Temporal specificity of the microglial response 
suggests that the role of microglia in optic nerve injury may involve more than 
removal of apoptotic debris.
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Chapter VI 
NOS during experimental glaucoma
6.1 Introduction
Nitric oxide (NO) is a vital component of brain physiology including synaptic 
plasticity, learning, memory, development and immunity. Excessive NO production 
can cause oxidative and nitrosative stress resulting in neurodegeneration and 
apoptosis (Frenzel J, Richter J, Eschrich K, 2005; McKinney et al., 2004). However, 
inhibition of NO production can be both neurodestructive and neuroprotective (Chiou, 
2001; Ciani, Baldinotti and Contestabile, 2001; Mohanakumar et al., 2002; Neufeld, 
Sawada and Becker, 1999). Controversy surrounds NO function during 
neurodegenerative disease.
Human neuronal nitric oxide synthase (NOS1) is located in optic nerve head 
astrocytes (Neufeld et al., 1997) and retinal ganglion cells (RGCs) (Neufeld et al., 
2000). Inducible NOS (NOS2) is not present (Neufeld et al., 1997), while endothelial 
NOS (NOS3) localises to small prelaminar blood vessel endothelia (Neufeld et al., 
1997). In the rat optic nerve, NOS is additionally present in pericytes (NOS1) and 
vascular endothelia of large vessels (NOS3, Neufeld et al., 1997). NOS1 has also 
been identified in human and rat neutrophils (Greenberg et al., 1998), while active 
macrophages produce NOS2. These peripheral cells may also have a role in RGC 
survival.
The potential effects of NOS on the optic nerve microenvironment have led to 
investigations into their role in glaucoma. Generally, NOS3 activity is thought to 
enhance blood flow and neuroprotect through reduction of vasoconstriction during 
glaucoma. NOS1 may serve either a neuroprotective or neurodestructive function. 
Once activated, NOS2 is likely to produce cytotoxic amounts of NO originating from
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active microglia and macrophages to exacerbate neuronal damage following nerve 
injury (reviewed by Neufeld, 2004).
In human glaucoma, some studies report upregulation of all NOS isoforms (Neufeld 
et al., 1997), while others contradict this (Pang et al., 2005). NOS1 expression has 
reportedly been elevated in astrocytes (Neufeld et al., 1997). NOS3 localisation has 
been found to extend to astrocytes and all blood vessel endothelia (Neufeld et al, 
1997), while NOS2 is also found in cells at the lamina cribrosa (Neufeld et al., 1997). 
However, other reports suggest that NOS2 is not upregulated during glaucoma (Pang 
et al., 2005).
Similar controversy is apparent from studies of NOS in experimental glaucoma. In 
experimental glaucoma via episcleral vein cautery, NOS2 expression is induced in rat 
optic nerve astrocytes, while NOS1 and NOS3 expression remained unaffected 
(Shareef et al., 1999). The effects of vein cautery may include ischaemic damage, and 
NOS2 may be a by-product of this reaction, particularly as episcleral vessel drainage 
vessel sclerosis induces experimental glaucoma without induction of NOS2 
expression (Pang et al., 2005).
Retinal NO production is also experimentally elevated following induction of 
experimental glaucoma via laser photocoagulation of the trabecular meshwork (Siu et 
al., 2002). Infiltrating peripheral macrophages, as well as resident glia and/or neurons, 
may influence NOS levels following glaucoma. Activated macrophages express 
NOS2 during immune regulation. Ligation of the macrophage signal regulatory 
protein OX41 can induce NO production (Adams et al., 1998). This signalling 
pathway may have a role to play during disease, particularly autoimmunity.
The neuroprotective effects of NOS2 inhibition reduced RGC loss to one third of 
experimental glaucoma levels following episcleral vein cautery (Neufeld et al., 1999). 
However, did not improve neurodegeneration following episcleral vessel sclerosis 
(Pang et al, 2005). NO has a role in potentiating anoxic or excitotoxic injury of RGCs 
in astrocyte cocultures (Morgan et al., 1999). Endogenous NO may also be involved 
in the control of RGC repair. Evidence suggests that NO acts on neurogenesis to
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facilitate differentiation into mature neurons (Moreno-Lopez et al., 2004), the 
manipulation of which may potentially result in neuroprotective or even regenerative 
effects. However, the issue of which NOS pathways can be manipulated to produce 
predominant neuroprotection remains unresolved, as evidence is contradictory.
The role of NOS 1 and NOS3 following episcleral drainage vessel sclerosis induced 
glaucoma has not been investigated, while contradictory evidence exists as to the 
involvement of NOS2 in glaucoma (Neufeld et al., 1999; Pang et al., 2005). In order 
to determine the role of NOS in glaucomatous RGC degeneration, the aim of this 
chapter was to determine if NOS expression (all three isoforms) differed between 
normal and hypertensive optic nerves. Aspects of ocular hypertension including 
duration of hypertension, area under the IOP elevation/duration curve, and standard 
deviation of IOP elevation will also be investigate in conjunction with NOS protein 
levels in order to dissect the exact role of NOS2 in the episcleral drainage vessel 
sclerosis model of glaucoma.
6.2 Methods
Methods used in this section are described in Chapter II, Section 2.7. 
Immunolabelling was used to localise optic nerve NOS isoforms. Similar to the 
immunolabelling results in Chapter V, no clear results were obtained in labelling for 
any NOS isoform until the optimisation of the final immunolabelling protocol, as 
detailed in Chapter II, Section 2.7, Figure 2.6.
Following IOP elevation, experimental animals were grouped for NOS labelling 
according to IOP elevation duration (T1-T5, total n=25), standard deviation of 
elevated IOP (S1-S5, total n=25) and area under the IOP versus time elevation curve 
(A1-A5 total n=25, Table 6.1). Normal and hypertensive rat optic nerve heads (n=5 of 
each, for each category within each group), were subjected to immunolabelling 
procedures twice each for NOS1, 2, and 3.
Labelling was quantified using Leica Qfluoro software, followed by data analysis in 
Microsoft Excel. Qualitative observations of NOS immunofluorescence in the
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normotensive and hypertensive optic nerves were identified. Statistical comparisons 
were made between levels of NOS-related immunofluorescence in contralateral 
(normotensive) and ipsilateral (hypertensive) optic nerves, following subtraction of 
control immunofluorescence from each. The sum of each pixel intensity multiplied by 
the number of pixels at that intensity (pixel xy) was calculated and compared between 
contralateral and ipsilateral optic nerves. Results describe the outcome of statistical 
comparisons using two-sample, two-way T-tests for analysis.
Table 6.1 Experimental animal groupings according to pressure elevations
Level GROUP “T” 
Duration of IOP 
elevation (days)
GROUP “A” 
Area under the 
pressure curve 
(mmHg)
GROUP “S” 
Standard deviation
1 1 -  7 (n=10) 0.9 -  22.7 (n=8) 0-1.511 (n=6)
2 1 1 -1 9  (n=19) 24.3 -  96.8 (n=16) 1.52-2.96 (n=13)
3 20-27  (n=ll) 97.2-151.1 (n=15) 3.20 - 3.75 (n=9)
4 3 3 -4 6  (n=10) 165.3-256.1 (n=8) 3.81-5.57 (n=16)
5 47 - 65 (n=7) 271.9-469.3 (n=10) 6.02 -12.76 (n=12)
6.3 Results 
6.3.1 NOS1
6.3.1.1 Distribution o f  NOS 1 in the normal and ocular hypertensive nerve
NOSl-immunorelated fluorescence was present in control optic nerve head (Figure 
6.1). In normal optic nerve heads, labelling could be found in cell processes, likely to 
be those of astrocytes. Retrobulbar optic nerve demonstrated similar NOS1 labelling.
After Tl durations of pressure elevation NOS1 labelling appeared brighter than 
controls, but did not alter in distribution (Figure 6.1, Tl). Labelling became 
increasingly sharper at T2 and T3, also with increasing localisation to well-defined 
astrocytic processes (Figure 6.1, T2 and T3). Upregulation of NOS1 was 
demonstrated by the presence of few NOS1 weakly positive axons with intense,
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widespread and sharp labelling of what appeared to be many highly organised 
astrocytic elements of the nerve by T4 (Figure 6.1, T4). At this stage, NOS1 labelling 
appeared to correlate well with the distribution and staining for GFAP (Chapter V, 
Section 5.3.1.1). At T5 NOS1 labelling appeared more diffuse than at any other time, 
and was reduced in intensity as compared to T3 and T4.
Group Al demonstrated a less dendritic NOS1 labelling pattern than controls, while 
labelling intensity appeared similar (Figure 6.1, Control and Al). Sharp labelling of 
cellular processes was regained during A2, and intensity appeared slightly increased 
as compared to controls and A l (Figure 6.1, Control, Al and A2). NOS1 labelling 
intensity appeared increased throughout A3 to A5 (Figure 6.1, A3, A4 and A5). 
Groups A3 and A4 demonstrated sharp labelling likely to be localised to astrocytic 
processes (Figure 6.1, A3 and A4), while group A5 labelling was more diffuse, and 
similar, though more intense, to control NOS1 labelling (Figure 6.1, Control and A5).
Standard deviation of IOP elevation initially appeared to have similar effects on 
NOS1 positivity to area under the pressure curve (Figure 6.1, SI and S2). Intensity 
increased with increasing standard deviation (Figure 6.1, S1-S4), while the highest 
deviations demonstrated a labelling intensity similar to controls (Figure 6.1, Control 
and S5). NOS1 labelling distribution also altered with increasing standard deviation of 
IOP elevation. SI and S2 labelling distributions were similar to Al and A2 (Figure
6.1, SI, S2, Al and A2). A more diffuse labelling pattern was observed in S3 (Figure
6.1, S3), while S4 labelling was sharper than all other “S” groups (Figure 6.1, S4). 
During S5, labelling returned to a diffuse pattern.
Following hypertension alterations in NOS1 labelling were varied. Significant 
changes in NOS1 with varying duration of ocular hypertension are summarised in 
Table 6.1. The effects of area under the pressure curve and standard deviation of 
pressure elevation (Table 6.2) on all NOS isoforms are as tabulated.
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Marker Duration of pressure elevation I Area under IOP curve Standard deviation of pressure elevation
Tl T2 T3 T4 T5 1 Al A2 A3 A4 A5 SI S2 S3 S4 S5
N0S1 ++ +++ + + + ++
NOS2 + ++ +++ + + + ++ + + +++ +
NOS3 I
NOS1 ++ + —
NOS2 +++
NOS3 -
Table 6.2 Summary of the effects of IOP elevation on NOS Alterations in each o f the three NOS enzymes are shown with changing 
duration o f elevated IOP, area under the IOP curve and standard deviation o f pressure elevation (n=25). Two-sample T-tests were used to 
compare control and ocular hypertensive nerve pixel (xy) for significant increases in fluorescence distributions. Significant elevations were 
tested at levels o f P<0.05 (+), P<0.01 (++) and P<0.001 (+++), significant reductions in pixel (xy) are indicated by (P<0.05), “— “ 
(P<0.01), and " (P<0.001).
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Figure 6.1 NOS1 immunolabelling at the optic nerve head As compared to 
controls NOS1 immunoreactivity occasionally appeared elevated following ocular 
hypertension (Tl to T5, A2 to A5 and S2 to S3). NOS1 positivity occasionally 
appeared axonal (T4) and, similar to GFAP, labelling within and between glial 
columns (T4). Single colour images are shown with NOS1 labelled green, scale bar 
indicates 50 pm.
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6.3.1.2 Alterations in optic nerve head NOS1 pixel (xy) with elevation o f IOP
Statistical analysis of pixel (xy) supported qualitative observations of NOS1 
immunofluourescence labelling. Significant elevations of optic nerve head NOS1, as 
determined by sum of (pixel xy), were recorded at T3 (P<0.01) and T4 (PO.OOl), 
following a minimum of 20 days IOP elevation (Table 6.1 and Figure 6.2). However, 
during the most chronic disease stage (T5) NOS1 labelling had reduced to a level that 
was not significantly different from normotensive controls.
NOS1
60000000
50000000
40000000
■C 30000000
£  20000000
10000000
0 0 I
13 T4 T5 A1
-10000000
Group
Figure 6.2 Effects o f pressure elevation on optic nerve head NOS1 Grey bars 
show the difference between contralateral control and ipsilateral ocular hypertensive 
nerve sum o f pixel (xy) values, grouped according to increasing duration o f ocular 
hypertension (Tl to T5), area under the IOP curve (Al to A5) and standard deviation 
o f IOP elevation (SI to S5). Significant differences were measured to levels o f P< 
0.05 (*), P<0.01 (**) and P<0.001 (***) using a two-sample T-test. Significant 
differences between ocular hypertensive groups were measured similarly and are 
indicated by brackets above with significance levels shown as stars.
Area under the IOP curve also produced significant elevation of NOS 1 in groups A3 
(P<0.05), A4 (P<0.05) and A5 (P<0.05, Figure 6.2). A combination of longer duration
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and magnitude of elevated pressure (represented in high area under the pressure 
curve) was therefore more likely to induce a NOS1 response during ocular 
hypertension, while at low area under the pressure curve, NOS1 did not appear to be 
activated.
Increased standard deviation of pressure elevation produced a significant elevation of 
NOS1 labelling in group S4 only (Figure 6.2). Both lower and the highest standard 
deviations did not result in increase o f NOS 1 levels.
6.3.2 NOS2
6.3.2.1 Distribution ofNOS2 in the normal and normal and ocular hypertensive nerve
NOS2 was not found in control optic nerves or in the majority of hypertensive nerves 
(Figure 6.3). However, in some cases, there appeared to be distinct patterns of NOS2 
distribution following hypertension. NOS2 was found in some optic nerve heads in an 
amoeboid form, and appeared to be localised to astroglial colums (Figure 6.3, T5). 
Alternatively, a more diffuse labelling pattern was recorded (Figure 6.3, T3 and T4), 
whereby NOS2 appeared to be localising to the glial processes of the optic nerve 
head. In some cases of ocular hypertension, NOS2 appeared to localise to vascular 
elements of the optic nerve (Figure 6.3, T3, T4 and A5). These changes will now be 
described in relation to aspects of experimental ocular hypertension.
At Tl, elevated IOP appeared to induce increased and diffuse NOS2 positive labelling 
in the optic nerve head as compared to controls (Figure 6.3, Control and Tl). 
Labelling was less diffuse by T2, and slightly increased as compared to controls 
(Figure 6.3, Control and T2). The labelling pattern of NOS2 during T2 appeared to 
localise to around the vasculature. T3 labelling was further increased in intensity as 
compared to controls, Tl and T2 and appeared to be much sharper (Figure 6.3, 
Control, T1-T3). At this stage NOS2 positivity as akin to the distribution of the optic 
nerve vasculature. By T4 NOS2 reaches its brightest levels. Labelling appeared very 
sharp, with a similar distribution to GFAP immunopositivity (Figure 6.3, T4). Small 
hollow circles of labelling were also seen at T4, which may indicate NOS2 positivity
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at optic nerve head microvessels (Figure 6.3, T4). By T5 a completely different 
labelling pattern was found. Sharply labelled NOS2 positive dots, localised in a 
similar manner to astroglial columns were found throughout the optic nerve head 
(Figure 6.3, T5).
NOS2 labelling also appeared slightly altered with area under the IOP 
duration/elevation curve, however, changes in labelling intensity were more subtle 
than for duration of IOP elevation, and alterations in intensity were not pronounced 
(Figure 6.3 A1 to A5). At A l, a few fairly thick sharply defined cellular processes 
were NOS2-positive (Figure 6.3, A l). A2 labelling was similar to A l, however, small 
hollow circles of NOS2 positivity could also be found (Figure 6.3, Al and A2). NOS2 
positive labelling at A3 also identified clearly defined cellular processes more 
numerous than Al and A2, but with a low labelling intensity (Figure 6.3, A3). 
Immunopositivity also appeared to localise to RGC axons at this stage. A4 NOS2 
positivity was as described for A2, while at A5 labelling was more fragmented, and in 
some cases appeared axonal (Figure 6.3, A5).
Standard deviation of pressure elevation also affected the labelling pattern of NOS2 
(Figure 6.3, SI to S5). At low standard deviations (Figure 6.3, SI) few thick cellular 
processes were identified as weakly NOS2 positive. At standard deviations 
represented by groups S2 and S3 NOS2 positivity similarly identified few cellular 
processes, and also localised to a hollow rounded pattern, which might be expected of 
vascular labelling (Figure 6.3, S2 and S3). More processes appeared labelled under S4 
conditions, while a low labelling intensity was maintained (Figure 6.3, S4), while S5 
optic nerves appeared to contain few thick NOS2 positive processes, similar to SI 
labelling, as well as some NOS2 positive RGC axons (Figure 6.3, SI and S5).
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Figure 6.3 NOS2 immunolabelling at the optic nerve head NOS2 
immunoreactivity was rarely detectable in control normotensive optic nerves. 
Following hypertension, labelling was varied in nature and appeared localised to 
glial columns (T3), and/orlocalised to amoeboid-shaped cells (T5). Localisation to the 
processes o f small microglia-shaped cells appeared under mild conditions o f 
hypertenstion (Al, A2, S3). Single colour images are shown. White bar equals 50pm.
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6.3.2.2 Changes in optic nerve head NOS2 pixel (xy) with ocular hypertension
Significant NOS2 elevation occurred at stage Tl of ocular hypertension, during initial 
disease (P<0.05, Table 6.2 and Figure 6.4, T l). NOS2 was not significantly elevated 
during T2. Significant elevation of NOS2 returned during T3 (P<0.01) and T4 
(P<0.001), and corresponded with significant NOS1 elevation. It is possible that 
NOS1 and NOS2 responses during these time points were similar. However, unlike 
the NOS1 response, NOS2 remained significantly (P<0.05) elevated during T5. NOS2 
elevation at this chronic stage was not as pronounced as during T3 and T4, indicating 
that the NOS2 response may have been reducing or ending at more chronic disease 
states No significant changes in levels of NOS expression were identified between 
hypertension optic nerves in groups S1-S5 or A1-A5, or when compared to 
contralateral normotensive optic nerves.
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Figure 6.4 Effects o f  pressure elevation on optic nerve head NOS2 The effects o f  
elevating IOP on optic nerve head NOS expression in terms o f duration (Tl to T5), 
area under the IOP curve (Al to A5) and standard deviation (SI to S5) are shown. 
Grey bars indicate the sum o f  (pixel xy). Data were compared using two-sample T- 
testing, at significance levels o f  P<0.05 (*), P<0.01 (**) and P<0.001 (***). 
Significance is shown as for Figure 6.3.
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6 3 3  NOS3
6.3.3.1 NOS3 distribution in the normal and hypertensive optic nerve
NOS3 sparsely labelled the optic nerve head (Figure 6.5). Only a low level of 
labelling could be distinguished (Figure 6.5, Control). This labelling appeared 
vascular in nature, and localised in mainly oval or rounded bands. These bands 
appeared to be made up from smaller bands radiating outwards from what was likely 
to be the vessel lumen (Figure 6.3, Control).
Following hypertension, NOS3 rarely appeared to be elevated, and a similar 
distribution pattern was often seen. NOS3 labelling occasionally appeared increased 
and/or fragmented around smaller vessels (Figure 6.5, T3, A l, A3, SI, S4 and S5). 
While occasionally labelling appeared to localise to larger vessels (Figure 6.5, T l, T3 
and SI). No pattern of alterations appeared to be produced by intergroup comparison 
between T1-T5, A1-A5 or S1-S5.
6.3.3.2 Changes in optic nerve head NOS3 pixel (xy) with ocular hypertension
Significant alteration of NOS3 immunofluorescence distribution as compared to 
normal did not occur within the time points, standard deviations of pressure elevation, 
areas under the pressure curve (Table 6.1 and Figure 6.6). One significant 
measurement was recorded from NOS3 data. This involved a significant elevation 
(P<0.05) between groups T2 and T3; however, neither of these groups were 
significantly different from controls.
63.4 Retrobulbar NOS during ocular hypertension
In order to determine whether the upregulation of NOS is typical of the optic nerve 
head and therefore likely to be involved in processes other than microglial scavenging 
NOS, nerve head and retrobulbar regions were compared.
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Figure 6.5 NOS3 immunolabelling at the optic nerve head NOS3 appeared to 
surround vessels in the optic nerve (all images, green labelling). Following 
hypertension NOS3 rarely appeared upregulated (Tl to T5, A l to A5 and SI to S5). 
Upregulation appeared as brighter more fragmented labelling and elevated area o f 
label, indicating proliferation o f  blood vessels as well as damage by hypertension). 
Bar represents 50pm.
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NOS2 was found in some retrobulbar optic nerves in a globular form. It was found 
that, similar to nerve head regions, NOS1 and NOS2 did significantly upregulate 
(PO.OOl), while NOS3 did not (P<0.05). Upregulation of these NOS isoforms was 
only found during T4 time points (data not shown).
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Figure 6.6 Effects o f  pressure elevation on optic nerve head NOS3 The 
fluorescence intensity distribution o f  NOS3 in normal and hypertensive optic nerve 
heads was compared using pixel (xy) values and a two-sample T-test. Significant 
alteration in the level o f  NOS3 enzyme following hypertension as compared to control 
was not found (P>0.05). One significant elevation in sum o f pixel (xy) was found 
when comparing between groups T2 and T3(P<0.05).
6.3.5 NOS isoform and cell m arker co-localisation
NOS1 did not qualitatively correlate well with the myeloid cell markers MHCII and 
CD45 Figure 6.7 a and b). NOS2 immunolabelling corresponded to microglial and 
immune cell labelling better than NOS1 labelling. NOS2 was occasionally associated 
with CD45 and MHCII in the ipsilateral optic nerve (Figure 6.8, a and b). NOS2 also 
occasionally colocalised with the pan-microglial marker 0X42 (Figure 6.8, d) or the 
components of the CD200 axis (Figure 6.8, d and e) However, NOS2 was not 
frequently associated with OX41 (Figure 6.8, c).
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Figure 6.7 Correlation o f  NOS1 with myeloid cell markers NOS1 immunopositivity 
shown in green, did not correlate with either MHCII (a, red) or CD45 (b, red) 
labelling in the optic nerve head. Nuclei are shown in blue. White bar represents 
50pm.
Figure 6.8 NOS2 colocalisation with microglial and immune cell markers
Hypertension induced upregulation o f NOS2 immunopositivity (green, all images). 
NOS2 labelling correlated well with CD45 (a, red), MHCII (b, red), and 0X41 (c, 
red). 0X42 (d, red), CD200 ligand (e, red) and CD200 receptor (f, red) labelling did 
not correlate with NOS2 positivity. Nuclei are labelled blue, white bar represents 
50pm.
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There did not appear to be any correlation between glial markers and NOS3 
immunoreactivity in any optic nerve region (not shown). The labelling pattern of 
GFAP positivity did not resemble NOS3 immunoreactivity (not shown).
6.4 Discussion
The role of NOS in glaucoma has been controversial for some time. This study 
indicated that NOS2 is likely to have a role during initiation of glaucomatous optic 
nerve degeneration. It is possible that secondary neurodegeneration is partially 
mediated by NOS1 in the degenerating optic nerve. NOS3 does not appear to be 
involved in glaucomatous RGC death.
Previous studies have examined the extent and localisation of NOS at the optic nerve 
head of normal and glaucomatous rat and human tissue (Neufeld 1997; Neufeld 
2000). However, no literature is available with regard to NOS alterations with 
duration of ocular hypertension in experimental glaucoma, including the model used 
in this study. The present study then confirms and extends the time frame of NOS 
upregulation in a reliable glaucoma model according to aspect of pressure elevation 
(duration of elevation and standard deviation of IOP elevation) which have not 
previously been investigated.
6.4.1 The distribution of optic nerve NOS isoforms
NOS distribution in the present study correlates well with the findings of others. Both 
human and experimental animals show a similar sparse distribution of NOS in the 
normal optic nerve in glia and capillaries (Shareef et al., 1999). In these areas native 
NOS upregulates in some studies o f experimental glaucoma (Shareef, et al., 1999), 
similar to the human disease (Neufeld et al., 1997). Consequently the mechanisms of 
NOS-induced cell death are likely to be similar in both human glaucoma and animal 
models of the disease.
However in contradiction to the present study, lack of NOS2 upregulation has 
previously been determined at 35 days duration of varying severity of ocular
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hypertension in the episcleral drainage vessel sclerosis glaucoma model (Pang et al., 
2005). At this duration o f hypertension no NOS2 activation was reported in the optic 
nerve, via several different techniques used to detect protein and mRNA. In contrast 
the present study identified NOS2 upregulation following episcleral drainage vessel 
sclerosis, and has both determined and extended the time scale of NOS elevation 
following episcleral drainage vessel sclerosis. Most importantly, the present study 
specifies the attributes of IOP in terms of duration, area under the IOP 
elevation/duration curve and standard deviation of IOP elevation that are likely to 
cause this NOS2 elevation.
6.4.2 Correlation of NOS with RGC death
6.4.2.1 Correlation o f  NOS 1 labelling with apoptotic cell death
NOS1 was significantly upregulated only following the initiation of RGC death in 
glaucoma (at T2), and during more intermediate disease stages where apoptosis 
occurred at its highest rate o f 5.38% (T3) and 4.47% (T4, Chapter VI, Figure 4.12 and 
Figure 6.2). At T5 RGC apoptosis was reduced to a rate of 1.46% above control 
levels. This indicates that the NOS1 response may have been transient during 
intermediate stages of disease, and was not involved during the crucial initiation and 
chronic disease states.
NOS1 elevation appeared to occur following significant elevation of RGC death, 
which occurred during both A l and A2. However, NOS1 elevation did not occur until 
apoptotic rates reached 3.27% above normal in A3, and continued during the 3.75% 
and 4.65% increases found in A4 and A5, when apoptotic rates were at their highest.
For standard deviation of IOP elevation groups, NOS1 elevation did not occur before 
initiation of RGC death, and was present only after a cumulative increase in apoptotic 
rate of 8.87%.
NOS1 became elevated only following the initiation of RGC apoptosis, and therefore 
was not involved during initiation of RGC death. Intermediate duration of
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hypertension and standard deviation of pressure elevation as well as intermediate to 
chronic are under the pressure curve, were therefore critical factors in elevation of 
NOS1 levels.
6.4.2.2 Correlation ofNOS2 labelling and apoptotic cell death
Significant NOS2 elevation occurred at stage Tl of ocular hypertension (P<0.05, 
Table 6.2 and Figure 6.4, T l), before significant increase of RGC death (apoptosis 
was increased by only 2.04%). Significant elevation of NOS2 was also recorded from 
the peak of apoptotic rate with duration of pressure elevation (T3) until the 
experimental end-point. Low, intermediate and high levels of apoptosis in area under 
the IOP duration/elevation curve were associated with NOS2 upregulation (Al, A3 
and A5). NOS2 elevation was associated with all levels of apoptosis with standard 
deviation of IOP elevation, excluding SI, as significant elevation occurred throughout 
groups S2 to S5.
6.4.2.3 Correlation ofNOS3 labelling and apoptotic cell death
Significant alteration of NOS3 immunofluorescence distribution as compared to 
normal did not occur within the levels of cell death tested (Table 6.1 and Figure 6.6). 
Lack of an alteration in NOS3 labelling indicates that this isoform was not involved in 
neuroprotection, degeneration or apoptosis of the RGC under these conditions.
6.4.3 Correlation of NOS upregulation with other markers in the optic nerve
In order to determine the likely origin of NOS following experimental glaucoma it is 
necessary to compare and contrast the labelling of other optic nerve markers used in 
this study (Chapter V) with labelling of NOS. This comparison may also give some 
clues as to the mechanisms underlying NOS, macro, and microglial regulation 
following experimental glaucoma.
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6.4.3.1 NOS1
Significant elevation of NOS1 as duration of IOP elevation increased corresponded 
with significant elevations of GFAP (P<0.05), CD200R (P<0.001), 0X41 (P<0.001) 
and 0X42 (P<0.001) at T3. This indicates that during T3, NOS1 elevation may have 
resulted from increased levels of resident macrophages (0X41) and/or microglia 
(0X42) as well as disruption o f the CD200 axis (CD200R). It is also possible at this 
stage that NOS1 was astrocytic in origin. However, during NOS1 elevation at T4 only 
CD45 (P<0.001), MHCII (P<0.05) and 0X41 (P<0.01) were significantly changed. 
Therefore the NOS 1 response at T3 and T4 appeared to differ. The T4 response was 
more likely to involve activated microglia implicated most importantly by 0X41 
elevation. It was possible to distinguish the NOS1 response from peripheral 
macrophages (0X41) and macrophagic microglia (0X41) at both T3 and T4 as a 
consequence of lack of 0X33 upregulation. These findings were supported both by 
statistical analysis of immunolabelled pixel intensities and qualitative observations of 
immunofluorescent images.
Significant elevation of NOS 1 during A3 corresponded with markers as in T3. During 
A4 the CD200L (P<0.05) together with CD45 (P<0.001) became significantly 
elevated with NOS1 indicating a slight alteration in the aetiology of the response as 
compared to A3. During A5 NOS1 elevation corresponded with significant elevation 
of 0X33 (P<0.05), as well as CD45. At A5 therefore, NOS1 may be microglial or 
invading peripheral cell in origin.
S4 NOS1 elevation only corresponded with elevation of microglial and macroglial 
markers (CD45, P<0.05; 0X41, P<0.05; 0X42, P<0.05), with no indication of 
peripheral cell infiltration. NOS1 produced during S4 is most likely to derive from 
activated optic nerve microglia.
In the majority NOS1 elevation was attributed to elevated astroglial and microglial 
activity. In some disease states it was not possible to determine whether NOS1 was 
microglial in nature, or originated from astrocytic cells.
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6.43.2 NOS2
During significant increase o f NOS2 at T l, microglia/immune cells (CD45, P<0.05) 
and components of the CD200 axis (P<0.001) were also significantly upregulated. It 
is likely therefore that T l NOS2 upregulation occurred in microglia as either a 
consequence or a cause of CD200 axis disruption. Correlation of immunofluorescence 
data indicates that NOS2 elevations at T3 occurred as a result of microglial or 
astroglial activation, while at T4 NOS2 may have originated from resident microglial 
cells.
6.4.33 NOS3
As NOS3 upregulation was not recorded, it was unlikely that this isoform of NOS was 
involved in either the glial or vascular reaction to experimental ocular hypertension. 
This indicates that perivascular microglial, involved in maintaining vascular tone, did 
not react to increase blood flow by way of NOS3 upregulation, and consequent NO 
release. The vascular system does therefore not appear to be involved in glaucomatous 
neurodegeneration or neuroprotection.
6.4.4 The role of NOS during initiation of RG cell death
Normally NO acts as a neurotransmitter, participating in interastrocytic and astrocyte- 
neuron interactions (reviewed by Guix et al., 2005). Microglia also express NOS once 
activated, as part of the immune response (reviewed by Minghetti et al, 2005). 
However, at high concentrations NO is toxic through the induction of apoptosis, and 
may exacerbate cell death via necrosis (Borutaite and Brown, 2003).
NOS2 is often used as a marker for active microglia due to the upregulation of this 
isoform during the immune response. It is this form of the enzyme that is the most 
likely candidate for the over expression of neurotoxic levels of NO due to the 
inducible nature of its activity. NOS1 and NOS3 are less likely to be involved in this 
type of response due to a constitutive activity maintained by calcium signalling.
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However, it is also possible that these isoforms become misregulated during disease to 
over produce NO resulting in either a protective or degenerative response.
The evidence presented here indicates that the NOS2 isoform is involved in the 
initiation of retinal ganglion cell death during experimental glaucoma, in concurrence 
with a disruption of microglial cell response (Chapter V). Therefore RGC death 
during glaucoma is likely to be initiated by separate factors such as mechanical 
damage to axons at the level of the lamina cribrosa, as well as disruption of microglial 
signalling axes and NOS2 upregulation.
This is the first study to indicate a role for NOS at early stages of disease, while there 
are many studies that support NOS2 and microglial activation following the induction 
of RGC death. The role of NOS in chronic glaucoma is less secure.
NOS3 is unlikely to have a role during the initiation of cell death, due to a lack of 
upregulation of this isoform during experimental glaucoma. However, the fragmented 
pattern of NOS3 observed following ocular hypertension might indicate disruption of 
the vasculature, or proliferation of small vessels as a result of ocular hypertension.
6.4.5 The role of NOS during secondary degeneration
During chronic glaucoma both human and animal studies have implicated NOS 
upregulation as a potential mediator of continued RGC death. Upregulation of NO has 
also been shown following chronic glaucoma (35 days) produced via laser treatment 
of the trabecular meshwork (Siu et al., 2002). Indications are that all NOS isoforms 
are upregulated in the optic nerve following similar treatment (Shareef et ah, 1999).
The present study confirms that at chronic IOP elevations associated with high levels 
of RGC apoptosis, NOS1 and NOS2 expression is upregulated at the optic nerve head. 
This is consistent with a role for these isoforms in RGC death, as well as in the 
ensuing immune response.
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6.4.5.1 NOS1
NOS1 upregulation represents a point of neuroglial as well as glia-glia 
communication, which may become compromised during glaucoma. NOS1 
upregulation in chronic glaucoma may be as a direct result of RGC stress. The source 
of this enzyme is likely to be RGCs, as well as astrocytes (Shareef et al., 1999), 
although microglia and other immune cells are also implicated. Over activation of this 
constitutive enzyme is likely to result in excessive NO, which has a deleterious effect 
on RGC survival through induction o f apoptosis. However, the effects of NOS1 
upregulation are unlikely to be as severe as those of NOS2, as this isoform has the 
capacity to generate huge amounts of NO.
6.4.5.2NOS2
NOS2 is not expressed under normal conditions. However, this inducible form of the 
enzyme produces high amounts of NO following activation, which is used during the 
immune response to destroy neighbouring cells (Lyons et al., 1992). NOS2 is likely 
to be over expressed by microglial cells in the optic nerve both during initiation, and 
as part of the immune response, following elevated IOP-induced RGC degeneration. 
Consequently, over expression may further influence RGC apoptosis via the provision 
of an environment conducive to cell death.
6.4.53 NOS3
The present study indicates that NOS3 does not have a role to play in glaucoma 
pathophysiology. However it has been hypothesised that NOS3 may play a vital role 
in vasospasm during glaucoma. Evidence suggests that initiation of glaucomatous 
damage at the lamina cribrosa (Hayreh, 1979) may include vasospasm resulting in 
ischaemia, as well as mechanical crushing of axons and diminished neurotrophic 
support. Astrocytes are closely coupled to vascular elements at the nerve head; 
consequently it is likely that alteration o f vascular NOS3 affects the function of 
astrocytes in glaucoma. This function may include glial proliferation and activation at 
the optic nerve head, increasing production of extracellular matrix (ECM) molecules,
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and further affecting IOP Agapova et al., 2001; Hernandez et a l , 2000; Hernandez et 
al., 2002). Effects of NOS3 on RGCs may be mediated through both increase of 
ocular blood flow, as well as astroglial responses. However, following episcleral vein 
sclerosis, a NOS3 response is not elicited, indicating that neither glia nor vasulature 
are affected by NOS3 during glaucoma in this model.
6.4.5.4 Potential pathways o f  secondary neurodegeneration
NO production, by NOS isoforms, are likely to affect RGC survival via similar 
mechanisms. However the present study shows that only NOS1 and NOS2 produced 
NO are likely to influence RGC survival during glaucoma.
It is likely that following production NO exerts effects on the cell through control of 
transcription factors (Hausladen et al., 1996; Peng et al., 1995; Zeiher et al., 1995), 
interactions with heme proteins or enzymes with iron-sulphur clusters (Stamler,
1994), as well as reacting with oxygen radicals to alter the redox balance (Chun et al.,
1995).
These reactions may combine to produce the high rate of cell death associated with 
NOS upregulation in the present study. However, due to the immediate reduction in 
RGC loss subsequent to NOS upregulation, it is also possible that these reactions are 
responsible for alleviating RGC damage and promoting survival.
6.4.6 Controversial NOS upregulation.
With many animal models available for the experimental induction of glaucoma* 
fundamental differences between these models are likely to influence disease 
pathophysiology. This is particularly apparent with regard to NOS in glaucoma. NOS 
upregulation remained uncorrelated with cell death (apoptosis) until the present study.
The present study showed how NOS isoforms 1 and 2, but not 3 were upregulated 
during chronic disease stages at high levels of RGC apoptosis. Others have reported 
upregulation of all NOS isoforms following vein cautery (Shareef et al., 1999).
195
Chanter VI NOS During Experimental Glaucoma
However, more recent publications suggest that NOS2 is not upregulated following 35 
days of experimental glaucoma (Pang, et al., 2005), while in the present study NOS 
upregulation was limited to 20 to 46 days, vein cautery upregulated NOS from 4 days 
to 3 months post-induction of ocular hypertension.
It is possible that the high levels of pressure elevation (1.6 times control pressure) in 
comparison to the present study were the cause of this discrepancy (Shareef et al., 
1999). As we have shown that NOS upregulation is dependent upon elevated pressure 
duration rather than degree or deviation, it is also possible that inter-model variations 
account for differences in NOS expression. This is supported by a lack of endothelial 
NOS upregulation in the present study, while following vein cautery this isoform is 
elevated (Shareef et al., 1999). The vein cautery model of glaucoma may produce 
undesirable effects on the ocular blood system through lack of drainage. These effects 
may include elevation of NOS3.
6.4.6.1 The episcleral drainage vessel sclerosis model and NOS2 upregulation
Current published data from the episcleral drainage vessel sclerosis model indicates 
that NOS2 upregulation does not occur following induction of ocular hypertension 
(Pang et al., 2005), which is contradictory to many glaucoma studies of both animals 
(Shareef et a l, 1999) and man (Neufeld et al, 1997). This data appears to be solid by 
virtue of a multitude of techniques used to verify a lack of NOS2 protein and mRNA, 
including immunohistochemistry, gene expression profiling and quantitative PCR 
(Pang et a l, 2005). Also, inhibition of NOS2 did not improve RGC degeneration 
following experimental glaucoma (Pang et al., 2005). However, there are also several 
apparent limitations of the design o f this study.
Pang et al. (2005) examined NOS2 only at 35 days of ocular hypertension. Despite 
production of a complete range of damage by this duration of ocular hypertension, 
actual glaucoma progression is not only dependent upon degree, but also duration of 
ocular hypertension. A severe oversight by Pang et al. (2005) is the potential 
fluctuation of NOS2 expression with duration of hypertension, and not solely with 
degree of damage (reviewed by Morrison et al., 2005). The present study, however
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examines NOS2 upregulation as a function of several aspects of the elevated IOP, and 
therefore, despite a relative lack o f impressive techniques provides a better indication 
of the true involvement of NOS2 in experimental glaucoma.
According to the optic nerve damage scale developed by Johnson et al. (1997) Pang et 
al. (2005) produced optic nerves with a range of damage from those unaffected by 
sclerosis, to those with severe damage in all areas of the nerve. Although this scale is 
a good indicator of RGC damage, it does not enable correlation of NOS2 alterations 
with RGC death, which is essential in any model of ocular hypertension. The present 
study was able to ascertain actual RGC death levels, and subsequently the effects of 
NOS2 can be accurately associated with apoptosis, and not merely nerve damage.
6.4.6.2 Origins o f  hypertensive optic nerve head NOS
Data presented here indicated that the cells responsible for NOS1 and NOS2 
upregulation are likely to be resident microglia and astrocytes. Astrocytic data is 
supported by studies using the vein cautery model of glaucoma where NOS2 
induction occurs in active astrocytes of the optic nerve (Shareef et al., 1999). 
However, no attempts have been made to correlate NOS upregulation with microglial 
upregulation in the vein cautery model, despite the potential importance of the 
immune reaction of these cells in pathophysiology.
6.4.7 Neuroprotection mediated by NOS inhibition
Immunohistochemical evidence has shown upregulation of all isoforms of the NOS 
enzyme, implicating NOS upregulation, and consequently NO production in RGC 
death during glaucoma. NOS upregulation in support astrocytes, closely associated 
with the nerve fibre bundles, is thought to be neurodestructive, whilst the NOS 
activity found in glia coupled to vascular epithelia is neuroprotective (Shareef et al., 
1999). Consequently, NOS inhibition should be effective in the prevention of 
neurodegeneration during experimental glaucoma, as well as in treatment of the 
human disease.
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Neufeld et al., (1999) have shown that RGC loss can be alleviated during glaucoma 
through direct inhibition o f NOS2 activity via aminoguanidine, while this is 
contradicted by more recent studies (Pang et al., 2005). However, the transient nature 
of NOS upregulation indicates a limited role in secondary neurodegeneration. 
Neuroprotection mediated by NOS inhibition may only be effective in 
neuroprotection under certain disease conditions or stages of progression, as the 
present study shows the transient nature of NOS 1 and NOS2 upregulation. Therefore 
the efficacy of this treatment for the alleviation of RGC loss is questionable. 
Combining NOS inhibition with other pharmacological agents, perhaps CD200 ligand 
peptide or other microglial inhibitors may be more effective in reducing glaucomatous 
cell loss.
6.4.8 Conclusions
This study clarifies the role of NOS during glaucoma. NOS2 may have a role during 
the initiation of RGC death in glaucoma. Both NOS1 and NOS2 are likely to be 
involved in glaucomatous secondary degeneration. These isoforms are produced 
through immune-mediated responses o f resident microglia and/or astrocytes. Specific 
production of cytotoxins is vital to optic nerve pathophysiology, and may assist in 
future development of pharmacological intervention of secondary degeneration, which 
in combination therapies could also alleviate IOP elevation.
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Chanter VII 
General discussion
7.1 Summary of findings
This study showed the progressive development, through logical manipulations, of a 
rodent model of ocular hypertension, based on the model used by Morrison et al. 
(1995). The model was used to generate and maintain mild experimental glaucoma 
representative of the human condition. Principle findings generated from this model 
are described in full in Table 7.1.
Novel techniques of silver staining and neurofilament labelling, normally applied to 
detect other systemic forms of neurodegeneration, were used for the first time to 
monitor glaucomatous neurodegeneration. Neurofilament labelling of RGCs appeared 
reduced following glaucoma, while silver staining of axonal degeneration was 
increased. These novel methods were used in conjunction with the more established 
techniques of qualitative light and electron microscopy of the optic nerve, which 
supported neurodegeneration following the induction of ocular hypertension.
As well as neurodegeneration, apoptotic cell death was also examined in the retina. 
Results of both TUNEL and active caspase 3 labelling of the retinal ganglion cell 
layer were used to support the hypothesis that the degeneration observed in the optic 
nerve occurred in conjunction with RGC death.
Fluctuation, duration and degree o f IOP elevation all appeared to play a vital role in 
RGC cell survival. Mild intraocular pressure (IOP) elevation resulted in consistent, 
but moderate RGC cell death with a late onset (11 days post-induction of 
hypertension). Cell death was at lower levels during chronic late disease stages (day 
47-65). Apoptotic cell death appeared to correlate in a linear manner with increased 
area under the IOP elevation/duration curve, indicating that death is dependent upon a
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combination of duration and magnitude of hypertension. The effects of IOP 
fluctuation varied; however, the highest standard deviation of IOP elevation (6.02- 
12.76) produced the greatest apoptotic rate of any IOP variable. Therefore a 
combination of these IOP variables is likely to affect rate of cell death following 
elevation of IOP, with perhaps the most important of these being IOP fluctuation.
This study provided evidence that both astrocytes and microglia are involved in the 
pathological processes of glaucomatous neurodegeneration and RGC death. Initial 
glaucomatous alterations in the optic nerve head included dissociation of the CD200 
axis, together with upregulation o f NOS2 (suggesting microglial activation) before the 
onset of significant levels of apoptosis.
Disengagement of the microglial regulatory system, the CD200 axis, before initiation 
of RGC apoptosis indicates that microglial changes may play a part in initiating RGC 
apoptosis. Subsequently microglia proliferate, indicated by increased 0X42 labelling 
at T2, coincident with the onset o f IOP-induced retinal ganglion cell (RGC) apoptosis 
Similarly, astrocytic reactivity and proliferation occurred at the same point in disease 
progression as onset of RGC death.
In intermediate stages of disease (T3 and T4) NOS1 and NOS2 were both 
upregulated, indicating further activation of microglia, and astrocytes following the 
onset of cell death. These upregulations coincided with increased detection of both 
astrocytic, pan-microglial and macrophage markers (T3). In intermediate stages of 
disease (T3) when RGC death is underway, there is further signalling through the 
CD200 axis, while microglia increase in both number (0X42) and reactivity (0X41).
At the longest duration o f hypertension, only one of these changes persist, that is 
N0S2 upregulation. This indicates that the microglial, but not astroglial response is 
sustained, and this discovery has important implications for ascertaining the chronic 
pathophysiology of glaucoma.
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Group Tl T2 T3 T4 T5 Al A2 A3 A4 A5 SI S2 S3 S4 S5
Duration 1 11 20 33 47 Area 0.9 24.3 97.2 165.3 271.9 SD 0 1.52 3.20 3.81 6.02
(days) - - - - - (mmHg) - - - - - - - - - -
7 19 27 46 65 22.7 96.8 151.1 256.1 469.3 1.511 2.96 3.75 5.57 12.76
% RGC 2.04 1.89 5.38 4.47 1.46 1.71 2.78 3.27 3.75 4.65 3.15 1.48 4.24 3.13 5.28
Apoptosis
GFAP * *** *
0X33 *
MHCII
CD45 * * *** *** *** * ** * *** *
0X42 ** *** ** *** * * *
0X41 *** **
CD200L *** *
CD200R *** *
N0S1 ** *** * * * *♦
NOS2 * ** *** * ♦ * ** ♦ * *** *
N0S3
Table 7.1 Summary of results This table summarises the main findings of the present study. Ocular hypertensive groups T1-T5, A1-A5 and 
S1-S5 are shown, together with their defining IOP variables. Apoptosis data for the retina is also shown for each group. Significant elevations of 
immunohistochemically probed proteins are indicated by * (PO.Ol), ** (P<0.05) and *** (PO.OOl).
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Other aspects of IOP elevation were also examined with respect to microglial, 
astrocyte and NOS upregulation. These findings are summarised in Table 7.1, and are 
described in detail in Chapters V and VI. In short, it is apparent that all aspects of IOP 
investigated had complex effects on the optic nerve head markers used. Duration, 
severity and fluctuation of IOP elevation all have important roles to play in the 
reaction of the optic nerve head cellular component to increased IOP.
7.2 Neiirodegeneration and death of the optic nerve in context
The study of neurodegeneration and regeneration can be easily facilitated in the visual 
system. The optic nerve, derived from the central nervous system (CNS), is a spatially 
and anatomically distinct CNS tract. This distinction allows easy identification and 
manipulation of the optic nerve. Optic nerve alterations can be measured in many 
ways, from clinical assessment to electron microscopy. Access to other CNS areas is 
far more restricted than the optic nerve. Therefore optic nerve manipulation can 
provide neurodegenerative changes representative of other central diseases, as well as 
those in glaucoma.
7.2.1 Potential of rodent model of ocular hypertension in the study of human 
disease
Despite the lack of a lamina cribrosa, the rat shares many optic nerve characteristics 
with the primate, rat glaucoma models are potentially representative of the human 
disease, highlighted by the histological techniques used in this study.
Experimental rat glaucoma resulted in progressive RGC loss, as in the human disease. 
Therefore effects of IOP elevation and/or glial activity are likely to be similar on RGC 
survival between species. However, despite this relationship, experimental results 
cannot be directly correlated to human disease.
Moderate pressure elevation in the rat may represent more severe clinical disease due 
to a lack of resistance to pressure induced damage at the nerve head, while severe 
pressure elevation in the rodent may represent a clinical situation that is rarely
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encountered. This is supported by the results of this study, which show cavernous 
degeneration typical of relatively mild rodent glaucoma, which is also typical of only 
the most severe human disease (Quigley et a l,  1981). Similarly the glial response 
documented in this study may therefore represent the glial response during severe 
human glaucoma, and thus limit the therapeutic implications of inhibiting this 
response.
7.2.2 Neurodegeneration in glaucoma
This study showed reduced immunohistochemical detection of neurofilament protein 
(TUJ-1) following ocular hypertension in the episcleral drainage model of glaucoma. 
Cytoskeletal components of the optic nerve, such as TUJ-1 are transported both 
retrogradely and anterogradely (Roy et al., 2000). Therefore a reduction in 
neurofilament protein is a good indication of the state of axonal transport. 
Cytoskeletal alteration of the optic nerve has implications for axonal transport, 
particularly retrograde transport o f neurotrophins, a lack of which may adversely 
affect cell survival (Roy et al., 2000). Indications are that retrogradely transported 
neurotrophic factors are essential for RGC survival and thus have particular interest in 
glaucoma, (reviewed by Caleo and Cenni, 2004).
Superior colliculus ablation, therefore loss of transportation, results in rapid apoptosis 
in about 50% RGC population within 48 hours (Cui and Harvey, 1995; Dreher et al., 
1983; Harvey and Robertson, 1992; Harvey et a l,  1994; Rabacchi et a l, 1994). Optic 
nerve transection is similarly associated with loss of trophic support but also has a 
later onset and rate of cell death (Berkelaar et a l,  1994; Garcia-Valenzuela et a l, 
1995; Isenmann and Bahr, 1997). Consequently loss of neurotrophin at the level of the 
retina is a good indicator of glaucomatous damage to the RGC. Loss of axonal 
transportation is implicated by reduction of neurofilament in the present study. This 
raises similarities between the episcleral drainage vessel sclerosis model of glaucoma, 
and other models of neurodegeneration, as well as the usefulness of TUJ-1 in studies 
of degeneration.
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7.2.3 Neurotrophins, apoptosis and IOP
Loss of neurotrophic factors occurs initially in the superior retina during experimental 
glaucoma (Johnson et al., 2000), and is associated with a slow onset and rate of RGC 
apoptosis of 8% per week. Despite the initial loss of neurotrophins in the superior 
retina (Johnson et al., 2000), RGC loss begins in the inferior retina following 
moderate pressure elevations (a mean daily elevation of 6.55 mmHg) and low 
apoptotic rate (an average of 3.47% total per retina) induced in the present study.
Loss of neurotrophic support may therefore not be involved during initiation of RGC 
loss in mild glaucoma. Compensation, by paracrine or autocrine signalling, may occur 
in superior regions such that retrograde delivery of factors may not be as essential to 
survival following mild insult.
7.3 RGC death as a function of IOP variables
Mean daily IOP was raised by 6.55 mmHg, and induced a mean apoptotic rate of 
3.47% per retina in the present study. In comparison to other studies of experimental 
glaucoma this is a relatively mild manifestation of disease (for a discussion of the 
clinical relevance see Section 7.2.1). In the majority, a wide range of higher IOP 
elevations and apoptotic rates are reported in experimental glaucoma.
Apoptosis generally appeared to increase with duration of pressure elevation (T1-T4), 
with a decrease at the highest durations (T5). Severity of pressure elevation as 
indicated by the area under the IOP elevation/duration curve related well to apoptotic 
rate, and increased with increasing apoptosis throughout. Percentage apoptosis 
fluctuated with standard deviation of pressure elevation, and a clear relationship was 
not apparent.
Several studies of ocular hypertension report the pattern and rate of RGC loss in 
relation to both duration and degree of pressure elevation. However, this is the first 
study to investigate the role of standard deviation of pressure elevation, or pressure
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fluctuation on RGC loss. Hence one of the most interesting results of this 
investigation was the correlation o f high pressure fluctuations with the greatest degree 
of apoptosis observed. Consequently, during clinical glaucoma a fluctuating IOP may 
predispose to a more vigorous disease progression.
Also, peak apoptosis and pressure fluctuations coincided with increases in pan- 
microglial marker (0X42) as well as increased optic nerve head NOS2 protein. This 
indicates that not only does fluctuation o f IOP induce RGC death, it is also involved 
with microglial proliferation, and possible activation. These findings have important 
implications for future glaucoma investigations and treatment.
In relation to other studies on apoptosis, RGC death was at very low levels in the 
present study. A total apoptotic rate of 15.24% occurred over a maximum of 65 days 
of ocular hypertension, resulting in a weekly RGC loss of 1.64%. Laquis et al. (1998) 
induced ocular hypertension for 70 days, resulting in a weekly RGC loss of 4%. An 
average IOP elevation 2.55 mmHg greater than the present study, partially accounts 
for the generation of higher apoptotic rates by Laquis et al. (1998). However, it is also 
likely that the use of a different method to generate hypertension (episcleral vein 
cautery) may also have resulted in greater levels of apoptosis.
Previous studies of the episcleral drainage vessel model of glaucoma indicate that 
RGC apoptosis occurs from day 1 post-IOP elevation (Johnson et al., 2000), with an 
overall rate of 0.142% per retina. However, much higher pressures were generated by 
Johnson et a l  (2000), and comparison with the present study highlights how IOP 
alteration, duration, fluctuation and severity can all contribute to apoptotic levels.
In conclusion, a lack of correlation between the many studies of RGC apoptosis 
following IOP elevation may be explained by several factors. The use of different 
glaucoma models, in terms o f species and strain of animal, as well as the technique 
used to elevate IOP may affect apoptotic rate. Also, the present study shows that IOP 
variables of duration, fluctuation and severity can affect RGC death.
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7.4 New perspectives on the primary and secondary insults of glaucoma
Glaucomatous optic nerve degeneration begins with an initial insult to the RGCs of 
optic nerve. This insult initiates RGC damage and/or death. In the rodent glaucoma 
model developed in the present study, the initial insult of pathologically raised IOP 
was used to induce RGC death. However, many studies indicate that even following 
the removal of the primary insult, for example, reduction of IOP to normal levels, 
RGC degeneration and death continues (Bakalash et al., 2002). It is thought that this 
continued cell loss, or secondary degeneration, results from numerous reactions 
derived from the cellular response to the initial insult (Abbas et al., 1996; Matsubara 
et al., 1999; Mosmann and Sad, 1996; Raibon et al., 2002). These reactions may 
propagate RGC damage, and induce a hostile optic nerve microenvironment 
conducive to cell death. These reactions may include formation of the astroglial scar, 
microglial activation and/or infiltration of peripheral immune cells (Abbas et al., 
1996; Matsubara et al., 1999; Mosmann and Sad, 1996; Raibon et al., 2002; Wang et 
al. 2002a), the former of which have both been identified and investigated in the 
present study.
7.4.1 Primary damage
Previous studies have not examined the effects of duration of pressure elevation, area 
under the IOP curve (combined effect of IOP level and duration) and standard 
deviation (fluctuations) of pressure elevation on the optic nerve. The effects of these 
variables on several optic nerve cellular markers were quantified. Indications are that 
there is a complex relationship between pressure variables, other than duration, and 
cellular alterations in the glaucomatous optic nerve.
Standard deviation of pressure elevation and area under the IOP curve affected onset 
and time course of glaucoma pathology. This is likely to be of particular interest in 
management of glaucoma treatment. Differences in pressure fluctuations and degree 
of pressure elevation all affected disease progression.
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7.4.2 Resultant secondary degeneration
Glaucoma is not generally regarded as an inflammatory disease. With new research, 
evidence is gradually being accumulated implicating a role for the immune system in 
secondary degeneration o f glaucomatous RGCs (Becher et a l , 2000; Tezel et a l , 
1999; Wax et a l , 1994). This opens a door for new avenues in glaucoma treatment. 
For instance, the use o f microglial inhibitors, such as tuftsin-1,3 or minocycline 
(Baptiste et a l , 2005), may abrogate unfavourable microglial responses in 
glaucomatous pathophysiology.
The glial response has been correlated with aspects of pressure elevation under 
experimental glaucoma conditions. For efficacy of microglial down-regulation, as a 
treatment, the IOP attributes which affect microglial activation need to be clear. This 
study showed that microglial activation appeared to occur via the CD200 axis during 
the initiation of disease, before significant RGC death. At this stage, duration of 
clinical pressure elevation is relatively mild. Activation, via the CD200 axis, also 
seems likely to occur during moderate pressure durations and area under the pressure 
curve, when apoptosis was relatively high. CD200 axis disruption coincided with 
upregulation of the myeloid cell marker CD45 (indicating possible microglial 
upregulation) and was followed by an increase in microglial cells (marked by the pan- 
microglial marker, 0X42), and thereafter microglial activation.
A glaucoma patient presenting with elevated IOP, before the onset of visual field loss, 
is very likely to benefit from inhibition of the CD200 axis disruption. However, an 
individual with some visual field loss would likely still benefit from inhibitors of 
microglial activation.
Inhibition of microglial activation, as a method of therapeutic intervention in 
glaucoma, may have considerable positive patient outcomes. However, regain of 
visual function and optic nerve regeneration should also be addressed in any future 
glaucoma therapy.
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7.5 Implications of astrocytic changes in secondary degeneration
Astrocytes are transiently upregulated following 11 days of ocular hypertension in 
conjunction with significant elevation of RGC apoptosis. It is therefore unlikely that 
the astrocytic response is involved in initiation of optic nerve damage. However, 
during activation, from days 11-27 (T2 and T3), A2, and S2 the astrocytic response 
may affect RGC survival.
Many studies have reported GFAP alterations under conditions of ocular 
hypertension. In particular Johnson et al. (2000) investigated the astroglial response 
from 3 to 14 days of IOP elevation in the same model as used in the present study. 
From 7 to 14 days o f ocular hypertension, astrocytic labelling with GFAP was 
reduced, and after 14 days normal levels of labelling returned. GFAP elevation would 
have been affected differently at an average IOP elevation of 16 mmHg (induced by 
Johnson et al., 2000), rather than the 6.55 mmHg elevation induced in the present 
study.
Astrocytic reactivity is also recorded in studies of primate experimental glaucoma 
(Yucel et al., 1999) and human glaucoma (Varela and Hernandez, 1997). This is a 
good indication that the present study produced astrocytic alterations more similar to 
the human disease, and it can therefore be inferred that the mild pressure elevations 
produced are more representative of the human condition.
Astrocytic alterations produced in this study are analogous to those of human 
glaucoma (Varela and Hernandez, 1997). Due to the upregulation of these cells during 
the initiation of cell death, and at fairly low IOP fluctuations and severity, these cells 
are likely to be involved in a transient response to RGC apoptosis. It is likely that 
upregulation of astrocytes is in some way an attempt to prevent either the effects of 
pressure alterations or to limit RGC death (reviewed by Fitch and Silver).
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7.6 Implications of microglial changes in secondary degeneration
Lack of a cell-specific marker that can distinguish microglia from peripheral 
macrophages is a major problem in studies of central pathophysiology (Guillemin and 
Brew, 2004). However, the present study showed how combinations of cellular 
markers can be used to clarify the microglial reaction in a disorder that also may 
involve compromise o f the blood-retinal barrier.
7.6.1 Parallels with other disease
Microglial alterations are not specific to glaucomatous neurodegeneration. Activation 
of these cells is found in Parkinson’s disease (Ouchi et al., 2005), multiple sclerois 
(Ayers et al., 2004), as well as nerve crush (Frank and Wolberg, 1996) and axotomy 
(Baptiste et al., 2005). Identification and inhibition o f microglial activation therefore 
has far-reaching implications for many pathological mechanisms and the treatment of 
several neurological conditions. Efficacy of treatment may be improved by 
combination therapies specific to the particular disease and the stage of pathology. For 
example, preventative therapy (such as CD200 axis inhibition), and if disease onset 
has occurred, preventative measures (such as microglial activation inhibitors) together 
with damage limitation and regenerative treatments.
Glaucoma does not only have correlations to other types of neurodegeneration in 
terms of microglial activation. Similarities can be draw between glaucoma and 
Alzheimer’s disease through an association of the inheritance of the apolipoprotein 
epsilon4 allele (Vickers et al., 2002). Mice expressing a human neurofilament gene 
develop neurofilamentous accumulations in RGC perikarya, useful in studying both 
Alzheimer’s disease and glaucomatous pathophysiology (Vickers et al., 1995a). In 
order to determine the exact role of microglia during glaucomatous pathophysiology, 
potential points of neuroglial interactions need to be further explored. Inhibition of 
these cellular pathways or knock-out of particular genes will further facilitate the 
study of glaucoma.
209
Chapter VII General Discussion
7.6.2 The immune system in glaucoma: peripheral and central
Controversy exists over the role o f the immune response in glaucoma (Tezel and 
Wax, 2004). There is compelling evidence to suggest that the peripheral immune 
system can actually alleviate RGC loss during glaucoma (Bakalash et al., 2002), 
particularly as compromise of the immune system can lead to enhanced RGC death.
It is likely that, to a certain degree, both central and peripheral immune responses 
function to eliminate debris from RGC degeneration following glaucoma. However, 
exacerbation of this immune response is a candidate for causing the continued 
secondary degeneration observed following reduction of IOP during glaucoma.
During optic nerve regeneration through peripheral nerve grafts, nerve injury induces 
apoptosis accompanied by microglial activation and removal of axonal debris 
(Schuetz and Thanos, 2004). This does not significantly affect neuronal survival, 
indicating that microglial activation may not have an important role in degeneration 
(Schuetz and Thanos, 2004). The microglial response in glaucoma may parallel the 
response in such axotomy models. Elevated microglial responses during peak RGC 
death, followed by reduced response during alleviation of RGC death (as shown in the 
present study) may similarly indicate a clearing function.
However, microglial upregulation during glaucoma may indicate a role for these cells, 
other than clearing debris during disease. Microglia activation involves many changes 
culminating in an immune response that may involve secretion of cellular toxins. If 
unregulated, the latter may damage RGCs. Microglia may signal to recruit and 
regulate T cell-mediated immune responses which target self-antigens at the site of 
damage. It has been suggested that boosting this reaction in neurodegeneration may be 
used as a vaccination therapy for therapeutic intervention (Schwartz, 2003). There is a 
fine line, however, between protective and degenerative autoimmunity.
Microglial cells can be isolated and identified by 0X42 positivity for investigations of 
pathophysiological mechanisms in cell culture (Chen et al., 2002). Cell culture 
investigation of microglial responses suffer from a propensity of cellular activation
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through culture techniques (Sergent-Tanguy et a l,  2003). It is therefore very difficult 
to determine the exact cellular pathways that lead to and result in microglial activation 
following hypertension. In vitro investigations into microglial activation should 
consequently be approached with caution. In vivo studies do not share these problems, 
as microglia are maintained in their natural environment in the CNS.
Following initial insult o f elevated IOP, retinal ganglion cell damage may be mediated 
through mechanisms such as aberrant immune signalling (reviewed by Tezel and 
Wax, 2004), excitotoxicity (reviewed by Lotery, 2005), neurotrophin deprivation or 
free radical damage (Ko et al., 2005) to name but a few. The peripheral and central 
immune systems may affect, or be affected by these other responses to IOP elevation. 
It is likely that the role of resident optic nerve microglia during glaucoma illustrated 
in this study serves to alter nerve pathophysiology in combination with other 
mechanisms. Some of the immune mechanisms likely to be affected during glaucoma 
are described in Figure 7.1. The role o f each of these pathways needs to be determined 
in order to accurately ascribe a function to the peripheral and central immune response 
in glaucomatous optic nerve degeneration.
7.6.3 Neuroregeneration and immunity
Due to the low capacity of central nerves to regenerate fully, regain of visual function 
is unlikely to be achieved through conventional glaucoma treatment, or the inhibition 
of microglial activation. Manipulation o f immune reaction in glaucoma is likely to 
induce an optic nerve microenvironment more conducive to nerve survival and 
regrowth (Reviewed by Schwartz, 2004 and Stoll et a l, 2002). Following the 
application of such a therapy, it is likely that any attempts to regenerate the nerve 
would be more successful. However, it is likely that there is a fine line between 
destructive and constructive autoimmunity.
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Figure 7.1 Glial mediated pathways following ocular hypertension Astrocytes 
and microglia may induce neuroprotective or degenerative pathways. Astrocytes may 
be neuroprotective by the secretion o f  nerve growth factors (NGF), while astroglial 
scar formation prevents regeneration. Disruption o f neuroglial signalling may induce 
microglial activation involving morphological changes, phagocytosis, and secretion 
o f signalling factors, with direct consequences for axonal regeneration. It is also 
possible that microglia interact with innate and adaptive immune systems to 
exacerbate phagocytosis or T-cell activation /  recruitment, respectively. T cell 
maturation into Thl cells will further exacerbate immune reaction and may prevent 
axonal regeneration. However, induction o f the Th2 response may cause tolerance, 
and prevent further axonal damage.
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While nerve regeneration in glaucoma is an extremely exciting prospect, ablation of 
the microglial response by preventing CD200 axis signalling is likely to prevent nerve 
loss and negate the requirement for regenerative treatment. However, it is also likely 
that glaucoma will not be detected until after CD200 axis disruption, when the visual 
field has begun to deteriorate. Inhibitors of microglial activation may be used at later 
stages of disease to prevent exacerbation of RGC loss, and provide an environment 
more conducive to RGC regeneration. The low regenerative capacity of the central 
nervous system has been diffused in recent years (Fawcett and Geller, 1998; Davies 
and Silver, 1998). Delivery of growth factors (Avwenagha et al., 2003), peripheral 
nerve grafts (Vidal-Sanz et al., 1987), and grafting of embryonic neurons may 
improve function following neurodegeneration (Shewan et al., 1995).
7.7 Celhcell interactions during disease
The evidence presented here suggests that neuroglial interactions (e.g. CD200 axis) 
become disrupted during glaucoma leading to microglial activation. Demonstration of 
this phenomenon indicates that perhaps other interactions in the nerve may also be 
affected during glaucoma, for example, astrocyte-axon communication. It may be the 
case that glaucoma induces production of a major neuroprotective agent, 
metallothionen, from astrocytes similar to in cortical injury (Chung et al., 2004a). The 
delicate balance of neuroprotective and degenerative interactions is clearly affected 
during glaucoma. The determination of the exact pathophysiology of the disease and 
the cellular interactions involved should provide suitable targets for high efficacy 
treatment.
There are many other pathways that may be affected through neuroglial interactions to 
influence retinal ganglion cell health and survival. The specific phosphatidylserine 
receptor (PtdSerR) present on active and quiescent microglia can be activated to 
eliminate neuronal debris, through neuroprotective and anti-inflammatory pathways 
(DeSimone et al., 2004). Recognition of neuronal debris through this receptor does 
not induce inflammation (DeSimone et al., 2004).
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It is interesting therefore to note that loss of retinal CD200-mediated down-regulation 
of microglial activation elevated microglial numbers (Dick at el., 2003), indicated in 
the present study by elevation o f 0X42 labelling in the optic nerve head These 
microglia express NOS2, a recognised marker of microglial activation (Dick at el., 
2003), which was also elevated in this study from the initiation of RGC death and 
onwards. However, following CD200 axis disruption retinal microglial cells retain a 
resting morphology and consequently, conventional microglial activation was not 
observed through CD200 axis disruption in the retina (Dick at el., 2003). This may 
indicate induction of an alternative signalling pathway through CD200 receptor 
activation, which is involved in microglial-mediated neuronal death by release of NO.
In contradiction, the findings of thesis have demonstrated that, following CD200 axis 
disruption, microglia resident in the optic nerve head do become activated (shown by 
elevated OX41 labelling). Microglial-mediated neuronal death, by release of NO, may 
also be involved in glaucomatous optic nerve head degeneration. However, due to the 
presence of conventional active microglia, it is possible that a slightly different 
cellular reaction is produced, or other signalling pathways are involved at the 
glaucomatous optic nerve head.
Potential candidates in such pathways are prostanoids, produced by cyclooxygenases 
(Cox-1 and Cox-2), which are involved in microglial activation and Wallerian 
degeneration of peripheral nerves (Durrenberger et al., 2004). It is possible that these 
chemical mediators of inflammation also have a role to play in the cellular 
interactions of glaucoma at the optic nerve head (Yuan and Neufeld, 2001.
7.8 Molecular mediators of neurodegeneration? NOS
During experimental glaucoma, NOS isoforms 1 and 2 were upregulated in the optic 
nerve. This discovery is particularly controversial. These isoforms are upregulated in 
some glaucoma models (Shareef et al., 1999) and the human disease (Neufeld et al., 
1997), while other models show no NOS2 upregulation (Pang et al., 2005). Also,
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inhibition of NOS2 can result in reduction of cell loss in some experimental glaucoma 
models (Neufeld et al., 1999) but not others (Pang et a l,  2005).
NOS1 upregulation is less controversial. Upregulation of this isoform of the NOS 
enzyme occurred after initial cell death, when apoptotic levels were at their peak (T3 
and T4). Therefore NOS1 upregulation can be associated with RGC apoptosis after 
the initial astrocytic reaction (T1 and T2), and during alterations in microglial cells at 
the optic nerve head.
However, this is not the case when looking at the duration/IOP elevation effects on 
NOS1. Upregulation of NOS 1 appeared at the lowest apoptotic levels when correlated 
with IOP elevation/duration, however upregulation was still associated with 
microglial alterations. In contrast only the lowest levels of apoptosis produced NOS1 
elevation when results were grouped according to IOP fluctuation. Although NOS1 
did not appear to have a clear relationship with RGC apoptosis, NOS1 elevation 
always corresponded with CD200 axis modulation and/or upregulation of microglial 
markers, and frequently followed GFAP elevation. It is therefore likely that NOS1 
upregulation was mediated by optic nerve head astrocytes or microglia, and was not 
directly involved in RGC apoptosis.
To date, only NOS2 protein and mRNA expression have been investigated in the 
episcleral vessel sclerosis model of glaucoma (Pang et a l,  2005). Indications are that 
NOS2 is not upregulated following 35 days of episcleral drainage vessel sclerosis- 
induced ocular hypertension, from stages of disease without damage, through to 
severe optic nerve damage (Pang et a l ,  2005). This study however, does not take into 
account several important aspect of ocular hypertension. These include the duration 
and fluctuation of IOP elevation, both of which are correlated with NOS2 levels in the 
present study.
Disagreement between results o f the present study and that of Pang et al. (2005) can 
be easily accounted for by IOP variables. Expression of NOS2 was not detected 
following a full range o f optic nerve damage following 35 days of hypertension by 
Pang et al. (2005). However, each hypertensive eye had endured pressure elevation of
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varying degrees for exactly 35 days, and as indicated by the present study, duration of 
IOP elevation, as well as severity and fluctuation of elevation can all affect NOS2 
levels. These other aspects o f IOP are not accounted for by Pang et al. (2005).
Levels of IOP elevation (7.04 mmHg) similar to the present study (6.55 mmHg) were 
produced by Shareef et al. (1999). Episcleral vein cauteiy in the rat, results in 
upregulation of all NOS isoforms from 4 days to 3 months post-induction of ocular 
hypertension (Shareef et al., 1999). An enhanced response, without any return to 
normal levels of NOS, and with the apparent upregulation of NOS3 (Shareef et al, 
1999% may indicate a different response to vein cautery and sclerosis. It is possible 
that vascular stress caused by vein cautery combines with the effects of elevated IOP 
to enhance NOS levels. However, upregulation of all NOS isoforms has been reported 
in the human condition (Neufeld et al., 1997). Unfortunately, NOS levels in human 
glaucoma optic nerve tissue have not been correlated with any aspects of IOP. 
Therefore it is not possible to put these results into context of the present study.
It is likely that NOS produced by either astrocytes or microglia as a response to the 
initial insult is involved in production o f neurotoxic levels of NO. Disruption of 
cell:cell interactions are likely to induce NOS upregulation. For example, RGC 
mediated regulation of microglial activation may participate in NOS regulation in the 
retina (for example via the CD200 axis). Similarly astrocyte:endothelial cell 
interactions are thought to affect NOS levels in glaucoma (Neufeld et al., 1997).
The CD200 axis appears to be in part responsible for upregulation of NOS. Indeed, 
upregulation stems from microglial activation, which occurs as a consequence of 
cellular signalling. Aberrant signalling may therefore exacerbate microglial activation 
and consequently the elevation of NOS levels. It is possible that the signalling 
pathways involved in microglial activation and NOS regulation either run in parallel, 
or are identical. These pathways may be represented by any of those shown in Figure 
7.1. However, at this early stage of investigation into the microglial-mediated 
alteration of the optic nerve microenvironment, the CD200 axis was positively 
identified as being involved in microglial activation, as well as NOS production.
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7.9 The future for glaucoma
7.9.1 Models
This study highlighted the importance o f the development of animal models of 
glaucoma to study the pathophysiological mechanisms of disease. The development of 
novel animal models for glaucoma research will assist in the treatment of the human 
disease. Certain animals, for example primates are particularly suited to the study of 
the optic nerve head, due to structural parallels with the human. However, it is more 
convenient to use small animal models in research. Popular laboratory species such as 
the mouse, guinea pig and rabbit are all used to generate experimental glaucoma. 
However, currently, rat models are increasingly popular due to several factors, 
including the variety of well-documented methods for generating glaucoma, as well as 
a wealth of information on the optic nerve structure. The aforementioned laboratory 
species, excluding the rat all suffer from a paucity of structural components at the 
optic nerve head. In particular, the mouse used frequently for modelling glaucoma 
does not even posses a true equivalent to the human nerve head. Hopefully, future 
glaucoma models will take into account the crucial role of the cells and tissues of the 
optic nerve head in the pathophysiology of glaucoma.
7.9.2 Research
The present study has demonstrated the importance of glia and the immune response 
in glaucomatous damage. Glaucoma is not traditionally thought of as an inflammatory 
condition. However, the evidence both here and in the current literature, suggests that 
the immune system is likely to play a role, at least in part, in the progression of 
glaucoma. The inhibition of the immune and microglial response are both interesting 
avenues for future research. The precise mechanisms of microglial activation during 
disease, including the disruption of NOS regulation will no doubt predominate in the 
future of glaucoma research.
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7.9.2.1 Neuroprotection studies
A major current target for glaucoma research is not only to ascertain the exact 
pathophysiologies of glaucomatous degeneration, but also to achieve adequate 
neuroprotection o f the RGC in the diseased optic nerve. In the episcleral drainage 
vessel sclerosis model neuroprotection studies with respect particularly to NOS2 
inhibition should continue due to conflicting evidence regarding this enzyme in 
glaucoma (see data presented here and Pang et al., 2005). It may also prove useful to 
investigate the effects of inhibiting microglial activation and/or proliferation on RGC 
protection. This would ascertain the exact role of microglia at each disease stage, as 
well as provide a strong platform on which potential clinical therapies might be based.
7.9.2.2 Future assessment o f  regeneration
Following neuroprotection, neuroregeneration of the RGC is a desirable target for 
glaucoma research. Reformation o f the dendritic field, as well as the axon following 
cell rescue will need to be quantitatively measured. A promising technique for such 
measurements is biolistic RGC labelling followed by Scholl analysis, however, the 
prospects of quantification of immunoreactivity in the assessment of regeneration are 
less promising.
TUJ-1 immunoreactivity, used as a measure of RGC degeneration (Cui and Harvey, 
1995), is phosphorylated in the growth gone of regenerating nerves (Fournier and 
McKerracher, 1997; Mason et al., 2000). Therefore TUJ-1 immunoreactivity, while a 
useful indicator of neurodegeneration, may not be a good indicator of regeneration as 
phosphorylation may prevent antibody-antigen interaction. Similarly silver staining 
may be of limited use in regeneration studies. Staining could be used to indicate 
cessation of degeneration, but not nerve regeneration. The prevention of degeneration 
is likely to involve alterations in optic nerve microenvironment which are supportive 
to growth. Silver staining is a quick, reliable and potentially quantitative measure that 
can be used to indicate when neuroregeneration might be supported in the nerve.
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7.9.3 Therapy
The compelling evidence presented here suggests that modulation of the local immune 
response and glial activity may potentially be of benefit to the glaucoma sufferer. 
There is also an increasing mass o f literature that suggests these responses have a 
crucial role to play in neurodegeneration. Hopefully future glaucoma treatment and 
research will yield preventative and restorative treatments for some of the debilitating 
neurodegenerative diseases that share a common pathway with glaucoma, as well as 
the disease itself.
7.10 Conclusions
The pathophysiology o f glaucomatous optic atrophy is extremely complex. There are 
a multitude of primary insults that can be applied to cells or animals to facilitate the 
study of the disease. The pressure-dependent form of glaucoma can be attributed to 
temporal aspects o f chronic pressure elevation as well as the degree of actual pressure 
achieved, and how much this pressure varies.
The effects o f pressure elevation include neurodegeneration and apoptosis of the 
retinal ganglion cell, as well as the induction of secondary insults. It is likely that 
these insults stem from aberrant cell signalling as a consequence of disease. The 
resulting disruption o f glial regulation may influence retinal ganglion cell survival, 
and even regeneration. Manipulation o f the glial reaction following hypertension may 
assist in the production of neuroprotection, and eventually regeneration of the RGC. 
However, the complete nature o f the glial reaction remains unclear, and it is unknown 
whether inhibition of glial activation will exacerbate or alleviate degeneration. Due to 
parallels between glaucoma and other central nervous system disorders any progress 
made in either research area has the potential for far reaching implications in the 
treatment of CNS dysfunction.
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7.11 Future work
Apoptotic RGC death as a function o f IOP variables are clearly very important with 
respect to the future treatment and monitoring of the disease process regardless of 
other factors involved. Any future work using the episcleral drainage vessel sclerosis 
model should take into account these factors. It is also possible that IOP variables not 
investigated in the present study are o f importance to the progression of glaucoma 
pathophysiology. Correlation of mean daily IOP, or total IOP elevation with apoptotic 
levels, neurodegeneration, expression o f optic nerve head cellular markers and NOS 
levels may provide additional information on the pathological mechanisms of 
glaucoma.
Activation of astrocytes occurs in conjunction with the onset of RGC death. 
Implications of preventing astrocytic activation could be investigated in the future in 
order to determine whether neuronal death occurs independently of this process. Also, 
the neuroglial interactions between astrocytes and RGCs that might influence 
activation and cell survival could be probed. Indications are that astrocytic cell death 
does not occur in this model of glaucoma, and are fairly resistant to IOP alterations. 
Future investigations could identify which aspects of astrocytic morphology and 
biochemistry are involved in this resistance. The implications of astrocytic activation 
at the optic nerve head with respect to efficacy of neuroregeneration also needs to be 
addressed in future studies. Active astrocytes form a potential barrier to 
neuroregeneration across the optic nerve head.
Microglia are likely to play a role in RGC degeneration during glaucoma. Indications 
are that CD200 axis signalling in involved. Inhibition of microglial activation, and 
consequent effects on RGC viability and regeneration is essential to future 
investigations. If possible, microglial proliferation and activation could be inhibited 
independently to show the effects on neurodegeneration and RGC death. 
Manipulation of the CD200 axis may also prove useful in future research using the 
episceral drainage vessel sclerosis model of glaucoma, in order to determine whether 
prevention of signalling through this axis can indeed prevent microglial activation and 
RGC degeneration. It may also be of interest to prevent the peripheral immune
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response in this model o f glaucoma, similar to Bakalash et al (2002) in order to verify 
whether this response does indeed play any role in glaucoma, and to absolutely 
segregate the peripheral and central responses to elevation of IOP.
This study clearly correlates raised NOS protein levels with ocular hypertension. Due 
to the controversy surrounding this issue, future work should include consolidation of 
this result. Detection of NOS mRNA, in both homogenates and tissue sections of optic 
nerve could be used to indicate transcriptional upregulation of the NOS genes, as well 
as the location of any alterations. Additionally verification of NOS dimerisation (and 
therefore activation) should also be investigated to confirm the involvement of NOS 
in glaucoma. Should NOS dimerisation increase it would be desirable to investigate 
NO and superoxide production in order to confirm the role of NOS in 
neurodegeneration.
There remains a multitude of potential investigations that could stem from this one 
study into the pathogenesis of glaucoma. As befits such a multifaceted disease, a huge 
amount of investigation is ongoing, worldwide, into one of the leading causes of 
irreversible blindness. Hopefully this thesis and future publications will assist in 
defining glaucoma pathophysiology and the development of clinically relevant
glaucoma medications.
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Appendix 1: Reagents
Sterile saline solutions
Hypertonic saline (1.75M) used during the microinjection procedure to sclerose the 
episcleral vasculature was made up by adding 1.022g NaCl (Sigma-Aldrich, UK) to 
10ml distilled water. The solution was stirred, followed by filtration to remove 
particles (0.22 pm filters, Millipore, UK), then autoclaved to ensure sterility.
Similarly, 0.9% sterile saline solution consisted of 0.9% (weight/volume) NaCl in 
distilled water. This solution was autoclaved and used to maintain hydration of the 
operated eye during surgical procedures.
Phosphate buffered saline (PBS)
PBS was used as a general buffering reagent in several experiments including 
perfusion and immunohistochemistry. A concentrated (100%) PBS solution was made 
up as a stock. This was diluted to 10% before use. 100% PBS consisted of 800g NaCl, 
142.4g disodium hydrogen orthophosphate, 20g potassium dihydrogen 
orthophosphate and 20g potassium chloride dissolved in 10 litres of distilled water. 
pH was adjusted to 7.5.
The composition o f  8% paraformaldehyde stock
PFA was used as a tissue fixative. PFA stock was made up by adding 8g of PFA 
powder (Sigma-Aldrich, UK) to a 100ml volume of PBS. This mixture was warmed 
and stirred, while 0.1 M NaOH was added drop-wise until a clear solution was 
obtained. Once cool, pH was adjusted to 7.4 using 0.1 M HC1.
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Neutral bufferedformalin (NBF)
Neutral buffered formalin (10%) was used as a fixative in some experiments. One litre 
of solution was made up by adding 100ml 40% formaldehyde, 4g monohydrate 
monobasic sodium phosphate and 6.5g anhydrous dibasic sodium phosphate, then 
topping up to one litre with distilled water.
Gelvatol
Gelvatol was used as a mountant for frozen sections with fluorescence labelling. 
Gelvatol consisted o f 0.08 g Na2 HPC>4 and 0.03 g KH2PO4 in 40ml double distilled 
water (pH7.2) to which 0.327 g NaCl, 0.024 g sodium azide and 0.6 g DABCO (1,4- 
Diazabicyclo[2.2.2]octane) were added. The solution was then protected from light, 
and polymerised by stirring in 10 g of gelvatol (vinyl alcohol 25) overnight. Glycerol 
(20ml) was added (pH6-7) and the mountant centrifuged at 12000 rpm for 15 minutes, 
and then 18000 rpm for 25 minutes. The mountant was stored at 4°C with protection 
from light.
Tris-buffered saline (TBS)
On occasions when PBS was not used as a general buffer, for example during the 
optimisation of immunolabelling techniques, TBS was used as an alternative. TBS 
consisted of 60.0 g Tris, 44.06 g NaCl, 1.39 g Tris base in 500 ml double distilled 
H2O, pH was adjusted to 7.5.
Appendix 2: Conference presentations, abstracts and publications
Conference presentations and abstracts 
January 2003
Farrant SY, Albon J, Erichsen JT, Boulton ME, Taylor MA, Morgan JE. 
Pathophysiology of retinal ganglion cell death in glaucoma. School of Optometry
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and Vision Sciences Postgraduate Poster Sessions, Cardiff University. (Poster 
presentation)
November 2003
Farrant SY, Albon J, Erichsen JT, Boulton ME, Taylor MA, Morgan JE. Glial cell 
activation in a rodent model of glaucomatous optic nerve degeneration. Society 
for Neuroscience annual meeting.
April 2004
Farrant SY, Albon J, Erichsen JT, Akhtar S, Boulton ME, Taylor MA, Morgan JE. 
Glial cell activation is associated with retinal ganglion cell apoptosis and 
neurodegeneration in experimental glaucoma. School of Optometry and Vision 
Sciences Postgraduate Poster Sessions, Cardiff University. (Poster presentation)
September 2004
Farrant SY, Albon J, Erichsen JT, Akhtar S, Boulton ME, Taylor MA, Morgan JE. 
The role of glia during secondary neurodegeneration in experimental glaucoma.
Cardiff Institute for tissue engineering and repair.
September 2004
Boulton ME, Datta A, Farrant S, Albon J, Erichsen JT, Morgan JE. Evidence for 
retinal ganglion cell remodelling in experimental glaucoma. XVI International 
Congress of Eye Research.
Published Abstracts
S.Y. Farrant, J. Albon, J.T. Erichsen, S. Akhtar, M.E. Boulton, M.A. Taylor, and 
J.E. Morgan Optic nerve degeneration in experimental glaucoma is associated 
with microglial activation. Invest. Ophthalmol. Vis. Sci. 2004 45. E-Abstract 2141.
S. Akhtar, A.V. Datta, J. Albon, S. Farrant, M. Taylor, J.T. Erichsen, M. Boulton, 
and J.E. Morgan Ultrastructural Analysis of Optic Nerve Axons in Experimental
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Glaucoma: Evidence for Axon Shrinkage Invest. Ophthalmol. Vis. Sci. 2005 46: E- 
Abstract 1236.
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